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Abstract 
 
 
Pathological changes in the dopaminergic system account for a number of devastating 
illnesses including schizophrenia, psychosis, depression, addiction, obsessive compulsive 
disorder or the most well known Parkinson’s disease (PD). The nigrostriatal pathway is an 
important component of the dopaminergic (DA) system mediating voluntary movement and 
originates in the ventral midbrain from where substantia nigra pars compacta (SN) neurons 
send their axons to the dorsal striatum. Massive loss of SN neurons as seen in PD leads to 
postural imbalance, rigidity, tremor and bradykinesia, however, the precise mechanisms 
involved in the maintenance and the demise of SN neurons are poorly understood.  
 
Endogenous neurotrophic factors such as the Glial cell line-derived neurotrophic factor 
(GDNF; signaling via the Ret receptor tyrosine kinase) and Brain-derived neurotrophic factor 
(BDNF; signaling via the TrkB receptor tyrosine kinase) were reported to have protective and 
rescuing properties on DA neurons; however, their physiological roles in SN neurons 
remained unknown. Inactivation of the oxidative stress suppressor DJ-1 causes PD; 
remarkably, mice lacking DJ-1 function do not display overt SN degeneration, suggesting that 
additional DJ-1 interactors compensate for loss of DJ-1 function. To begin characterizing the 
cellular and molecular networks mediating SN neuron survival, I used mouse genetics to 
investigate the roles and the interaction between GDNF/BDNF-mediated trophic signaling 
and the DJ-1-mediated stress response in SN neurons.  
 
While mice lacking TrkB function specifically in SN neurons display a normal complement of 
SN neurons up to 24-months, loss of Ret function in DA neurons causes adult-onset and 
progressive SN degeneration, suggesting that GDNF/Ret signaling is required for long-term 
maintenance of SN neurons. I then generated and aged mice lacking Ret and DJ-1 and found 
remarkably that they display an enhanced SN degeneration relative to mice lacking Ret. Thus, 
DJ-1 promotes survival of Ret-deprived SN neurons. Interestingly, the survival requirement 
for Ret and DJ-1 is restricted to those SN neurons which express the ion channel GIRK2, 
project exclusively to the striatum and specifically degenerate in PD. This is the first in vivo 
evidence for a pro-survival role of DJ-1.  
 
To understand how DJ-1 interacts molecularly with Ret signaling, I performed epistasis 
analysis in Drosophila melanogaster. Although DJ-1 orthologs DJ-1A and DJ-1B are 
dispensable for fly development, the developmental defects induced by targeting 
constitutively active Ret to the retina were suppressed in a background of reduced DJ-1A/B 
function. Moreover, DJ-1A/B interacted genetically with Ras/ERK, but not PI3K/Akt 
signaling to regulate photoreceptor neuron development. Flies with reduced ERK activity and 
lacking DJ-1B function had more severe defects in photoreceptor neuron and wing 
development than flies with reduced ERK function. These observations establish, for the first 
time, a physiological role for DJ-1B in the intact Drosophila.    
 
Our findings suggest that the triple interaction between aging, trophic insufficiency and 
cellular stress may cause Parkinsonism. Because Ret and DJ-1 show convergence of their pro-
survival activities, we predict that striatal delivery of GDNF might be most effective in PD 
patients carrying DJ-1 mutations. A better understanding of the molecular connections 
between trophic signaling, cellular stress and aging will accelerate the process of drug 
development in PD.  
 
 
 
 
 
                                                                                                                       
6 
 
Zusammenfassung 
 
Pathologische Veränderungen im dopaminergen System sind für einige verheerende 
Krankheiten verantwortlich, unter anderem Schizophrenie, Psychosen, Depression, 
Drogenabhängigkeit, Zwangsneurosen und am besten bekannt, die Parkinson’sche Krankheit 
(PD). Die nigrostriatale Nervenbahn ist ein wichtiger Bestandteil des dopaminergen (DA) 
Systems und ist zuständig für bewusst ausgeführte Bewegungen. Sie entspringt im ventralen 
Mesencephalon, von wo die Axone der substantia nigra pars compacta (SN) Neurone ins 
dorsale Striatum verlaufen. Der massive Verlust von SN Neuronen, wie bei PD, führt zu den 
bekannten Symptomen Haltungsinstabilität, Muskelstarre, Zittern und verlangsamte 
Bewegungen. Allerdings sind die Mechanismen, die für die Erhaltung, bzw. den Verlust der 
SN Neurone verantwortlich sind, bisher nur schlecht verstanden. 
 
Körpereigene neurotrophe Faktoren wie der Glial cell line-derived neurotrophic factor 
(GDNF, Signaltransduktion ueber die Ret Rezeptor Tyrosinkinase) und der Brain-derived 
neurotrophic factor (BDNF, Signaltransduktion ueber die TrkB Rezeptor Tyrosinkinase) 
wurden mit schützenden und erhaltenden Eigenschaften in DA Neuronen in Verbindung 
gebracht. Allerdings sind ihre physiologischen Funktionen noch weitgehend unbekannt. 
Inaktivierung von DJ-1, das vor oxidativem Stress schützt, führt bei Menschen zu PD. 
Erstaunlicherweise zeigen Mäuse, welchen DJ-1 fehlt, keinen Verlust von SN Neuronen, was 
impliziert, dass weitere Interaktionspartner von DJ-1 den Verlust der DJ-1 Aktivität 
kompensieren können. Um die zellulären und molekularen Netzwerke zu charakterisieren, die 
für den Erhalt von SN Neuronen verantwortlich sind, verwendete ich genetische Methoden in 
der Maus. Hierbei war ich besonders an der Interaktion der neurotrophen Effekte von 
GDNF/BDNF und der DJ-1 vermittelte Stressantwort in SN Neuronen interessiert. 
 
Während Mäuse, welchen der TrkB Rezeptor spezifisch in SN Neuronen fehlt, bis zum Alter 
von 24 Monaten eine normale Anzahl und Morphologie von SN Neuronen zeigen, tritt bei 
Verlust der Ret Funktion in DA Neuronen in adulten Mäusen eine fortschreitende 
Degeneration von SN Neuronen auf. Dies deutet darauf hin, dass GDNF/Ret vermittelte 
Signale für das langfristige Überleben von SN Neuronen benötigt werden. Ich generierte und 
alterte daraufhin Mäuse, welchen Ret und DJ-1 fehlte und konnte interessanterweise zeigen, 
dass bei diesen eine verstärkte SN Degeneration im Vergleich zu Mäusen auftrat, welchen nur 
der Ret Rezeptor fehlte. DJ-1 unterstützt also das Überleben von Wachstumsfaktor-
deprivierten SN Neuronen. Interessanterweise ist dieser Effekt beschränkt auf Zellen, die den 
Ionenkanal GIRK2 exprimieren und ausschließlich Axone ins Striatum senden. Diese Zellen 
sterben auch speziell in der Parkinson’schen Krankheit ab. Diese Ergebnisse sind der erste in-
vivo Beleg für eine positive Überlebensfunktion von DJ-1. 
 
Um die Interaktion von DJ-1 und Ret-vermittelter Signaltransduktion auf molekularer Ebene 
zu untersuchen, führte ich eine Epistaseanalyse in Drosophila melanogaster durch. Obwohl 
die Drosophila DJ-1 Orthologe DJ-1A und DJ-1B für die Entwicklung von Drosophila 
erlässlich sind, konnte ein genetischer Hintergrund mit reduzierter DJ-1A/B Aktivität 
Augenentwicklungsdefekte unterdrücken, die durch Überexpression einer konstitutiv aktiven 
Ret Rezeptor in der Retina induziert wurden. Des weiteren interagierte DJ-1A/B genetisch mit 
dem Ras/ERK Signalweg, aber nicht mit dem PI3K/Akt Signalweg in der Regulation der 
Photorezeptorneuronenentwicklung. Fliegen mit reduzierter ERK Aktivität und fehlendem 
DJ-1B zeigten schwerwiegendere Defekte in der Photorezeptorneuron- und 
Flügelentwicklung als Fliegen mit reduzierter ERK Aktivität, aber normalem DJ-1B Level. 
Diese Beobachtungen zeigen zum ersten Mal eine physiologische Funktion für DJ-1B in 
Drosophila. 
 
Unsere Ergebnisse legen nahe, dass die Interaktion der drei Faktoren Alterung, Mangel an 
trophischen Signalen und zellulärer Stress, Parkinson-ähnliche Symptome hervorrufen kann. 
Da Ret und DJ-1 konvergente überlebensfördernde Aktivitäten zeigen, sagen wir voraus, dass 
                                                                                                                       
7 
 
eine intrastriatale Behandlung mit GDNF in Parkinson-Patienten mit DJ-1 Mutationen 
besonders wirksam sein könnte. Ein besseres Verständnis der molekularen Zusammenhänge 
zwischen trophischen Signalen, zellulärem Stress und Alterung wird den Prozess der 
Medikamentenentwicklung für PD deutlich beschleunigen. 
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A. Genetics and biochemistry of Parkinson’s disease 
 
1.1 Neurodegenerative diseases: a challenge for modern neuroscience 
 
The formation, activity and maintenance of nerve cells (neurons) are crucial for our 
capacity to perceive, analyze and react to the external world. Death of specific neuronal 
populations is seen in neurodegenerative diseases and has devastating consequences for 
affected individuals. Loss of memory and dementia are typical signs of Alzheimer’s 
disease (AD) and mainly result from the depletion of acetylcholine-secreting cortical 
and hippocampal neurons; loss of voluntary movement, rigidity, tremor and imbalance 
are defining symptoms of Parkinson’s disease (PD) and are mainly caused by 
degeneration of dopamine-secreting neurons in the substantia nigra pars compacta; 
uncontrolled movements (chorea) seen in Huntington’s disease (HD) arise from loss of 
gamma-aminobutyric-acid-secreting inhibitory neurons in the striatum; finally, muscle 
weakness and progressive paralysis are typical signs of Amyotrophic lateral sclerosis 
(ALS) in which depletion of brain and spinal cord motoneurons leads to loss of 
acetylcholine-mediated muscle control (Figure 1).  
 
Although manifesting with very different symptoms, neurodegenerative diseases share 
some common features, both at the clinical and cellular/molecular levels. These 
disorders typically affect individuals in their mid-life and the symptoms gradually 
worsen over time. Most of patients with neurodegenerative disease are sporadic, i.e. 
without any family history or known genetic defect. However, a minority of patients 
does inherit these disorders and it is the analysis of these families that provided 
essential clues about the pathophysiological processes that lead to nerve cell 
degeneration in these disorders. The identification of genes associated with familial 
neurodegenerative disease represented a breakthrough in neurodegeneration research as 
it allowed the generation of animal models that recapitulate these mutations and their 
detailed behavioral, anatomical and molecular analysis. It soon became clear that 
neurodegenerative disorders resemble each other in some aspects (Figure 1).  
 
Dysfunction of the protein quality control and clearance machinery emerged as a 
common theme in neurodegeneration. Diseases as diverse as AD, PD, HD, ALS or 
Prion disease (caused by infectious Prion [PrPSc] particles accumulating in extracellular 
brain regions) display aggregation and deposition of misfolded proteins that lead to 
progressive CNS amyloidosis. Because of this distinctive property, neurodegenerative 
disorders are also called “protein clearance diseases”. Accumulation of insoluble 
proteins impairs the function of the proteasome, the cellular machinery responsible for 
protein clearance. As a result, there is a general proteostasis defect, which has 
deleterious consequences for the cell. Another major recurring theme is the presence of 
mitochondrial dysfunction leading to enhanced production of reactive oxygen species 
(ROS). Increased levels of ROS (oxidative stress) negatively impact on cell viability, as 
ROS can covalently modify proteins, lipids and nucleic acids.  
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Figure 1. Anatomic and molecular aspects of neurodegenerative diseases. Each neurodegenerative 
disease shows relative specificity for a restricted brain region. AD affects mainly the temporal and 
parietal cortex and the hippocampus (yellow); Frontotemporal dementia (FTD) affects the frontal and 
temporal lobes of the cortex (red); Midbrain dopaminergic (DA) substantia nigra pars compacta (SN) 
neurons are lost in PD (purple); medium spiny striatal neurons are lost in HD (green); spinal cord (blue) 
and brain (not shown) motoneurons are lost in Amyotrophic lateral sclerosis (ALS). Shown in the middle 
is the age at disease onset; inherited forms (red) of disease start earlier, while sporadic forms (blue) 
display a slower progression. The lower part illustrates the common and most prominent pathological 
triggers of neurodegeneration. Abnormal protein aggregation generates oligomers and insoluble species 
(pink) that impair the proteasome and generate reactive oxygen species (ROS). Protein aggregates can 
further trap other functional proteins (other colors), leading to their inactivation. Mitochondrial 
dysfunction also generates ROS. The sum of all pathological insults initiates the apoptotic program that 
starts with cytochrome c release from mitochondria and culminates with the activation of caspases. It is 
currently unclear whether neurotrophic factor insufficiency has a disease-promoting effect or whether 
neurotrophic factor delivery into the diseased brain can halt neurodegeneration.  
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These and additional, yet unidentified pathological changes seem to converge on 
highly-conserved apoptotic pathways that culminate with the activation of caspases, 
which are highly specialized cysteine-aspartic proteases that execute the apoptotic 
program leading to cell death (Figure 1).  
 
Although extensive research succeeded in identifying a number of risk factors and 
pathological mechanisms that might cause neurodegeneration, we currently do not 
know why only specific neuronal populations are lost in certain patients during aging. 
This lack of understanding of disease etiology is reflected in our poor therapeutic 
arsenal to treat neurodegeneration. No therapy to date is able to slow down or prevent 
neuronal cell death. The existing therapies are all symptomatic, have moderate efficacy 
and important side effects. Another major preoccupation is the increasing incidence of 
neurodegenerative disease in our aging society. There is high probability to develop 
AD after 85 years of age, and PD is most common in those above the age of 70 years. 
Amyotrophic lateral sclerosis (ALS), a disease in which motoneurons are specifically 
lost, rises sharply after the age of 40 years (Figure 1). The rising prevalence of 
neurodegenerative disease worldwide will have dramatic consequences for our 
economy and health care system if effective therapies are not soon developed. 
 
Neurotrophic factors are molecules regulating neuronal survival and function and have 
been proposed to be potential therapeutic agents for these degenerative disorders. 
Current clinical trials dealing with neurotrophic factor delivery into the diseased brain 
have serious limitations and yield conflicting results, suggesting that improvements in 
both technology and understanding of neurotrophic factor biology are necessary. 
 
 
The first part of the present work investigates the physiological relevance of two 
important neurotrophic factors, the Glial cell line-derived neurotrophic factor (GDNF) 
and the Brain-derived neurotrophic factor (BDNF) in the aging substantia nigra pars 
compacta (SN) neurons, the midbrain population that is lost in PD. Using mouse 
genetics, I provide evidence that GDNF signaling via the Ret receptor tyrosine kinase is 
required for maintenance of aging SN neurons. In the second part, I provide the first in 
vivo evidence for a pro-survival role of DJ-1 in mouse SN neurons; moreover, using 
genetic analysis in Drosophila melanogaster, I show that DJ-1 interacts genetically 
with Ret-associated signaling and uncover a novel physiological role for the Drosophila 
orthologue DJ-1B during retinal and wing development.   
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1.2. Two centuries of Parkinson’s disease research 
 
PD is a condition that has been known since ancient times. It is referred to in the 
ancient Indian medical system of Ayurveda under the name Kampavata, as far as 5000 
BC. The physician Galen first described it in the Western literature in 175 AD, and 
named it ‘shaking palsy’. However, it is only in 1817 that a detailed medical assay was 
published on PD. In his classical monograph “An essay on the shaking palsy”, James 
Parkinson (1755-1824) described with amazing precision the core clinical features of 
PD. He described the disease as involving “involuntary tremulous motion, with 
lessened muscular power, in parts not in action and even when supported… [and] with 
a propensity to bend the trunk forwards”. The term ‘Parkinson’s disease’ was coined 
later by Jean-Martin Charcot. In 1912, the neurologist Frederic Lewy identified the 
presence of spherical cytoplasmic inclusions (Lewy bodies) in the brains of PD 
patients. The underlying biochemical changes in PD were identified largely thanks to 
the work of the Swedish pharmacologist Arvid Carlsson (born 1923). He demonstrated 
that dopamine was a neurotransmitter in the brain and not just a precursor of 
norepinephrine and developed methods to measure dopamine concentrations. In 1957, 
he performed a breakthrough experiment that led to the identification of dopamine as a 
critical regulator of movement. Carlsson treated animals with reserpine which depleted 
neurotransmitter stores which caused a strong decrease in dopamine levels and loss of 
movement control, similar to PD; he then administered the dopamine precursor L-
DOPA (L-3,4-dihydroxyphenylalanine) to animals and succeeded in completely 
blocking the inhibitory effects of reserpine.  L-DOPA was the first drug used to treat 
PD symptoms, and entered clinical practice in 1967 (Bjorklund and Dunnett, 2007). 
Subsequent studies established that the bulk of dopamine in the human brain was 
located in the striatum and that PD patients display a marked loss of striatal dopamine. 
Subsequent refinements of histological techniques allowed identification and mapping 
of midbrain substantia nigra pars compacta (SN) neurons, which densely innervate the 
striatum and which were found to be dramatically depleted in PD patients (Figure 2). In 
1997 Maria Spillantini found that alpha-synuclein is the major component of Lewy 
Bodies (Spillantini et al., 1997). During the last 12 years, the study of familial PD led 
to the identification of PD-associated genes and the generation of animal models that 
recapitulate some features of PD, thus opening the molecular biology era of PD.  
 
1.3. Loss of substantia nigra neurons causes Parkinson’s disease 
 
The demonstration by Carlsson that DA is a neurotransmitter in the brain was followed 
by the discovery that loss of substantia nigra pars compacta (SN) neurons leads to loss 
of striatal dopamine, which is responsible for the major symptoms of PD (Bjorklund 
and Dunnett, 2007). Substantia nigra is the largest structure in the midbrain, is located 
ventrally and plays an important role in movement, reward, addiction and learning. Its 
Latin name signifies “black substance” as parts of the human substantia nigra appear 
darker than neighboring areas due to the presence of the pigment melanin. Anatomical 
studies found that substantia nigra consists of 2 parts, with different connections and 
functions. The substantia nigra pars reticulata is the output of the basal ganglia and 
conveys signals to other brain regions involved in motor control (see below). The 
substantia nigra pars compacta (hereafter referred to as SN), with its melanine-
containing DA cell bodies, is responsible for the darker appearance of this region 
(Figure 2A,C); loss of SN neurons as seen in PD leads to the disappearance of the 
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typical melanin pigment and the remaining SN neurons display intracytoplasmic 
protein aggregates containing alpha-synuclein (Lewy Bodies; Figure 2B,D,E).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Loss of substantia nigra (SN) neurons causes Parkinson’s disease. Pathological examination 
of a healthy patient (A) reveals typical pigmented DA neurons in the SN (arrows); in contrast, loss of SN 
neurons leads to pigment disappearance in the PD brain (B, arrows). Magnification of the SN area 
reveals a dense network of melanin-pigmented SN neurons in the healthy brain (C) while most of SN 
neurons are lost in PD (D). Some of the remaining neurons in PD contain insoluble cytoplasmic protein 
aggregates (Lewy Bodies, E) that are made of aggregated alpha-synuclein and other proteins. The 
melanin-containing granules have a red-brown hue and are distributed in the cytosol of all SN neurons 
(C-E). The picture in E is the higher magnification of the dark-boxed area in D. Adapted from 
Agamanolis, 2006.  
 
SN serves mainly as input to the basal ganglia circuit, by supplying the striatum with 
dopamine (nigrostriatal pathway; Figure 3). Although the dorsal striatum is the major 
projection area for nigral DA neurons, SN neurons were recently found to project to 
other brain areas, including cortical and limbic areas (Bjorklund and Dunnett, 2007).  
 
All DA neurons in the SN are positive for the DA marker tyrosine hydroxylase (TH), 
an enzyme involved in dopamine biosynthesis. However, two DA subpopulations were 
identified in the SN, based on the selective expression of additional markers and 
differential connectivity patterns. The majority (approx. 75 %) of TH-positive DA 
neurons in the SN also express the G protein-activated inward rectifier potassium 
channel 2 (GIRK2) and project exclusively to the striatum. A minority (approx. 25 %) 
of TH-positive SN DA neurons expresses the calcium-binding protein Calbindin; it is 
these neurons that project to limbic and cortical areas (Bjorklund and Dunnett, 2007; 
Korotkova et al., 2004).  
 
1.3.1 Most substantia nigra neurons innervate the dorsal striatum 
 
The development of the nigrostriatal system begins at the embryonic day E7.5 when the 
first progenitors located in the mesencephalon give rise to multiple cell types. In a 
second step, undifferentiated cells are progressively specified to become DA, by the 
orchestrated action of several extracellular modulators (Sonic hedgehog, Wnt1/5a, 
TGF-β, FGF-20) and intracellular transcription factors (Otx2, Gx2, En1/2, Lmx1a/b, 
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Pax2/3/5/7/8, Gli1/2/3, Nkx, Nurr1) (Smidt and Burbach, 2007). The midbrain 
precursor cells exit the cell cycle at E10-E11.5 and start expressing the first DA 
markers, including the tyrosine hydroxylase (TH) and other enzymes involved in the 
dopamine biosynthesis pathway (Abeliovich and Hammond, 2007). At E11.5 DA 
neurons engage in the process of axonal pathfinding and follow guidance cues provided 
by the Semaphorin family ligands, Slits, Netrins and  Ephrins  to reach their target area, 
the striatum (Abeliovich and Hammond, 2007). Upon completing target innervation 
(around E14.5), DA axons compete to establish synapses and survive; several target-
derived neurotrophic factors have been proposed for DA neurons (Burke, 2003; 
Krieglstein, 2004; Smidt and Burbach, 2007), including GDNF and BDNF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Dopaminergic cell groups and the nigrostriatal pathway. (A) Dopaminergic and non-DA 
(adrenergic and noradrenergic) neurons in the mouse brain expressing the tyrosine hydroxylase (TH) 
marker are visualized here in 3D (cell bodies are in yellow). Nine groups of DA neurons are found in the 
mouse brain (A8-A16, according to the classification by (Dahlstroem and Fuxe, 1964); three groups from 
these DA neurons are found in the midbrain : A8-retrorubral field, A9-substantia nigra (SN) and A10-
ventral tegmental area (VTA). There are additional, non-DA neurons that also express the TH enzyme, 
which regulates synthesis of all dopamine, adrenaline and noradrenaline (groups A1-A7, localized caudal 
to the midbrain; not labeled). (B) The nigrostriatal pathway is shown in a sagital section of the mouse 
brain stained for TH. The SN cell bodies, located in the ventral midbrain send their axons (via the medial 
forebrain bundle) to the dorsal striatum. Note that the neighboring VTA neurons (also labeled by TH) 
innervate preferentially the ventral striatum. The picture in A was generated by the Brain Explorer 
software using the TH-expression data from the Allen Brain Atlas (www.brain-map.org).  
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Dopaminergic axons originating from the SN and innervating the dorsal striatum 
(Figure 3) travel through a major axon track (the medial forebrain bundle, MFB), that 
contains both ascending and descending fibers from different brain regions (Burke, 
2003; Hattori, 1993).Transection of the MFB leads to massive degeneration of SN cell 
bodies and axons, and is a commonly used DA lesion in experimental studies 
investigating the survival requirements of SN cell bodies (Deumens et al., 2002). The 
dramatic degeneration of SN cell bodies after MFB axotomy also suggests that survival 
signals must travel retrogradely from the DA terminals in the striatum, along DA 
axons, to support survival of SN cell bodies. Finally, dopaminergic axons reaching the 
striatum elaborate distal terminations (axon terminals) that release dopamine to 
modulate motor control. 
 
In contrast to the fast synaptic transmission mediated by glutamate or GABA 
(milliseconds) and involving opening of ion channels, dopamine mediates a slow 
synaptic transmission (hundreds of milliseconds to minutes) to impact its striatal target 
neurons. This slow synaptic transmission is mediated by dopamine binding to 
dopamine receptors. Five post-synaptic dopamine receptors have been identified, which 
either stimulate (D1, D5) or inhibit (D2-4) adenylyl cyclase activity and cAMP 
production. D1 and D2 receptors are abundant in the striatum and although they have 
opposite effects at the molecular level, they often have a synergistic action when more 
complex outputs are considered. Dopamine, acting via D1-5 receptors, exerts profound 
effects on postsynaptic neurons, ranging from short-term changes to long-term 
modulation of plasticity and synaptic efficacy (Greengard, 2001). 
 
1.3.2. The basal ganglia modulate movement 
 
Dopamine depletion due to loss of SN neurons as seen in PD leads to a severe 
impairment of voluntary movement and are responsible for the characteristic motor 
symptoms in PD:  tremor at rest, postural imbalance, poverty of voluntary movements 
(akinesia), slowness and impaired scaling of movement (bradykinesia) and muscle 
rigidity (Dauer and Przedborski, 2003). These motor symptoms are the result of altered 
circuitry within the basal ganglia, a group of subcortical nuclei that are highly 
interconnected with the cerebral cortex, the thalamus and the brain stem (McHaffie et 
al., 2005). The basal ganglia consist of SN, the striatum globus pallidus (GP) and 
subthalamic nucleus (STN) (Figure 4) (Groenewegen, 2003). The striatum is the main 
input nucleus in the basal ganglia and receives excitatory (glutamatergic) input from the 
cortex and the thalamus and DA input from the SN. The DA input, transduced via 
dopamine D1 and D2 receptors has a modulatory role on striatal output activity. This 
information is processed by a striatal network comprising 10 % interneurons and 90 % 
GABAergic projection neurons, the so-called “medium spiny neurons” (MSNs). 
Striatal neurons then send inhibitory (GABAergic) connections to the GP external 
(GPe) and internal (GPi) segments and to the SN pars reticulata. The axis STR/GPi is 
known as the “direct” pathway and the STR/GPe/STN axis as the “indirect” pathway 
(Obeso et al., 2008). The output nuclei (GPi and SN pars reticulata) consist of 
GABAergic neurons that fire spontaneously at high frequency, continuously inhibiting 
neurons in target areas, such as the thalamus. Activation of striatal neurons by cortical 
inputs leads to inhibition of this output nuclei, via the direct pathway, and stimulates 
movement. The indirect pathway consists of two successive inhibitions and thus 
sustains the inhibitory action of the output nuclei, thus inhibiting movement (Figure 4). 
Loss of dopamine as seen in PD disrupts the cortico-striatal balance, leading to reduced 
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activity in the direct pathway and increased activity in the indirect pathway. As a 
consequence, there is hyperactivity in the STN and the STR and excessive inhibitory 
output in the GPi (Obeso et al., 2008), although the precise chain of events is 
incompletely understood (Nambu, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Basal ganglia and the control of movement. The striatum is the input structure of the basal 
ganglia. It receives excitatory input from the cortex and the thalamus and modulatory dopaminergic input 
from the substantia nigra pars compacta (SN). Two pathways originate in the striatum: the direct 
pathway (STR/GPi) that promotes movement and the indirect pathway (STR/GPe/STN/GPi) that inhibits 
movement. Loss of SN neurons leads to imbalance in the striatal output; the activity of the direct 
pathway is decreased and the indirect pathway is overactive. As a consequence, there is increased 
inhibitory activity in the GPi, which inhibits voluntary movement initiation (via the cortex) but also 
decreases movement execution (via inhibition of motor nuclei in the brain stem). GPe, globus palidus 
external segment; GPi, globus palidus internal segment; STN, subthalamic nucleus; STR, striatum. 
Excitatory connections use glutamate (glu) while inhibition is GABA-mediated (GABA). Adapted from 
(Groenewegen, 2003; Nambu, 2008). 
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1.3.3. The VTA neurons regulate emotional states and cognition 
 
Besides SN neurons, another DA population is present in the ventral midbrain: the 
ventral tegmental area (VTA), the so-called A10 group (Figure 3) (Haber and Fudge, 
1997). VTA neurons are TH-positive and the majority of them express the calcium-
binding protein Calbindin, while a small fraction expresses the ion potassium channel 
GIRK2. VTA neurons play little, if any, role in movement control and mainly project to 
the limbic (including nucleus accumbens and the amygdala in the anteromedial and 
ventral striatum; and the septum; the mesolimbic pathway) and cortical (cingulated, 
prefrontal and perirhinal cortex; mesocortical pathway) areas (Fields et al., 2007). The 
mesolimbic and mesocortical pathways are involved in the regulation of emotional and 
cognitive states respectively; in addition, they are major regulators of reward behaviors 
and control drug and alcohol addiction (Bjorklund and Dunnett, 2007; Fields et al., 
2007; Kauer, 2004).   
 
 
1.3.4. Regional specificity and classification of Parkinsonian syndromes  
 
PD has proven to be a heterogeneous condition. Although SN is dramatically affected 
in PD patients, neurodegeneration in PD extends beyond the SN, and affects (although 
with less severity) the neignboring DA VTA (A10) and retrorubral field (A8) regions, 
the noradrenergic (locus coeruleus), serotonergic (raphe) and the cholinergic (nucleus 
basalis of Meynert); in addition, the cerebral cortex, the olfactory bulb and the 
autonomic nervous systems are also affected and LB presence was equally documented 
in these brain areas (Dauer and Przedborski, 2003).This extended neurodegenerative 
pattern is likely underlying the non-motor symptoms observed in PD, including 
dementia and depression (Dauer and Przedborski, 2003).  
 
Second, several partially distinct disorders manifest with PD symptoms. The term 
Parkinsonism has therefore been coined to encompass all syndromes that manifest with 
motor symptoms similar to PD. While nigrostriatal degeneration is the common 
pathological substrate of all Parkinsonism forms, additional changes might differentiate 
between PD and non-PD Parkinsonism (Figure 5). For example, in Multiple system 
atrophy (MSA; in which alpha-synuclein aggregates in glial cells), besides loss of SN 
neurons, striatal and basal ganglia output neurons (GPi and SN pars reticulata) are lost, 
in contrast to PD (Halliday, 2007). Similarly, some AD patients or patients with 
progressive supranuclear palsy (PSP) also manifest with Parkinsonism, although they 
display Tau, but not alpha-synuclein, aggregates (Forman et al., 2005); moreover, PSP 
patients also display loss of basal ganglia output neurons, similar to MSA patients 
(Halliday, 2007). The presence of LBs is also detected in dementia with LBs (DLB), 
making the distinction between PD and DLB difficult (Figure 5). These differences 
argue for a better understanding of the underlying molecular and cellular changes that 
generate this diversity of Parkinsonian phenotypes. In addition, the identification and 
development of specific biomarkers might improve the clinical diagnosis and 
therapeutic outcome for Parkinsonian disorders.  
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Figure 5. Classification of major diseases that manifest with Parkinsonism. Several molecularly 
distinct pathologies cause degeneration of SN neurons and manifest with PD-like symptoms. The 
presence of Lewy Bodies in SN neurons is by far the most common form of Parkinsonism. However, 
diseases that manifest with LBs in SN neurons and concurrent dementia (dementia with Lewy Bodies, 
DLB; Parkinson’s disease dementia, PDD) are difficult to differentiate pathologically. Moreover, 
neuropathological examination of a subset of patients with Parkinsonism reveals that they do not display 
LBs in SN neurons; these patients display either alpha-synuclein inclusions in glial cells (Multiple 
system atrophy, MSA) or Tau inclusions in different brain areas. Tau mutations cause accumulation of 
aggregated Tau and concurrent frontotemporal dementia (FTD), while Tau pathology in sporadic cases 
without senile plaques is associated with either corticobasal degeneration (CBD) or progressive nuclear 
suprapalsy (PSP), in addition to Parkinsonism. The presence of senile plaques in sporadic patients is an 
indication of concurrent Alzheimer’s disease (AD) or Lewy Body variant of Alzheimer’s disease 
(LBVAD). In addition to motor impairments, all these concurrent disorders manifest with non-motor 
symptoms (e.g. dementia, depression, autonomic failure). Note that additional disorders might cause 
Parkinsonism in humans. Adapted from (Forman et al., 2005).  
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1.4. Genes associated with familial Parkinson’s disease 
 
One major advance in PD research was the identification of familial PD and the 
analysis of the underlying mutations in these families. The systematic analysis of 
extended pedigrees ultimately led to the discovery of PD-associated genes (Gasser, 
2009b; Henchcliffe and Beal, 2008). About 10 % of all PD cases are genetic, the rest 
being sporadic (with no family history and no identified genetic defect). It is commonly 
believed that understanding the neurodegeneration in monogenic PD would lead to a 
better understanding of sporadic PD, which is likely caused by an interaction between a 
network of weakly-acting gene alterations and environmental factors. The genes linked 
to monogenic PD display either an autosomal-dominant or autosomal-recessive pattern 
of inheritance. Mutations in alpha-synuclein and LRRK2 (also called Dardarin) cause 
autosomal dominant PD, while mutations in Parkin, PINK1 or DJ-1 cause autosomal 
recessive PD (Table 1).  
 
Locus Gene Inheritance Function 
PARK1/4 α-Synuclein AD Involved in synaptic vesicle formation 
PARK2 Parkin AR Ubiquitin E3 ligase 
PARK6 PINK1 AR Mitochondrial kinase 
PARK7 DJ-1 AR Oxidative stress suppressor 
PARK8 LRRK2 AD Multi-domain protein kinase 
PARK9* ATP13A2 AR P-type ATPase 
PARK13* OMI/HTRA2 AD? Serine protease 
Table 1. The genes linked to familial Parkinson’s disease. Mutations in alpha-synuclein or LRRK2 
(also called Dardarin) cause autosomal dominant (AD) PD. Mutations in Parkin, PINK1 or DJ-1 cause 
autosomal recessive (AR) PD. * Mutations in two additional genes, ATP13A2 and OMI/HTRA2 have 
been tentatively associated with PD however, additional genetic evidence and replication are required. 
Note that additional loci were reported to be associated with PD or act as risk factors for PD 
development, but the evidence is currently weak (Gasser, 2009a; Hardy et al., 2009; Thomas and Beal, 
2007).  
 
1.4.1. The alpha-synuclein gene encodes a presynaptic terminal protein 
 
Before its identification as a PD-linked gene, alpha-synuclein (α-syn) was found to be 
the major component of Lewy Bodies, the cytoplasmic insoluble aggregates often 
observed in the surviving SN neurons in PD (Spillantini et al., 1997). The identification 
of α-syn mutations in families with PD came therefore as a big surprise. The most 
common α-syn mutations are missense substitutions Ala53Thr (A53T) 
(Polymeropoulos et al., 1997) and Ala30Pro (A30P) (Kruger et al., 1998), although 
additional mutations were found (Gasser, 2009). These mutations induce a L-DOPA 
responsive Parkinsonism with a relatively early onset for A53T and somewhat later 
onset for A30P. Autopsy of patients with α-syn mutations showed cell loss in the SN 
and accumulation of α-syn not only in SN neurons but also in other neuronal 
populations, showing that dominant PD with α-syn mutations overlaps (but is not 
identical) with typical sporadic late-onset PD (Gasser, 2009). Remarkably, 
multiplications of the wild-type α-syn sequence (duplications and triplications) also 
cause Parkinsonism with α-syn inclusions (and with or without dementia) in some 
families (Ibanez et al., 2004; Singleton et al., 2003). This result is important as it shows 
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that mere increase in α-syn levels is toxic for neurons. Interestingly, further support for 
this hypothesis comes from the observation that triplications of α-syn induce an early 
onset (35 years) and high prevalence of dementia, while duplications have a later onset 
(Chartier-Harlin et al., 2004). As mentioned above the pathology of α-syn duplications 
was also detected in the cortex (with regions of spongiosis and gliosis) and α-syn 
inclusions were found both in cortical neurons (mostly in the lower cortical layers) and 
glial cells.  These observations support the hypothesis that PD and DLB reflect the 
same pathogenic process (abnormal α-syn accumulation) with variable levels of 
severity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Structure of proteins linked to Parkinson’s disease. Alpha-synuclein and DJ-1 are small 
proteins that lack conserved domains. Alpha-helixes are displayed in light blue and beta-sheets are in 
dark blue. The most common mutations are displayed only for alpha-synuclein and DJ-1. The 3D 
structure of the DJ-1 homodimer is displayed on the right. The second view of the dimer (below) is 
rotated by 90° relative to the top view. The oxidative-stress reactive Cysteine 106 is displayed in yellow, 
while the Leucine 166, mutated in PD, is displayed in red. Parkin contains an ubiquitin like domain 
(UBL) located N-terminally, a central linker region and a C-terminal domain comprising two RING 
(really interesting new gene domain) finger domains and a IBR (in-between Ring domain) domain. 
PINK1 contains an N-terminal mitochondrial targeting sequence, a putative transmembrane domain and 
a Serine/threonine kinase domain. LRRK2 is a large protein that comprises an ANK (ankyrin repeat) 
domain, a LRR (leucine rich repeat) domain, a ROC (Ras of complex proteins) domain, a COR (C-
terminal of ROC), a WD40 (Trp-Asp 40 repeats) and a kinase domain. DJ-1 3D structure is from (Wilson 
et al., 2003).  
 
The α-syn protein is a natively unfolded presynaptic protein, that is believed to regulate 
synaptic vesicle recycling and neurotransmitter storage and compartmentalization, and 
during these processes it associates with vesicular and membranous structures 
(Abeliovich et al., 2000; Yavich et al., 2006; Yavich et al., 2004). The protein consists 
of an N-terminal amphipathic region, a middle region containing a non-amyloid-beta 
component domain and a C-terminal acidic region (Figure 6). Removal of amino acids 
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71-82 prevents aggregation of overexpressed α-syn, while overexpression of the non-
amyloid-beta domain alone led to increased aggregation and neurotoxicity in vivo 
(Periquet et al., 2007).The presence of the central hydrophobic non-amyloid-beta 
domain makes α-syn susceptible to aggregation. The A53T and A30P mutations 
increase the aggregation capacity of the protein (Dauer and Przedborski, 2003) and 
aggregated α-syn is the major component of LBs (Spillantini et al.,1997). 
Phosphorylation of α-syn at Ser129 was found to enhance its aggregation, and Ser129 
phosphorylated α-syn is a major component of LBs (Anderson et al., 2006; Smith et al., 
2005a). Truncated versions of α-syn have also been observed in LBs (Smith et al., 
2005) and overexpression of C-terminally truncated α-syn in mouse SN neurons 
strongly increased aggregate formation and led to dopaminergic cell loss in vivo 
(Tofaris et al., 2006).  
 
1.4.2. The LRRK2 gene encodes a multi-domain kinase  
 
The second major locus for an autosomal dominant PD harbors the very large LRRK2 
(Leucin-rich repeat kinase 2; also called Dardarin) gene consisting of 51 exons and 
coding for a 2527 amino acid kinase (Paisan-Ruiz et al., 2004; Zimprich et al., 2004). 
Mutations in LRRK2 cause typical L-DOPA responsive parkinsonism with relatively 
late-onset (late fifties) (Funayama et al., 2002) and remarkably, LRRK2-associated PD 
is much more prevalent than α-syn-associated PD; between 5-15% of dominant families 
carried mutations in LRRK2, as assessed across different populations (Berg et al., 2005) 
and a great majority of them carry the Gly2019Ser (G2019S) mutation (Gasser, 2009). 
The pathology of LRRK2-linked parkinsonism is unclear; post-mortem analysis of 
patients from one family found typical Lewy body disease, but also include variations 
like dementia with LBs (DLB, in which LBs are present in both the SN and the cortex), 
nigral degeneration without α-syn inclusions and rarely, PSP-like Tau aggregation 
(Ross et al., 2006; Zimprich et al., 2004). LRRK2 mutations might thus represent an 
upstream event in the cascade leading to neurodegeneration with different pathologies 
(Gasser, 2009).  
 
The LRRK2 gene encodes a multidomain protein that possesses a Rho/Ras-like GTPase 
domain, a protein kinase domain of the MAPKKK family, as well as WD40-repeat and 
a leucine-rich repeat domains (Figure 6). Close to the GTPase domain, an additional 
domain termed COR (for carboxy-terminal of Ras) has an unknown function. The 
LRRK2 protein was found in the Golgi apparatus, in lysosomes and synaptic vesicles 
but also associated with the outer mitochondrial membrane (Biskup et al., 2006; Galter 
et al., 2006; Higashi et al., 2007; Simon-Sanchez et al., 2006; Taymans et al., 2006). 
The G2019S mutation is associated with increased kinase activity (Gloeckner et al., 
2006; Smith et al., 2005b; West et al., 2007) and mutant G2019S LRRK2 is found in 
LBs (Zhu et al., 2006). LRRK2 kinase activity is required for neurotoxicity in vitro 
(Greggio et al., 2006) and G2019S LRRK2 induces a reduction in neurite growth and 
branching in vitro  and causes aggregate formation and SN degeneration when virally 
delivered into the rat brain (MacLeod et al., 2006). Thus, inhibition of kinase activity is 
a potential therapeutic strategy for LRRK2-linked Parkinsonism.  
 
The identification and genetic analysis of families with a recessive pattern of PD-
inheritance ultimately led to the isolation of 3 additional genes, which cause PD when 
inactivated: Parkin, Pink1 and DJ-1. Families carrying these autosomal recessive 
mutations experience an early onset of symptoms (second to fourth decade) and 
                                                                                                                      Introduction                                
24 
 
clinically show L-DOPA responsive Parkinsonism. Because of this rapid progression, 
recessive Parkinsonism is also called autosomal-recessive juvenile Parkinsonism (AR-
JP). Interestingly, although recessive Parkinsonism appears to progress rapidly, the 
development of dementia is slowed down in AR-JP patients compared to sporadic PD 
patients.  
 
1.4.3. The Parkin gene encodes an Ubiquitin E3 ligase 
 
The first gene linked to AR-JP to be identified was Parkin (Kitada et al., 1998) and 
Parkin mutations turned out to be a common cause of early onset AR-JP, estimated to 
account for 10 % of all cases (Periquet et al., 2003). Numerous mutations (missense 
mutations, nonsense mutations leading to premature termination of translation and 
exonic rearrangements [deletions, duplications, triplications]) were identified (Gasser, 
2009). Except for the earlier onset, the clinical picture of most Parkin-linked AR-JP is 
quite similar to that of sporadic disease. The neuropathology of Parkin-linked AJ-RP is 
still a matter of debate; although degeneration of SN neurons and gliosis in SN and the 
locus coeruleus have been documented, many studies found no LBs in the remaining 
SN neurons, suggesting that Parkin-linked AR-JP might differ in some ways from the 
typical idiopathic (sporadic) PD (Hardy et al., 2009). It is therefore possible that some 
Parkin mutations cause SN degeneration in the absence of α-syn aggregation.  
 
The Parkin gene encodes a 465 amino acid protein, containing an N-terminal ubiquitin 
like domain, a central linker domain and a C-terminal RING domain that consists of 2 
RING motifs separated by an in between RING domain (Figure 6). The protein is an 
ubiquitin E3 ligase and participates in the targeting of misfolded proteins to the 
proteasome for degradation (Shimura et al., 2000; Zhang et al., 2000). Parkin appears to 
be a multipurpose protein that confers neuroprotection against a wide range on insults 
(Feany and Pallanck, 2003). It activates the NFkB signaling (Henn et al., 2007) and can 
promote PI3k/Akt signaling by interacting with ubiquitin interacting motifs (UIM) of 
Eps15. Eps15 is an adaptor protein of Epidermal growth factor receptor (EGFR) 
endocytosis and trafficking and its ubiquitination by Parkin interferes with its 
interaction with EGFR, therefore delaying EGFR degradation and prolonging PI3K/Akt 
survival signaling (Fallon et al., 2006). Besides loss of ubiquitin E3 ligase activity, 
aggregation of Parkin represents another loss-of-function mechanism, relevant for 
sporadic PD: oxidative damage alters Parkin solubility and phosphorylation by the 
cyclin-dependent kinase 5 (Cdk5) renders Parkin insoluble (Avraham et al., 2007). 
Finally, accumulating evidence suggests that Parkin regulates mitochondria function 
via several mechanisms, including regulation of fusion/fission (Van Laar and Berman, 
2009), mitochondrial transport (Yang et al., 2005a) and remarkably, targeting of 
dysfunctional mitochondria for autophagic degradation (Narendra et al., 2008).  
 
1.4.4. The PINK1 gene encodes a mitochondrial kinase 
 
Inactivating mutations in the PINK1 (phosphatase and tensin (PTEN) homolog-induced 
putative kinase 1) gene were identified in 2004 (Valente et al., 2004). The PINK1-
linked AR-JP displays an early onset (32-48 years), a slow progression and is L-DOPA 
responsive (Valente et al., 2004). Patients with PINK1 mutations appear to have a 
higher prevalence of psychiatric disturbances (anxiety and depression), which are only 
rarely observed in patients carrying Parkin mutations (Ephraty et al., 2007). 
Interestingly, a compound heterozygous PINK1 mutation was found in a sporadic PD 
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patient with late onset (in the seventh decade and negative family history for movement 
disorders) and rapid progression (Gelmetti et al., 2008), suggesting that decreased 
PINK1 function induces a slowly progressive SN degeneration that leads to overt 
symptoms only during aging. No post-mortem examination of PD patients carrying 
PINK1 mutations has been reported so far.  
 
The PINK1 protein has 581 amino acids and consists of an N-terminal mitochondrial 
targeting sequence and a highly conserved protein kinase domain similar to 
Serine/Threonine kinases of the Ca2+ Calmodulin family (Figure 6). Its localization is 
suggested to be mitochondrial (Gandhi et al., 2006) and its functions are only beginning 
to be elucidated. PD-associated PINK1 mutations lead to altered kinase activity and 
mitochondrial dysfunction (Beilina et al., 2005; Leutenegger et al., 2006) and 
truncation of the C-terminal domain of PINK1 reduces its serine/threonine kinase 
activity (Sim et al., 2006). While in vitro overexpression of PINK1 protects cells from 
staurosporine-induced cell death, overexpression of PD-associated PINK1 mutants 
(Petit et al., 2005) or PINK1 knockdown (Deng et al., 2005) fail to confer protection. 
Evidence also accumulates for a role of PINK1 in mitochondria dynamics, including 
fusion/fission (Van Laar and Berman, 2009) or transport (Weihofen et al., 2009), 
although its relevance to SN neurodegeneration remains to be demonstrated.  
 
1.5. DJ-1 is an oxidative stress suppressor 
 
The third locus for AR-JP was found to be mutated in a Dutch family (van Duijn et al., 
2001) and the gene was identified as the oncogene DJ-1 (Bonifati et al., 2003; 
Nagakubo et al., 1997). Indeed, increased levels of DJ-1 were found in several cancers 
(Kim et al., 2005a). A number of DJ-1 loss-of-function mutations, including 
homozygous and heterozygous point mutations, truncations and exonic deletions, were 
identified in PD patients (Bonifati, 2007). The clinical features of DJ-1-linked AR-JP 
appear to be similar to that of Parkin and PINK1-cases, and thus similar to that of 
sporadic PD, but this is based on a rather small number of identified patients. 
Interestingly, in one recessive DJ-1 family, early-onset Parkinsonism, dementia and 
ALS were found to co-exist, suggesting that although rare, DJ-1 mutations might cause 
an extended clinical phenotype (Annesi et al., 2005). Remarkably, a family with AR-JP 
was identified and found to harbor heterozygous loss-of-function mutations in both DJ-
1 and PINK1, suggesting that interaction between hypomorphic alleles of DJ-1 and 
PINK1 cause Parkinsonism (Tang et al., 2006). To date, no pathological examination 
was reported for AR-JP patients carrying DJ-1 mutations. Interestingly, while in 
sporadic PD patients DJ-1 is rarely present in Lewy bodies (Neumann et al., 2004; 
Rizzu et al., 2004), it was found to co-localize with α-syn-immunoreactive glial 
inclusions in MSA and with a subset of pathological Tau inclusions in a number of 
neurodegenerative tauopathies, including AD (Neumann et al., 2004; Rizzu et al., 
2004). Remarkably, increased levels of DJ-1 were found in the frontal cortex of PD and 
AD patients compared to healthy controls (Choi et al., 2006).  
 
DJ-1 shows a ubiquitous expression but is strongly expressed in testis, brain and kidney 
and has been implicated in processes as diverse as male fertility, oncogenesis and 
neuroprotection (Nagakubo et al., 1997; Olzmann et al., 2004). In the brain, DJ-1 is 
expressed in both neurons and glia; moreover, its presence in areas involved in motor 
control like basal ganglia, thalamus, substantia nigra, red nucleus or the motor cortex 
(Bandopadhyay et al., 2005; Kotaria et al., 2005; Shang et al., 2004) suggests that loss 
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of DJ-1 might underlie the motor dysfunction seen in PD. At the subcellular level, DJ-1 
is mostly localized to the cytosol, but appears to translocate to mitochondria under 
oxidative stress conditions (Blackinton et al., 2005; Canet-Aviles et al., 2004) and can 
enter the nucleus following serum stimulation or after prolonged cellular stress 
(Nagakubo et al., 1997; Zhang et al., 2005). Several in vitro studies suggested that DJ-1 
is a versatile co-transcriptional regulator; once in the nucleus DJ-1 co-transcriptionally 
promotes expression of genes involved in oxidative stress response, anti-apoptosis, or 
genes regulating male fertility (Kahle et al., 2009b). Remarkably, DJ-1 was also 
detected in the extracellular space and its levels in plasma of PD patients correlated 
with disease progression (Waragai et al., 2007), suggesting that DJ-1 could serve as a 
biomarker for PD.  
 
1.5.1. Structural biology of DJ-1 
 
The DJ-1 gene encodes a 189 amino acid protein that comprises eleven β-strands (β1-
β11) and eight alpha-helixes (αA-αH) (Honbou et al., 2003; Tao and Tong, 2003; 
Wilson et al., 2003) (Figure 6). The central β-sheet of the structure contains 7 strands 
(β1,2,5,6,7,10,11). Outside of this central β-sheet, strands β3 and β4 form a β-hairpin 
that is involved in DJ-1 dimerization and strands β8 and β9 form a β-α-β motif together 
with the helix αF. Most of the α-helices flank the two faces of the β-sheet, with the 
exception of helix αH, situated at the extreme C-terminus, which also mediates DJ-1 
dimerization (Wilson et al., 2003). DJ-1 tertiary structure (Figure 6) has some 
resemblance with proteins from a superfamily that includes the archetypical bacterial 
ThiJ and PfpI proteases. However, in contrast to these proteins, DJ-1 appears to have 
no protease activity, because its catalytic triad is distorted and its putative active site is 
occluded by the additional C-terminal helix (αH) (Martinat et al., 2004; Wilson et al., 
2003). The disease causing DJ-1 mutant Leu166Pro disrupts the αG helix and leads to 
overall destabilization of DJ-1 and subsequent degradation by the ubiquitin-proteasome 
system (Gorner et al., 2004; Macedo et al., 2003; Miller et al., 2003; Moore et al., 
2003; Olzmann et al., 2004).  
 
1.5.2. DJ-1 controls the oxidative stress response 
 
Research in the last 10 years identified several cellular functions for DJ-1 (Figure 7). 
Converging in vitro and in vivo evidence indicates that DJ-1 is a potent oxidative stress 
suppressor. In cultured cells exposed to oxidative stress conditions, the isoelectric point 
(pI) of DJ-1 shows an acidic mobility shift (Kahle et al., 2009b) and further studies 
revealed that the cysteine residue Cys106, which is conserved among all members of 
the DJ-1/ThiJ/PfpI superfamily, is the key target of oxidative modifications (Kinumi et 
al., 2004). Mild oxidation of this cysteine residue leads to a sulfinic acid derivative (-
SO2-), while further oxidation leads to sulfonic acid (-SO3-) derivatives (Figure 7); 
remarkably, mild oxidation to sulfinic acid promotes chaperone activity of DJ-1 
towards α-syn, both in vitro (Shendelman et al., 2004; Zhou and Freed, 2005; Zhou et 
al., 2006) and in animal models (Shendelman et al., 2004), while further oxidation 
impairs this activity (Zhou et al., 2006). It has thus been proposed that the sulfinic acid-
containing DJ-1 is the active form of DJ-1 (Blackinton et al., 2009b; Canet-Aviles et 
al., 2004).  
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Figure 7. Putative functions for DJ-1. Converging in vitro and in vivo evidence suggests that DJ-1 is a 
potent oxidative stress suppressor. The protein can translocate to the mitochondria under conditions of 
oxidative stress; there, DJ-1 interacts with the resident chaperone mHsp70, and apparently with PINK1. 
Oxidative stress induces DJ-1 oxidation at the Cys106 residue, leading to a sulfinic acid derivative (DJ-
1-CH2SO2- in green) that has enhanced chaperone activity towards misfolded α-syn; the Cys106 primed 
sulfinic derivative might also interact with Parkin. Further oxidation to a sulfonic derivative (DJ-1-CH2-
SO3- in red) inhibits DJ-1 function. Mutation of Cysteine106 inhibits the anti-oxidant and pro-survival 
activities of DJ-1 in vivo. Moreover, DJ-1 might inhibit the tumor suppressor PTEN, thereby promoting 
PI3K/Akt signaling. It can also negatively regulate JNK signaling, either by sequestering the ASK-1 
activator Daxx in the nucleus, or by preventing MEKK1 from activating JNK, in UV-stressed cells. DJ-1 
can also bind mRNA and influence translation of several targets. Finally, DJ-1 could act as co-
transcriptional regulator to induce anti-oxidative genes (it promotes Nrf2 transcriptional activity by 
inhibiting its negative regulator Keap1) or survival genes (by promoting the activity of p54nrb or by 
inhibiting the pro-apoptotic transcription factor pyrimidine tract-binding associated splicing factor, PSF) 
or by binding to p53 to inhibit its pro-apoptotic targets. SUMOylation of DJ-1 is required for 
translocation to the nucleus. In vivo confirmation is required for most of the above proposed functions of 
DJ-1.  
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Interestingly, the amount of DJ-1 oxidized at Cys106 increases steadily with age both 
in humans and in mice (Meulener et al., 2006). Further in vivo support for a crucial role 
of Cys106 in DJ-1 anti-oxidative function comes from Drosophila studies; flies lacking 
DJ-1B, one of the two Drosophila homologues, are more sensitive to oxidative stress 
caused by PD-associated toxins like paraquat or rotenone or following H2O2 treatment; 
this sensitivity can be complemented by overexpression of wild-type fly DJ-1B and DJ-
1A, suggesting that the two Drosophila DJ-1 genes have a similar anti-oxidant function 
(Menzies et al., 2005; Meulener et al., 2006). Importantly, overexpression of DJ-1B in 
which Cys106 was mutated to alanine failed to rescue the increased lethality of DJ-1B 
null flies towards paraquat, providing direct in vivo evidence for a crucial role of 
Cys106 in DJ-1 function (Meulener et al., 2006). Besides Cys106 oxidation, DJ-1 was 
also found to be carbonylated and methionine-oxidized in the frontal cortex of PD and 
AD patients relative to controls (Choi et al., 2006), suggesting that DJ-1 may undergo 
extensive oxidative modifications in age-related neurodegenerative disorders. Another 
evidence for involvement of DJ-1 in oxidative stress control comes from in vitro 
studies where DJ-1 was identified as a co-transcriptional regulator that promotes 
expression of oxidative-stress responsive genes. DJ-1 was found to stabilize the 
Nuclear factor erythroid 2-related factor (Nrf2), a master regulator of antioxidant 
transcriptional responses by preventing it from interacting with Keap1. Keap1 
negatively regulates Nrf2, by promoting its ubiquitination and subsequent degradation; 
stable Nrf2 activates numerous anti-oxidant genes, thereby exerting pro-survival effects 
(Clements et al., 2006).  
 
1.5.3. Mitochondrial functions of DJ-1 
 
Under conditions of oxidative stress, DJ-1 translocates to the mitochondria, and this 
event depends on an intact Cys106, suggesting that Cys106-oxidized DJ-1 might 
undergo mitochondrial re-localization (Canet-aviles et al., 2004). Moreover, wild-type 
DJ-1 protects cells against mitochondrial toxins in vitro and an engineered construct 
targeting DJ-1 to mitochondria led to significantly enhanced protection against H2O2 
stress (Junn et al., 2009). Although DJ-1 did not rescue the mitochondrial morphology 
alterations resulting from impaired PINK1 and Parkin function in vitro (Exner et al., 
2007; Yang et al., 2006) recent evidence suggests that DJ-1 influences mitochondrial 
morphology (Blackinton et al., 2009b), probably via a PINK1/Parkin-independent 
mechanism (Dodson and Guo, 2007).  
 
1.5.4. DJ-1 and signal transduction 
 
The human DJ-1 gene was initially identified and cloned in the laboratory of Hiroyoshi 
Ariga (Nagakubo et al, 1997). DJ-1 expression was induced by serum addition to 
starved HeLa cells, and the protein accumulated both in the cytoplasm and the nucleus. 
Moreover, DJ-1 displayed transforming activity when transfected into NIH3T3 cells; 
interestingly, when DJ-1 and c-myc or H-Ras were co-transfected, a synergistic effect 
was observed and the efficacy of DJ-1/H-ras was three times higher as the efficacy of 
H-Ras/c-myc (Nagakubo et al, 1997). These studies suggested that DJ-1 might display 
pro-mitogenic properties and might interact with Ras-signaling, at least in oncogenic 
conditions. A second study found that DJ-1 negatively regulates the PTEN 
phosphatase, the major negative regulator of the PI3K/Akt signaling. Increased DJ-
1levels in breast cancer patients inversely correlated with PTEN immunoreactivity and 
DJ-1 interacted genetically with PTEN, both in Drosophila and in vitro (Kim et al., 
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2005a). Furthermore, DJ-1was found to modulate the activation status of the Akt kinase 
in CO7, A549 and NIH-3T3 cells (Kim et al., 2005), suggesting that altered PTEN 
activity might impact on the PI3K/Akt-dependent neuron survival in PD associated 
with DJ-1 mutations. Another possible DJ-1 interactor was suggested to be the tumor 
suppressor p53. DJ-1 knockdown in zebrafish increased the levels of p53 and its target 
gene, the apoptotic mediator Bax (Bretaud et al., 2007). In addition, DJ-1 interacts 
physically with p53 in several cell types and inhibits its transcriptional activity; 
consequently, DJ-1 overexpression leads to reduced Bax levels (Fan et al., 2008b).  
 
DJ-1 was also found to inhibit JNK signaling in vitro. Via its nuclear interaction with 
the death protein Daxx in SH-SY5Y dopaminergic neuroblastoma cells, DJ-1 
sequesters Daxx in the nucleus thus preventing it from gaining access to the cytoplasm. 
Cytoplasmic Daxx has pro-apoptotic effects - it binds to the intracellular domain of the 
Fas receptor and also directly activates the Apoptosis signal-regulating kinase 1 
(ASK1), an upstream activator of the pro-apoptotic JNK signaling (Junn et al., 2005). 
In a second study, DJ-1 suppressed the ultraviolet-induced JNK activation in HEK293 
cells by direct interaction the JNK upstream activator MEKK1 in the cytoplasm and 
inhibition of its nuclear translocation (Mo et al., 2008). Thus, DJ-1 might function as a 
negative regulator of JNK signaling.  
 
1.6. Mechanisms of substantia nigra cell death in Parkinson’s disease 
 
1.6.1. Animal models of Parkinson’s disease  
 
To understand the mechanisms underlying the demise of SN neurons and the 
occurrence of behavioral deficits in PD, the generation of animal models displaying 
select genetic and environmental alterations appears to be a necessary step. Following 
identification of familial PD-associated genes, numerous animal models have been 
developed in which individual or combined genetic and toxicologic manipulations have 
been performed. Ranging from Caenorhabditis elegans to non-human primates and 
with a strong focus on rodents, the current pre-clinical research in PD reached a 
considerable size. In the mouse, overexpression of α-syn using several promoters leads 
to protein accumulation in SN neurons and to behavioral alterations; similarly, deletion 
of the recessive genes DJ-1, PINK1 or Parkin-1 leads to mild physiological (altered 
dopamine dynamics) and behavioral (hypoactivity) impairments (Levine et al., 2004; 
Moore and Dawson, 2008). However, these models generally fail to display adult-onset 
and progressive DA degeneration, suggesting that they might be useful in modeling 
some aspects of PD (Moore and Dawson, 2008). In contrast, flies overexpressing 
mutant human α-syn (Feany and Bender, 2000) or lacking PINK1 or Parkin (Clark et 
al., 2006; Park et al., 2006; Yang et al., 2006) function show loss of DA neurons and 
motor deficits and might be used to understand certain aspects of DA neuron function 
and maintenance. A second, independent approach was intoxication with DA-specific 
toxins, including 1–methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP), 6-
hydroxydopamine (6-OHDA), rotenone or paraquat, following observations that 
exposure to these agents causes Parkinsonism in humans (Dauer and Przedborski, 
2003). Interestingly, when DJ-1, Pink1 or Parkin knockout mice and Drosophila 
mutants are exposed to these DA toxins, they display more severe DA deficits and 
generally display loss of SN neurons, suggesting that additional factors (environmental 
and/or genetic) might be involved in the development of recessive PD (Dauer and 
Przedborski, 2003; Moore and Dawson, 2008; Terzioglu and Galter, 2008; Whitworth 
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and Pallanck, 2008). These results raise the possibility that the phenotypic differences 
observed between patients carrying PD mutations and rodents might be due to the 
presence of additional (yet unidentified) modifiers, both genetic and environmental. 
Therefore, the search for these interactors in rodents might improve our understanding 
of the human nigral pathology. Integration of mechanistic information from cellular and 
animal models, in vitro studies and clinical studies (imaging, clinical trials, biopsies or 
post-mortem studies) revealed several common denominators that appear to be 
associated with DA neuron dysfunction and cell death (Figure 8).  
 
 
 
 
Figure 8. Mechanisms of cell death in Parkinson’s disease. Several pathogenic processes emerged as 
putative contributors to neurodegeneration in PD. 1. Alpha-synuclein and protein aggregation. 
Aggregated alpha-synuclein (α-syn) forms oligomers (protofibrils) and insoluble aggregates that can 
impair the proteasome. In addition, insoluble α-syn aggregates can recruit other functional proteins 
leading to their inactivation. Aggregate formation and protofibrils impair the mitochondrial function 
leading to generation of ROS; 2. Recessive-PD genes and mitochondrial impairment. Loss of DJ-1, 
PINK1 or Parkin activity decreases mitochondrial function and contributes to ROS formation. While DJ-
1 translocates to mitochondria in response to oxidative stress, PINK1 and Parkin act in a similar (yet 
poorly defined) pathway to regulate mitochondrial maintenance and possibly morphology. Loss of DJ-1 
function might decrease the activity of mitochondrial complexes I-IV and thereby lead to decreased ATP 
production; 3. Mitochondrial toxins. Inhibition of mitochondrial activity by complex I-IV inhibitors (like 
rotenone or MPTP) or by oxidative stress generators (rotenone) is sufficient to cause Parkinsonism, 
further implicating the mitochondria in PD pathogenesis; 4. Altered dopamine release and storage. Loss 
of DJ-1, PINK1 or Parkin function decreases the amount of released dopamine, although it is not clear 
whether these proteins act directly at the pre-synaptic terminal or the decreased ATP production and 
mitochondrial impairment they generate are responsible for altered neurotransmission. Furthermore, α-
syn protofibrils might directly act on synaptic vesicles to induce leakage of dopamine into the cytosol. 
Free dopamine has a high propensity to auto-oxidize, generating ROS; oxidized dopamine can covalently 
bind Parkin and inactivate its function in the ubiquitin-proteasome pathway; 5. Decreased pro-survival 
signaling might accelerate cell dysfunction and cell death. Loss of trophic signaling might further 
accelerate cellular stress and dysfunction, however, the evidence so far is incomplete. Moreover, failure 
to induce oxidative-stress responsive genes might increase ROS levels and lead to oxidation of numerous 
proteins or to DNA oxidative damage. Chronic oxidative stress might lead to induction of pro-apoptotic 
proteins, including the mitochondrial pore-forming protein BAX or receptors for apoptotic ligands, like 
TNF; 6. Aging is the major risk factor to develop PD and age-related changes in cellular signaling and 
function of mitochondria or maintenance of DNA function are believed to act as a substrate on which 
PD-linked mutations act to eventually mediate neuron demise. Therefore, it is possible that an interaction 
between age-related molecular changes and sub-lethal cellular alterations due to gene mutation and/or 
environmental stress leads to overt neurodegeneration; 7. Activation of pro-apoptotic pathways occurs 
through at least 2 pathways. Dysfunctional mitochondria lead to the opening of the mitochondrial 
permeability transition pore (mediated by BAX and BAK, and promoted by tBid - after priming by 
caspase-3) leading to cytochrome c release and formation of the apoptosome complex (intrinsic apoptotic 
pathway). Up-regulation of cell-death receptors (like TNFRs) and release of pro-apoptotic cytokines by 
microglia might activate the extrinsic apoptotic pathway, leading to caspase-8 and then caspase-3 
activation. While active caspases can be held in check by IAP proteins (like XIAP), SMAC and 
OMI/HTRA2 released by the mitochondria might release this inhibition. Active effector caspase-3 and 
caspase-7 (not shown) use their cysteine-aspartyl protease activity to cleave at specific aspartic residues 
of numerous substrates, resulting in the apoptotic process. A third apoptotic pathway was proposed to 
originate downstream of ER stress (through activation of caspase-12), although its physiological and 
pathological roles are unclear yet (Szegezdi et al., 2003). Please note that the pathological relevance of 
several putative cell-death mechanisms presented here, issued from in vitro studies awaits confirmation 
in animal models. Adapted from (Abou-Sleiman et al., 2006; Bredesen et al., 2006; Dauer and 
Przedborski, 2003; Dawson and Dawson, 2003; Mattson and Magnus, 2006; Moore et al., 2005a; 
Thomas and Beal, 2007; Vila and Przedborski, 2004).  
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Although the pathological mechanisms that lead to SN degeneration might be multiple 
(Figure 8), several pathways are considered to be central to DA dysfunction and cell 
death in a variety of systems: protein aggregation leading to proteasomal impairment 
(Figure 8.1), mitochondrial dysfunction (Figure 8.2, also caused by specific DA-toxins; 
Figure 8.3), altered dopamine release (Figure 8.4) that could all converge to generate 
oxidative stress. Aging (Figure 8.6) is known to impact on cell viability, but the 
mechanisms behind are unclear; decreased trophic signaling (Figure 8.5) might be a 
contributing factor, although its relevance is poorly understood. Finally, all these 
dysfunctions seem to converge on highly-conserved cell death pathways (Figure 8.7). 
Oxidative stress emerges as the major link between proteasomal impairment and 
mitochondrial dysfunction since inhibition of either the ubiquitin proteasome system 
(UPS) or mitochondrial respiration complexes generated ROS, a major determinant of 
DA dysfunction (Abou-Sleiman et al., 2006). Below, I will describe in more detail the 
protein aggregation stress/proteasomal impairment pathway and the mitochondrial 
dysfunction pathway, for which extensive evidence suggests a critical role in PD 
pathology.  
 
1.6.2. Proteostasis defects impair neuron viability  
 
The presence of α-syn in Lewy Bodies and the identification of point mutations and 
multiplications of the α-syn gene in PD argue for a critical role of protein aggregation 
in PD pathogenesis. In addition, Parkin is an ubiquitin E3 ligase that functions in the 
ubiquitin-proteasome system (UPS) to eliminate misfolded proteins (Shimura et al., 
2000). Accumulation and aggregation of mutant α-syn has also been observed in vitro 
and in animal models (Dauer and Przedborski, 2004). The physiological function of α-
syn has not been elucidated, but α-syn is associated with synaptic vesicles (Outeiro and 
Lindquist, 2003). Mutant α-syn has a high propensity to aggregate and forms oligomers 
termed protofibrils; several oligomers assemble into amyloid fibrils like those seen in 
LBs (Dauer and Przedborski, 2003). It is currently believed that α-syn protofibrils are 
actually the toxic species, and that fibrils might exert protective effects by sequestering 
toxic oligomers; in Drosophila, overexpression of the chaperone heat-shock protein 70 
(HSP70) rescues DA degeneration caused by mutant α-syn overexpression, without 
reducing aggregate load (Auluck et al., 2002). In addition, α-syn aggregation might be a 
protective response to α-syn toxicity, at least in Drosophila (Chen and Feany, 2005) 
Protofibrils were also detected in brains from PD patients with triplication of the α-syn 
gene (Miller et al., 2004). Moreover, protofibrils were found to permeabilize dopamine-
containing synaptic vesicles (Volles et al., 2001) freeing dopamine into the cytosol. 
Free dopamine is highly prone to auto-oxidation and generates reactive oxygen species 
(ROS); dopamine is also oxidized to dopamine quinones, which were shown to 
stabilize the α-syn protofibrils (Conway et al., 2001) and dopamine can covalently link 
and inactivate Parkin (LaVoie et al., 2005). Since Parkin functions as an ubiquitin E3 
ligase, its inactivation might further impair the proteasome, and thus impair cell 
viability.   
 
1.6.3. Dysfunctional mitochondria might promote neurodegeneration  
 
Recent evidence that recessive PD-associated DJ-1, PINK1 and Parkin have important 
roles in mitochondria identifies the mitochondria as important players in PD pathology. 
DJ-1 translocates to the mitochondria under stress conditions (Canet-aviles et al, 
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(Gandhi et al., 2006)2004), and PINK1 (Gandhi et al., 2006) possesses a N-terminal 
mitochondrial targeting sequence and localizes to mitochondria (Valente et al., 2004); 
within mitochondria,  PINK1 might localize to the outer and inner mitochondrial 
membranes (Gandhi et al.,2006; Silvestri et al.,2005). Parkin localizes mainly in the 
cytosol and the ER; however, a pool of Parkin associates with the cytoplasmic surface 
of the outer mitochondrial membrane (Darios et al., 2003).  
 
Perhaps the most solid indication that PINK1 and Parkin play important functions in 
mitochondria comes from Drosophila studies. PINK1 and Parkin mutant flies display 
mitochondrial dysfunction, followed by loss of DA neurons and defects in flight 
muscles (Greene et al., 2003; Pesah et al., 2004); remarkably, Parkin overexpression 
rescued the Pink1 mutant phenotypes, but not vice versa, providing the first in vivo 
evidence that the two genes function in the same pathway to regulate mitochondrial 
function (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). Interestingly, although 
DJ-1 was found to interact physically with PINK1 (Tang et al., 2006) and, in conditions 
of oxidative stress with Parkin (Moore et al., 2005b), DJ-1 overexpression did not 
rescue the PINK1 and Parkin Drosophila phenotypes  (Dodson and Guo, 2007), 
suggesting that DJ-1 might function in a different pathway. Moreover, PD patients with 
PINK1 (Hoepken et al., 2007) or Parkin (Muftuoglu et al., 2004) mutations display 
reduced activities of mitochondrial respiratory chain complexes, further suggesting a 
crucial role of both PINK1 and Parkin in mitochondria. A possible common function 
might be the regulation of mitochondrial fission and fusion machineries or 
mitochondrial transport (Van Laar and Berman, 2009) although its relevance to SN 
neuron survival remains to be demonstrated. DJ-1 deficient flies do not display loss of 
DA neurons and such severe mitochondrial defects but are selectively more sensitive to 
mitochondrial toxins like MPTP and rotenone (Menzies et al., 2005; Meulener et al., 
2006). 
 
There is evidence for a strong correlation between mitochondria and the UPS. 
Mitochondria generates ATP, required in UPS function;  inhibition of complex I with 
rotenone led to 20 % ATP depletion and to increased ROS and to a marked reduction of 
proteasome activity (Shamoto-Nagai et al., 2003). Proteasomal inhibition renders 
neurons more sensitive to the mitochondrial inhibitor MPTP (Sullivan et al., 2004) and 
defects in mitochondrial complex I result in decreased proteasome activity (Hoglinger 
et al., 2003). Overexpression of aggregate-prone α-syn in mice leads to mitochondrial 
degeneration and to increased cellular sensitivity towards mitochondrial complex I 
inhibitors; conversely, loss of α-syn function promotes resistance to mitochondrial 
inhibitors (Abou-Sleiman et al., 2006; Martin et al., 2006). The best example of a tight 
connection between mitochondria and the UPS is perhaps the observation that chronic 
rotenone exposure in rats results in the formation of Lewy body-like aggregates in 
addition to Parkinsonism (Betarbet et al., 2000).  
 
1.6.4. Current challenges in Parkinson’s disease research  
 
The analysis of the newly generated PD cellular and animal models allowed us to gain 
the first insights into the development of PD. While protein aggregation, mitochondrial 
dysfunction and the generation of ROS emerged as major cell-death promoters and 
provided some mechanistic answers, even more questions emerged. Why does 
neurodegeneration in PD affect SN neurons with relative specificity? Why do 
monogenic forms of PD manifest clinically only after several decades, although the 
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underlying mutations are inborn? What is the connection between sporadic and genetic 
forms of PD and what is the role of aging as modulator of neurodegeneration? In 
addition, are the genes linked to monogenic PD playing a prominent role in sporadic 
PD, and are they acting in a common pathogenic pathway? What are the environmental 
factors that accelerate or delay the onset of neurodegenerative disease? Can we identify 
specific biomarkers to follow disease progression and most importantly, will we be able 
to prevent, stop or cure neurodegenerative disease in the (near) future? These are the 
major challenges in neurodegeneration research for the next decades and we can only 
hope that some of these questions and challenges will receive appropriate answers and 
practical solutions.  
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B. Neurotrophic factors. BDNF/TrkB and GDNF/Ret 
signaling 
               
1.7. Neurotrophic factors are potent survival agents for neurons 
 
Neurotrophic factors (NFs) are secreted proteins that regulate development, 
maintenance, function and plasticity in the vertebrate nervous system. Although they 
were originally identified as neuronal survival factors, NFs control many other neuronal 
processes ranging from cell proliferation, differentiation to axon guidance, dendritic 
growth and modulation of synaptic formation and function (Chao, 2003; Davies, 2003). 
Several groups of closely related molecules make up the neurotrophic factors family: 
the neurotrophins, the GDNF family ligands and the neurotrophic cytokines (Table 2). 
 
Family Neurotrophic factor Preferred receptor (s) 
Neurotrophins Nerve Growth factor (NGF) TrkA, p75NTR 
Brain-derived neurotrophic factor (BDNF) TrkB, p75NTR 
Neurotrophin-3 (NT-3) TrkC, p75NTR 
Neurotrophin 4 (NT-4) TrkB, p75NTR 
GDNF family  Glial cell line-derived neurotrophic factor (GDNF) GFRα1/Ret, GFRα1/NCAM 
of ligands Neurturin (NRTN) GFRα2/Ret, GFRα2/NCAM 
Artemin (ARTN) GFRα3/Ret 
Persephin (PSPN) GFRα4/Ret
Neurotrophic  Ciliary neurotrophic factor (CNTF) gp130, LIFRβ, CNTFRα 
cytokines Leukaemia-inhibitory factor (LIF) gp130, LIFRβ 
Cardiotrophin-1 (CT-1) gp130, LIFRβ 
Oncostatin-M (OSM) gp130, OSMRβ 
Interleukin-6 (IL-6) gp130, IL6Rα 
 
Table 2. Families of neurotrophic factors. Neurotrophins constitute the first identified and best 
understood family of neurotrophic factors; all neurotrophins signal via Trk or p75NTR receptors. The 
GDNF family ligands (GFLs) use GFRα co-receptors and induce activation of the Ret RTK, as their 
common signaling receptor. Some GFLs can also signal independently of Ret, via GFRα/NCAM. 
Neurotrophic cytokines signal via gp130 but also have additional co-receptors. In contrast to Trk and 
Ret, the gp130 receptor has no intrinsic kinase activity and is tyrosine-phosphorylated by other cellular 
kinases.  
 
The first family of neurotrophic factors to be identified were the neurotrophins, the best 
understood trophic factors in the nervous system to date (Figure 9). Pioneering work by 
Rita Levi-Montalcini and Victor Hamburger resulted in the identification of the first 
neurotrophic factor, the nerve growth factor (NGF). NGF was purified based on its 
ability to support survival of sympathetic and sensory spinal neurons in culture (Chao, 
2009; Levi-Montalcini, 1987; Shooter, 2001). Subsequent studies demonstrated that 
NGF is synthesized and secreted by sympathetic and sensory target organs; once 
secreted, NGF is taken up by sympathetic and sensory nerve terminals via receptor-
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mediated endocytosis and is transported through axons to neuronal cell bodies, where it 
mediates neuron survival and differentiation (Korsching, 1993). The second 
neurotrophin to be characterized, brain-derived neurotrophic factor (BDNF) was 
purified from pig brain as a survival factor for several neuronal populations not 
responsive to NGF (Barde et al., 1982). Two other neurotrophins NT-3 and NT-4 (also 
known as NT-5) were characterized in mammals (Figure 9). Neurotrophins are all 
derived from a common ancestral gene, are similar in sequence, and were therefore 
collectively named neurotrophins (Hallbook, 1999). Two additional neurotrophins, NT-
6 and NT-7 are only found in fish and probably do not have mammalian orthologs 
(Huang and Reichardt, 2001). 
 
1.7.1. The neurotrophic factor hypothesis and extensions 
 
In the developing nervous system, natural cell death eliminates 50 % or more of 
neuronal populations. The central concept of the neurotrophic factor hypothesis is that 
limited amounts of secreted neurotrophic factors by the targets of innervation regulate 
the number of surviving neurons to match with the size of the target area (Purves et al., 
1988; Thoenen et al., 1987). According to this hypothesis, developing neurons engage 
in a competition for trophic factors and neurons deprived of trophic support die by 
apoptosis. The foundations of this theory were the early observations that neurons are 
able to grow toward increasing concentrations of NGF (Gundersen and Barrett, 1979, 
1980).While this model explains some aspects of neuronal development and the critical 
roles of NFs in regulation of neuron survival and function, the neurotrophic factor 
hypothesis cannot incorporate the diversity of functions and roles for NFs anymore. 
Most importantly, the diversity of functions regulated by neurotrophic factors 
(including neuron migration, neurite outgrowth, axon guidance, dendritic 
morphogenesis or synaptic plasticity) suggests that considerable revisions are required 
for the neurotrophic factor hypothesis to account for the extreme versatility (and 
beauty) of NF action. 
 
 1.8. Neurotrophins signal via Trk receptors and p75NTR.  
 
The identification of the first neurotrophin NGF opened the era of cellular and 
molecular studies of neurotrophin action in the nervous system. NGF was shown to be 
internalized at nerve terminals and to be transported along axons in small vesicles by an 
energy- and microtubule dependent process; it was also found to exert both local and 
nuclear actions which regulate respectively growth cone motility and gene expression 
(Segal, 2003). However, these effects could not be explained molecularly, in the 
absence of an NGF receptor. 
 
Initial efforts to identify a neurotrophin receptor resulted in the discovery of the low 
affinity receptor for NGF, p75NTR, which was subsequently shown to bind all 
neurotrophins (Rodriguez-Tebar et al., 1991). p75NTR is a distant member of the 
tumor necrosis factor receptor family and contains a “death” domain in its intracellular 
part (Chao, 1994). While for many years the roles of p75NTR remained unclear, the 
emerging picture of p75NTR is that of a versatile regulator of several crucial biological 
processes, including neuronal survival and apoptosis (see below).   
 
An important advance in the neurotrophin field was facilitated by new discoveries from 
cancer research. Gene transfer assays from carcinoma cells led to the isolation of a 
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novel oncogene which represented a fusion between the nonmuscle tropomyosin gene 
and the transmembrane and cytoplasmic domains of a novel tyrosine kinase. The proto-
oncogene was named tropomyosin-related kinase (trk) and is now commonly referred 
to as trkA (Barbacid et al., 1991; Huang and Reichardt, 2003); trkB and trkC genes 
were subsequently identified because of their high sequence homology with trkA. The 
breakthrough in neurotrophin biology came in 1991 with the identification of Trk 
receptors as specific binding partners for neurotrophins. TrkA was identified as a 
receptor for NGF (Kaplan et al., 1991; Klein et al., 1991a), TrkB was found to bind 
BDNF and NT-4 (Klein et al., 1991b) and TrkC binds NT-3 (Lamballe et al., 1991). 
NT-3 can also bind less efficiently to TrkA and TrkB (Huang and Reichardt, 2003). 
Endogenous signaling by Trk receptors was shown to mediate neuron survival and/or 
differentiation during development in all neuronal populations examined to date; in 
addition to neuronal survival, growth and differentiation, neurotrophin-induced Trk 
receptor activation was shown to mediate axonal and dendritic remodeling; assembly 
and remodeling of the cytoskeleton; membrane trafficking and fusion; and synapse 
formation, function and plasticity (Arancio and Chao, 2007; Chao, 2003; Reichardt, 
2006; Zweifel et al., 2005).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Neurotrophins signal via Trk receptors and p75NTR. NGF binds to TrkA, BDNF and NT4 
to TrkB and NT3 binds TrkC. Neurotrophins also bind the low affinity receptor p75NTR (on the right). 
Trk receptors contain three leucine rich repeats (LRR1-3) in the extracellular part flanked by two cystein-
rich domains (C1,C2) and two immunoglobulin G (IgG1, IgG2) domains for ligand binding; they also 
contain a catalytic tyrosine kinase  (TK) domain in the intracellular part. p75NTR has four cysteine-rich 
repeats (C1-C4) in the extracellular part and a death domain (DD) in the intracellular part.  
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Given the high structural similarity of neurotrophins and their receptors, it does not 
come as a surprise that the signaling pathways they initiate share many common 
features. In the following, I will describe the signaling mediated by BDNF.  
 
1.8.1. BDNF signaling via TrkB 
 
Since neurotrophins were initially believed to act specifically in the nervous system, it 
came as a surprise that their receptors TrkA-C also possess tyrosine kinase activity, 
similar to the receptors for mitogenic growth factors like plateled derived growth factor 
(PDGF) or epidermal growth factor (EGF). Neurotrophins function generally as non-
covalently associated homodimers (Figure 9). The most important site at which Trk 
receptors interact with neurotrophins has been localized to the most proximal 
immunoglobulin (IgG2 in Figure 9) domain of each receptor (Ultsch et al., 1999). 
Ligand engagement of Trk receptors results in phosphorylation of their cytoplasmic 
tyrosine residues. 10 conserved tyrosine residues are contained within the cytoplasmic 
part of Trk receptors, while three residues (Y670, Y674, and Y675) are found in the 
auto-regulatory loop of the kinase domain that regulates kinase activation. 
Phosphorylation of these 3 tyrosines further activates the receptor (Inagaki et al., 1995). 
Phosphorylation of the other tyrosine residues creates docking sites for adapter proteins 
containing phosphotyrosine-binding (PTB) and Src-homology-2 (SH-2) motifs 
(Pawson and Nash, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. BDNF signaling via TrkB and p75NTR. BDNF can promote survival of different neuronal 
population by engaging TrkB and/or p75NTR receptors. Binding of BDNF homodimer to TrkB induces 
TrkB dimerization and trans-autophosphorylation on conserved tyrosine residues in the cytoplasmic part 
of the receptor. Phosphorylated tyrosines serve as docking sites for the Shc adaptor that recruits further 
adaptors to activate the Ras/ERK signaling and PI3K/Akt signaling pathways. BDNF binding to p75NTR 
leads to recruitment of TRAF6 and activation of NFkB pro-survival pathway; in contrast, activation of 
JNK signaling mediates pro-apoptotic effects. It appears that p75NTR binding to mature neurotrophins 
promote survival, while binding to proneurotrophins induces apoptosis (Lu et al., 2005). 
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These adapter proteins couple Trk receptors to intracellular signaling pathways, which 
include the Ras/ERK (extracellular signal–regulated kinase) protein kinase pathway, 
the phosphatidylinositol-3-kinase (PI-3 kinase)/Akt kinase pathway, and phospholipase 
C (PLC)-γ 1 (Chao, 2003; Kaplan and Miller, 2000). The PI3K/Akt and Ras/ERK 
signaling pathways promote survival in a broad variety of neuronal cell types (see 
below).  
 
1.8.2. BDNF signaling via p75NTR  
 
p75NTR emerged as a versatile regulator of neurotrophin signals. The traditional view 
that p75NTR is a pro-survival molecule was shattered in 2001 when p75NTR was 
found to bind with high affinity to proneurotrophins and to mediate apoptosis (Lee et 
al., 2001). Proneurotrophins are the uncleaved precursors of neurotrophins, and are 
processes by extracellular proteases (like matrix metalloproteinase 7, MMP7) to release 
the mature neurotrophins. proBDNF was subsequently shown to induce apoptosis by 
activating p75NTR (Teng et al., 2005) and mounting evidence suggests that  binding of 
p75NTR to mature neurotrophins promotes cell survival, while binding to 
proneurotrophins promotes apoptosis (Lu et al., 2005). p75NTR does not contain any 
catalytic domain in its intracellular side (Figure 10) but can recruit several adaptors to 
signal; thus, its pro-survival activities are mediated by the association with TRAF6 and 
subsequent activation of NFkB signaling, while its pro-apoptotic activities require 
cdc42-activation of ASK1, the initiator of JNK signaling (Figure 10). p75NTR also has 
modulatory roles on neurotrophin signaling (Bibel et al., 1999), and forms the signal-
transmitting subunit of the Nogo receptor complex (NogoR, Lingo, p75NTR) that 
inhibits axon growth downstream of inhibitory glycoproteins like Nogo (Lu et al., 
2005; Reichardt, 2006).  
 
1.9. GDNF family ligands signal via the Ret receptor tyrosine kinase 
 
The Glial cell line-derived neurotrophic factor (GDNF) is the prototypical member of 
the GDNF family ligands (GFLs) that also includes Neurturin (NRTN), Artemin 
(ARTN) and Persephin (PSPN). GFLs play important roles during the development and 
function of the nervous system. GDNF was isolated in 1993 as a growth factor 
promoting survival of embryonic midbrain dopaminergic neurons (Lin et al., 1993) 
(Lin et al, 1993). This discovery raised hopes that GDNF might be used as therapeutic 
agent to treat PD. Subsequently, GDNF was found to be a potent survival factor for 
motoneurons (Henderson et al., 1994) (Arenas et al., 1995) and central noradrenergic 
neurons (Arenas et al., 1995). In addition to its pro-survival roles in neurons, GDNF 
and the related GFLs have additional functions in neuronal proliferation, migration, 
differentiation and synapse formation (Paratcha and Ledda, 2008) and also play crucial 
roles as morphogenetic factors in kidney and spermatogonia development (Airaksinen 
and Saarma, 2002).  
 
Unlike other ligands for receptor tyrosine kinases, GDNF and the related GFLs require 
a glycosylphosphatidylinositol (GPI)-anchored cell surface protein as a ligand binding 
component (Figure 11). This co-receptor was termed GDNF family receptor (GFRα); 
four GFRα co-receptors for GFLs exist: GFRα1 (binds GDNF), GFRα2 (binds NRTN), 
GFRα3 (binds ARTN) and GFRα4 (binds PSPN). GFLs, acting as homo-dimers bind 
the GFRα co-receptor to form a high-affinity complex. Subsequently, the GFL- GFRα 
complex recruits the Ret receptor tyrosine kinase, the signaling receptor of the GDNF 
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family ligands. Thus, Ret RTK is the common signal transducer of all GDNF family 
ligands. To date, Ret is the only known RTK that does not bind directly to its ligands 
but requires co-receptors for activation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. GDNF family ligands (GFLs) signal via the Ret receptor tyrosine kinase. Soluble GFLs, 
acting as homodimers, recruit one of the GFRα1-4 co-receptors. Each GFL has a high affinity for its 
corresponding GFRα (as indicated), while weaker binding is known to occur between GDNF and 
GFRα2, ARTN and GFRα1 or NRTN and GFRα4 (not shown). The GFL/GFRα complex then recruits 
the Ret receptor tyrosine kinase and induces its dimerization and trans-autophosphorylation, leading to 
activation of the kinase activity of Ret.  
 
Ret was initially identified as a novel rearranged transforming gene in NIH3T3 cells 
transfected with human lymphoma DNA (Takahashi et al., 1985). This transforming 
gene resulted from the fusion between two unlinked DNA fragments which occurred 
during the transfection process. The resulting chimeric gene encodes a fusion protein 
comprising an N-terminal domain with a dimerizing motif fused to a carboxy-terminal 
tyrosine kinase domain (Takahashi and Cooper, 1987). Subsequently, the name Ret 
(Rearranged during transfection) was retained to designate the gene encoding the 
receptor tyrosine kinase that contains the kinase domain of the fused oncogene 
(Iwamoto et al., 1993; Takahashi et al., 1988). The human Ret gene lies on the 
chromosome band 10q11.2 and comprises 21 exons. Homologues of Ret have been 
identified in higher and lower vertebrates, including the fruit fly Drosophila 
melanogaster (Hahn and Bishop, 2001).  To date, more than 100 mutations were 
described in the Ret gene; mutations leading to constitutive activation of Ret cause 
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cancer, while loss of Ret function causes severe enteric denervation leading to 
megacolon (Hirschsprung’s disease [HSCR]). Germline mutations leading to 
constitutive activity of Ret have been identified in three related dominantly inherited 
cancer syndromes: multiple endocrine neoplasia type 2A (MEN2A), 2B (MEN2B) and 
familial medullary thyroid carcinoma (FMTC) (Santoro et al., 2004). Substitution of 
cysteine Cys634 (located in the cysteine-rich domain at the boundary with the trans-
membrane domain) with other amino acids accounts for 85 % of all MEN2A cases and 
leads to the formation of a covalent link between two mutated RetMEN2A receptors (thus 
generating a dimer that displays constitutive kinase activity) (Figure 12). Substitution 
of methionine 918 from the kinase domain of Ret with threonine (M918T) accounts for 
95 % of all MEN2B cases and leads to a constitutively active, monomeric, RetMEN2B 
receptor (Santoro et al., 2004) (Figure 12).  
 
1.9.1. Structural aspects of Ret signaling  
 
According to the classical RTK paradigm, GFLs –acting as homo-dimers– recruit 2 
molecules of GFRα and subsequently 2 molecules of Ret receptor (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Activation of Ret signaling by GDNF and constitutively active Ret forms. The formation 
of the GDNF/GFRα1 complex recruits two molecules of Ret receptor and promotes Ret 
autophoshorylation on conserved tyrosine residues. A similar situation is seen when the other GFLs 
recruit their GFRα2-4 co-receptors to activate Ret (not shown). Mutations in the extracellular cysteine-
rich domain (C634R) lead to constitutive-active dimeric Ret receptor. Mutations in the tyrosine kinase 
domain (M955T) also have the same effect, but the receptor remains monomeric. The C634R and 
M955T mutations are the most common Ret mutations, which cause multiple endocrine neoplasia (MEN 
type 2A and 2B, respectively) in humans.  
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Formation of the GDNF/GFRα/Ret tripartite complex promotes RET dimerization and 
receptor trans-autophosphorylation within the RET intracellular kinase domain leading 
to recruitement of phospho-tyrosine-binding adaptors that lead to activation of 
downstream signaling cascades (Figure 12).  
 
Ret is a single-pass transmembrane protein (Figure 13). In its extracellular part, Ret 
contains four cadherin-like repeats, a calcium-binding site and a cysteine-rich domain. 
The intracellular portion features a typical tyrosine kinase domain. Based on their 
homology to cadherins, the cadherin-like domains might mediate cell adhesion; 
however, their function is currently ill defined (Anders et al., 2001). The calcium 
binding site, located between the second and third cadherin-like domain, is needed for 
the folding, secretion and the signal transduction capacity of Ret (Nozaki et al., 1998; 
van Weering et al., 1998). The cysteine-rich domain contains 16 cysteine residues and 
was suggested to play a role in receptor folding and binding to the GFRα co-receptor 
(Runeberg-Roos and Saarma, 2007). Mutations in this domain can lead to protein 
misfolding; intriguingly, mutation of the same cysteine residues can lead to either 
protein degradation (loss-of-function) or constitutive activation (gain-of-function) and 
families with both endocrine neoplasia type 2 (MEN2) tumors and HSCR have been 
identified (Dvorakova et al., 2005).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Structural organization of the Ret receptor tyrosine kinase. In the extracellular part, four 
cadherin-like domains and a Ca2+ binding site might regulate the adhesive properties of Ret. A cysteine-
rich domain is responsible for receptor folding and binding to the ligand/co-receptor complex. In the 
intracellular part, the tyrosine kinase domain, consisting of two parts, mediates auto-phosphorylation 
following receptor activation. Three Ret isoforms are known to exist, which differ in their C-terminal 
sequence, however only two (Ret9 and Ret51) are conserved over a broad range of species.  
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The transmembrane (TM) domain of Ret is no longer seen as a passive link between the 
extracellular ligand-sensing part and the intracellular signal-transducing part and recent 
evidence suggests that it plays an active role during the activation of Ret.  The TM 
domain may drive self-association of two Ret molecules, which may facilitate complex 
formation during GFL/GFRα/Ret signal transduction (Runeberg-Roos and Saarma, 
2007); consequently, mutations in three residues within the TM domain were found in 
patients with MEN2 tumors (Kjaer et al., 2006). Below the TM domain, the 
juxtamembrane domain of Ret might be involved in the control of cell migration via 
cAMP/PKA-dependent phosphorylation of its serine 696 (Asai et al., 2006; Fukuda et 
al., 2002).  
 
A central function of the Ret RTK is carried out by its intracellular kinase domain 
(KD). The KD of Ret is homologous to that of other tyrosine kinases (e.g. FGFR-1, 
VGFR-2) (Tuccinardi et al., 2007). Ligand-induced Ret dimerization juxtaposes the 
two catalytic domains, thereby allowing mutual trans-phosphorylation; 
phosphotyrosines propagate the signal by recruiting intracellular proteins. Studies using 
phosphopeptide mapping and mass spectrometry identified 12 autophosphorylation 
sites in the Ret RTK (Kawamoto et al., 2004; Liu et al., 1996) but only five tyrosines 
have been found phosphorylated in intact cells so far. Three of these tyrosine are found 
within the KD (Y905, Y981, Y1015), and two in the C-terminal tail (Y1062, Y1096); 
of note, the Y1096 residue is only found in the Ret51 isoform (Coulpier et al., 2002; 
Salvatore et al., 2001). Tyrosine 905 is the autocatalytic residue, whose 
phosphorylation generates a conformational change that allows kinase activation; the 
other four phosphorylated tyrosines serve as docking sites for adaptor proteins, with 
tyrosine 1062 playing the most prominent role in activation of Ret-downstream 
signaling. Indeed, mutation of Y1062 in mice induces severe defects in the 
development of the enteric nervous system and nephrogenesis, which are seen in Ret 
null mice (Jijiwa et al., 2004); in addition Y1062 is required for the transforming 
activity of oncogenic Ret (Degl'Innocenti et al., 2004).  
 
Three C-terminal Ret splicing variants are generated by alternative splicing of the 3’ 
region: Ret9, Ret43 and Ret51. Ret9 and Ret51 are conserved over a broad range of 
species and consist of 1072 and 1114 amino acids, respectively (Kodama et al., 2005). 
Ret9 and Ret51 differ in the amino acid sequences immediately downstream from 
Y1062: following glycine 1063, Ret9 has 9 extra residues, while Ret51 has 51 amino 
acids, which include the phosphorylation site Y1096. Therefore, the two Ret isoforms 
were suspected to display differences in signaling capacities; indeed, Vassilis Pachnis 
and colleagues generated mice that only expressed Ret9 or Ret51. Mice lacking Ret9 
had a phenotype similar to Ret null mice, albeit milder, while lack of Ret51 did not 
significantly affect development (Schuchardt et al., 1994). Moreover, only Ret9 is able 
to rescue the phenotype of Ret-null mice (de Graaff et al., 2001; Srinivas et al., 1999). 
Thus, Ret9 but not Ret51 appears to be crucial for normal development. Additional 
differences between the two isoforms were also noticed in the regulation of mouse 
inner-medullary collecting duct cell survival, which is promoted by Ret51 but not Ret9 
(Lee et al., 2002) and in oncogenic transformation where Ret51 mutants are more active 
than the corresponding Ret9 mutants (Iwashita et al., 1999). Therefore, it appears that 
Ret51 and Ret9 isoforms fulfill different functions.  
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1.9.2. Dynamic aspects of Ret signaling 
 
Binding of adaptors to phosphorylated Y1062 triggers activation of several signaling 
pathways; binding of Shc and FRS2 proteins mediates recruitment of the Grb2-SOS 
complex that leads to Ras/ERK stimulation, while binding of the Grb2-GAB1/2 
complex leads to stimulation of the PI3K/Akt pathway. Binding of DOK4 and DOK5 
adaptors is implicated in ERK stimulation, while binding of ShcC and IRS is required 
to trigger PI3K/Akt activation (Santoro et al., 2004). Moreover, binding of the DOK1 
adaptor to phosphorylated Y1062 leads to c-Jun N-terminal kinase (JNK) activation via 
recruitment of the NCK adaptor (Manie et al., 2001). The extraordinary versatility of 
Y1062, which can recruit this diversity of adaptors, suggests a model whereby 
competition between various signaling intermediates for binding to the phosphorylated 
Y1062 docking site allows switching between different biological responses to Ret-
dependent signaling. Several factors have been suggested to contribute to substrate 
selection including the subcellular localization of Ret, its turn-over rate, the proportion 
of activated Ret in the cell or the genetic background (Runeberg-Roos and Saarma, 
2007). Ret signaling activates two major signaling cascades that promote cell survival 
in diverse neuronal and non-neuronal populations and which are described in more 
detail below: the Ras/ERK (MAPK) and the PI3K/Akt pathways (Figure 14).   
 
1.9.2.1. Ret signaling via the Ras/ERK pathway 
 
The Mitogen-activated protein kinase (MAPK) pathway is an evolutionary conserved 
pathway that regulates diverse cellular programs including embryogenesis, 
proliferation, cell size, differentiation or survival, based on cues derived from the cell 
surface and the metabolic state of the cell (Dhillon et al., 2007). Tyrosine-
phosphorylated Ret recruits the PTB-containing adaptor protein Shc; after Shc 
phosphorylation, a complex containing the SH2/SH3-containing adaptor protein Grb2 
and the SH3-binding Ras exchange factor SOS is recruited (Figure 14). SOS is a 
guanine nucleotide exchange factor (GEF) for the small GTP-ase protein Ras (Figure 
14). Membrane associated Ras (via C-terminal farnesylation) interacts with SOS, which 
facilitates exchange of GDP with GTP and thereby maintains Ras in an active state. 
GTP-bound Ras has an increased affinity for several substrates, including PI3K (see 
below) or the kinase Raf. Binding of active Ras to the  Ser/Thr kinase Raf (also termed 
mitogen activated protein kinase kinase kinase [MAPKKK]) allows Raf activation by 
other proteins (following repeated cycles of phosphorylation and de-phosphorylation 
and protein-protein interactions that are incompletely understood) (McKay and 
Morrison, 2007). Once activated, the Raf kinase phosphorylates and activates the 
MEK1/2 (MAPKK) kinase. Activated MEK1/2 then phosphorylates the extracellular 
signal-regulated kinases (ERKs, also called MAPKs) on both serine and tyrosine 
residues in their activation loop. Once phosphorylated, ERK1/2 (also known as 
p44MAPK and p42MAPK) use their Ser/Thr activity to phosphorylate several cytoplasmic 
(e.g. the RSK protein) or nuclear targets. Thus, translocation of activated ERK1/2 to the 
nucleus leads to activation of several transcription factors, including c-Fos and c-Myc, 
p53, SMAD1-4, Sap-1a, SP1 and Elk-1 to control cell motility, proliferation, 
differentiation or survival downstream of Ras (Dhillon et al., 2007; Raman et al., 2007; 
Turjanski et al., 2007). A prominent pro-survival effect of ERK1/2 is via 
phosphorylation and activation of RSK (p90 ribosomal S6 kinase) kinases, which then 
phsophorylate the transcription factor CREB (cAMP responsive  
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Figure 14. Ret signaling via the Ras/MAPK and PI3K/Akt pathways. Activation of Ret by the 
GDNF/GFRα1 complex (or by the other GFLs/GFRα 2-4 complexes) leads to recruitment of molecular 
adaptors that bind to phosphorylated tyrosine residues. These adaptors recruit additional transducers; Shc 
recruits Grb2 and then SOS which induces Ras activation; GTP-bound Ras promotes activation of Raf 
and signaling via the ERK/MAPK pathway. In contrast to this transient mode of Ras activation, signaling 
via FRS2/Grb2/Crk/Rap1 provides a more sustained activation of MAPK. Phosphorylated ERK 
translocates to the nucleus where it phosphorylates additional targets (not shown), but can also 
phosphorylate RSK1 to activate CREB; in addition, it phosphorylates the pro-caspase 9 thereby 
inhibiting caspase-3 activation. Binding of the Shc/Grb2/Gab1 complex to phosphorylated tyrosine 
residues induces recruitment and activation of the PI3K, which phosphorylates phosphoinositides from 
the plasma membrane and provides a docking site for the protein kinase B (Akt). Membrane-associated 
Akt is then phosphorylated by PDK1 and the mTOR/Rictor/SIN1/mLST8 complex. Activated Akt 
promotes survival by modifying several downstream targets, via both non-transcriptional and 
transcriptional effects (see text for details). Note that Ras can also directly bind and activate the PI3K 
(not shown).   
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element binding protein) to induce activation of pro-survival genes (Reichardt, 2006). 
ERK were also shown to directly phosphorylate pro-caspase 9, thereby blocking 
caspase-3 activation (Allan et al., 2003). Besides ERK1/2, three other MAPKs (ERK3, 
ERK5 and ERK7) have a distinct regulation and are less well understood (Raman et al, 
2007). Increasing evidence suggests a tight temporal and spatial dynamics of Ras/ERK 
signaling. Thus, while transiently activated Ras at the nerve terminal mediates growth 
cone motility or exocytosis, retrograde transport of the ligand/receptor complex via 
endosomes (i.e. signaling endosomes) in the cell soma induces a prolonged activation 
of ERK signaling, that is required for neuronal survival or differentiation (Huang and 
Reichardt, 2003; Reichardt, 2006). Moreover, while transient Ras activation requires 
the Shc/Grb2/SOS adaptors, prolonged Ras/ERK activation appears to require a 
different set of adaptors. The FRS2 adaptor is phosphorylated by active RTK receptors 
and recruits the adaptor proteins Grb2 and Crk and the tyrosine kinase Src; Crk then 
binds the Rap1 exchange factor C3G, which then activates the Raf kinase and thus 
ERK signaling (Huang and Reichardt, 2003; Reichardt, 2006; Figure 14).  
 
1.9.2.2. Ret signaling via the PI3K/Akt pathway 
 
The phosphoinositide-3-kinase (PI3K) is a major regulator of cell survival in diverse 
cellular populations (Manning and Cantley, 2007). Three families of PI3K are known 
to date, the predominant form of PI3K existing as a heterodimer of a catalytic subunit 
(molecular weight 110 kDa) and a regulatory subunit (molecular weight 85 kDa 
(Fruman et al., 1998). Two major modes for PI3K activation are known; PI3K can be 
directly activated by GTP-bound Ras or it can be recruited via the formation of the 
Grb2/Gab1/2 complex (Figure 14). Once activated, PI3K phosphorylates the D-3 
position of the inositol ring of phosphoinositides (PI) in the membrane and generates 
PI(3,4)P2 and PI(3,4,5)P3 (PI di-and tri-phosphates); phosphoinositides generated by 
PI3K participate in the activation of the protein kinase B (also called Akt), which has 
emerged as a critical regulator of signaling and one of the most versatile and important 
protein in physiology and disease (Manning and Cantley, 2007).  
 
Phosphatidylinositides generated following PI3K action recruit both Akt and the 
phosphatidylinositide-dependent protein kinase (PDK-1) at the plasma membrane. Both 
Akt and PDK-1 possess pleckstrin homology (PH) domains, which exhibit high affinity 
for PI(3,4)P2 and PI(3,4,5)P3. Membrane-associated Akt is then phosphorylated by 
PDK1 at Threonine 308 (Kim and Chung, 2002); following this initial phosphorylation, 
a second kinase phosphorylates Akt at Serine 473; this unknown enzyme, long termed 
PDK2 is now identified as mTOR kinase complex 2 (mTORC2) (Guertin and Sabatini, 
2007; Manning and Cantley, 2007). Phosphorylation at both Thr308 and Ser473 are 
required to fully activate the Akt kinase. PTEN is the major negative regulator of the 
PI3K (Salmena et al., 2008). It is best knwon for its lipid-phosphatase activity and 
PI(3,4,5)P3 is one of its substrates; PI(3,4,5)P3 de-phosphorylation reduces the 
activation of the PI3K: Besides its lipid-phosphatase activity, it also posesses a protein-
phosphatase activity (its substrates known so far are phosphorylated IRS-1(Weng et al., 
2001), Shc (Gu et al., 1999) and can mediate protein-protein interactions to control 
genome maintenance, cell cycle progression or apoptosis, independently of PI3K/Akt 
(Salmena et al., 2008).   
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Activated Akt phosphorylates numerous downstream targets (Figure 14). Most relevant 
for survival are its effects on pro-apoptotic proteins, both at transcriptional and non-
transcriptional level. Thus, Akt can directly phosphorylate Bad, a Bcl-2 family member 
that promotes apoptosis through sequestration of Bcl-XL, which otherwise would 
inhibit Bax, a pro-apoptotic protein. Following Bad phosphorylation by Akt, 14-3-3 
proteins bind to phosphorylated Bad, thereby preventing Bad from promoting apoptosis 
(Kim and Chung, 2002). A second target of Akt is the pro-caspase 9; during apoptosis, 
release of cytochrome c from mitochondria promotes the formation of the apoptosome 
(cytochrome c and APAF-1) followed by activation of procaspase-9 and subsequent 
activation of effector caspases (3 and 7; (Bredesen et al., 2006). Direct phosphorylation 
of pro-caspase 9 by Akt renders it resistant to processing and activation (Kim and 
Chung, 2002). Elevated levels of GSK-3β promote apoptosis, and GSK-3β 
phosphorylation by Akt inhibits its pro-apoptotic action. Akt also promotes NFkB 
signaling by phosphorylating the inhibitory binding partner of NFkB, IkB (Brunet et 
al., 2001); NFkB is released from the inhibition and translocates to the nucleus to 
promote transcription of pro-survival genes (Bcl-2 family members and IAPs). The 
Forkhead family of transcription factors (FKHRLs) induce expression of several pro-
apoptotic genes, and FOXO (the Forkhead box transcription factor, class O) has 
prominent pro-apoptotic roles (Brunet et al., 2001); following direct phosphorylation 
by Akt, FOXO associate with 14-3-3 proteins which promote its export from the 
nucleus and sequestration in the cytoplasm (Brunet et al., 2001).  
 
1.9.3. GDNF and Ret can signal independently of each other 
 
1.9.3.1. Ret-independent GDNF signaling 
 
The expression of GFRα proteins in several regions devoid of Ret and the ability of 
GDNF to trigger downstream signaling in Ret-deficient cell lines and primary neurons 
suggested the existence of a Ret-independent GDNF/GFRα1 signaling. Carlos Ibanez 
and collaborators identified the Neural Cell Adhesion Molecule (NCAM) as a novel 
GDNF receptor in neurons (Paratcha et al., 2003). The association between GFRα1 and 
NCAM generated a high-affinity receptor for GDNF and following ligand-induced 
NCAM activation, the cytoplasmic Src-like kinase Fyn and the focal adhesion kinase 
(FAK) were activated (Figure 15); remarkably while presence of GDNF promoted cell 
adhesion via Fyn and FAK, GFRα1 inhibited NCAM-mediated cell-adhesion in the 
absence of GDNF (Paratcha et al., 2003). GDNF binding to NCAM stimulates 
Schwann cell migration and axonal growth in hippocampal and cortical neurons in a 
Ret-independent manner. Mice that lack GFRα1 only in cells that do not express Ret 
(but still express GFRα1 in cells expressing Ret) were recently found to display loss of 
parvalbumin-immunoreactive cortical interneurons, further confirming the in vivo 
relevance of Ret-independent GDNF signaling (Canty et al., 2009). In a recent study, 
Carlos Ibanez and collaborators found a novel function for GDNF/GFRα1complex, 
working independently of Ret but requiring NCAM function, as mediators of 
hippocampal and cortical synapse formation. While all cell adhesion systems studied so 
far involve the direct interaction between membrane-bound partners in trans, GFRα1-
mediated cell adhesion is dependent on the presence of its ligand, GDNF; GDNF 
promotes the cell-adhesion capacity of GFRα1 during trans-homophilic cell adhesion 
that occurs during synapse formation (Ledda et al., 2007) providing the first example of 
a ligand-induced cell adhesion system. Finally, GDNF/GFRα1signaling promotes 
differentiation and migration of cortical GABAergic neurons, in a Ret- and NCAM-
                                                                                                                      Introduction                                
48 
 
independent manner (Pozas and Ibanez, 2005), suggesting that existence of additional 
transmembrane receptors for GDNF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. GDNF and Ret can signal independently of each other. Left: In cells lacking Ret but 
expressing GFRα1-2, GDNF (or ARTN, not shown) can recruit the neural cell adhesion molecule 
(NCAM) and induce activation of Fyn and FAK kinases. Note that the existence of alternative GDNF 
receptors has been postulated. Right: In superior cervical ganglion (SCG) cells, activation of TrkA by 
NGF leads to phosphorylation and activation of Ret signaling, probably in an indirect manner (e.g. by 
recruitment of a downstream kinase).  
 
1.9.3.2. GFL-independent Ret signaling 
 
Although embryonic sympathetic superior cervical ganglion (SCG) neurons require 
NGF/TrkA signaling for survival, postnatal SCGs do not depend on NGF/TrkA 
survival signals anymore.  In postnatal SCGs, NGF-acting via TrkA- promotes 
phosphorylation of the Ret RTK in a GFL-independent manner thus inducing enhanced 
Ret-mediated growth, metabolism and gene expression (Tsui-Pierchala et al., 2002). 
Although the exact mechanism of activation is unclear, TrkA does not directly 
associate with Ret, suggesting that TrkA indirectly promotes Ret phosphorylation.  
 
1.9.4. Study of Ret signaling in Drosophila melanogaster 
 
The Drosophila compound eye is composed of an orderly array of about 800 identical 
units called ommatidia. Each ommatidium contains eight photoreceptors neurons called 
R1-R8, four non-neuronal lens secreting cone cells, seven pigment cells and a sensory 
bristle (Figure 16). Each photoreceptor extends a single rhabdomere, the light sensing 
organelle containing the visual pigment Rhodopsin. R1-R6 photoreceptors have larger 
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rhabdomeres and are called “outer photorecetors”, as they surround the smaller “inner” 
rhabdomeres of R7 and R8 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Drosophila eye development and constitutively active Ret signaling. (A) Picture of a 
control Drosophila eye, showing the regular organization of ommatidia. On the right side, histological 
analysis of retinal organization reveals the presence of an organized array of photoreceptor neurons, 
within each ommatidium (yellow circle). Each ommatidium contains 8 photoreceptors, however, only 7 
photoreceptors are in the same plane. Each photoreceptor contains a cell body (white) and a light-sensing 
organelle (rhabdomere, in blue). (B) Expression of a constitutively active version of Ret during 
development (targeted specifically to photoreceptor neurons using a photoreceptor-specific driver GMR; 
i.e. GMR-dRetMEN2B) leads to severe defects in eye development. The eye has a rough appearance, is 
disorganized and has a reduced size. Histologically, the ommatidia are also affected; the size of 
individual photoreceptors is increased and the photoreceptors display positioning defects. In addition, 
non-neuronal cells display defects in development, and ommatidia are often fused together (white line) 
and abnormally positioned with respect to each other. (C) During eye development, the formation of the 
morphogenetic furrow (MF, white arrow) initiates the cell differentiation process in the embryonic retina. 
The MF proceeds from right to left (yellow arrow) and leaves behind differentiated cells. In red, Elav 
labeling reveals photoreceptor neurons; in blue, atonal staining reveals non-differentiated cells, while the 
green signal marks the armadillo-labeled cells that stopped proliferating within the MF. (D) After 
passage of the MF, the first cell to differentiate is the photoreceptor 8 (R8), followed by R2 and R5, then 
by R3 and R4, followed by R1 and R6. The last photoreceptor to differentiate is R7.  After differentiation 
of R cells, non-neuronal cells are recruited in each ommatidium and at the end, all excess non-
differentiated cells are eliminated by apoptosis.  
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During embryonic development, the eye forms from a monolayer epithelium called eye 
imaginal disc. In early stages, all undifferentiated cells divide synchronously. The 
formation of an apical constriction in the disc epithelium (called morphogenetic furrow, 
MF; Figure 16C) marks the beginning of the differentiation process (in the middle of 
the third instar larval stage). The MF generated a wave of differentiation signals that 
traverses the entire antennal disc, from posterior to anterior (Figure 16C). While 
anterior to MF, all cells divide synchronously, in MF division stops; after MF passage, 
cells undergo two further synchronous cell divisions (Heberlein and Moses, 1995). The 
first photoreceptor neuron to be specified after MF passage is R8. Every newly 
specified R8 cell behaves as a founder cell for one ommatidium by initiating the 
sequential recruitment of other cells (Figure 16D) (Frankfort and Mardon, 2002). 
Shortly after, R2 and R5 are added, followed by R3 and R4 to form a five-cell pre-
cluster. At this stage, all remaining undifferentiated cells undergo a coordinated S-
phase and then undergo mitosis in a process called “second mitotic wave”, resulting in 
R1 and R6 recruitment. R7 is the last photoreceptor neuron to be specified (Voas and 
Rebay, 2004). After all photoreceptors have been specified, non-neuronal cells join the 
ommatidium. First, four lens-secreting cone cells, then primary, secondary and tertiary 
pigment cells (1’, 2’, 3’ PCs); finally, unused cells are eliminated by apoptosis, at 
which point the fly has completed about half of the pupal development (Voas and 
Rebay, 2004). 
 
Recruitment of cells in the developing retina involves a stereotyped sequence of 
inductive interactions between extensive networks of intercellular signaling events. 
Thus, a complex interplay between RTK (Sevenless and EGF), Notch, Hedgehog, 
Wingless and Decapentaplegic (Dpp/TGF-beta) pathways is required for many aspects 
of retinal development, including eye fate specification, regulation of proliferative vs. 
differentiative choice points and establishment of distinct cell fates (Baker, 2007; 
Hsiung and Moses, 2002).       
 
The recruitment of the last R7 photoreceptor is dependent on the function of the 
sevenless (sev) gene, which encodes the sevenless receptor tyrosine kinase (sevRTK). 
The sevRTK binds to its specific ligand, bride-of-sevenless (Boss). Out of five equal-
potential cells that express sev, only one finds itself in direct contact with the Boss-
expressing R8 cell and goes on to become the R7 cell. The other four cells of this 
equivalence group, which do not contact the R8 cell, instead adopt the fate of non-
neuronal lens-secreting cone cells. Ectopic expression of Boss or expression of 
activated forms of SevRTK and its downstream effectors leads to transformation of 
cone cells into R7 cells; activation of the Ras/Raf/MEK/ERK signaling cascade 
downstream of sevRTK leads to very similar phenotypes, suggesting that the 
Ras/Raf/MEK/ERK signaling cassette mediates the differentiation of the R7 cell 
induced by the Boss-sevRTK interaction (Karim et al., 1996). 
 
The extremely stereotyped control of Drosophila eye development and the evolutionary 
conservation of the genes controlling retinal development made Drosophila an 
organism of choice in the study of signal transduction. Numerous major player in RTK 
signaling have been initially identified and characterized in the fly, including the 
members of the Ras/MAPK signaling. Although Ret is expressed in Drosophila in 
tissues that roughly parallel their mammalian counterparts (Hahn and Bishop, 2001) its 
expression in the developing eye is weak (Read et al., 2005) and its ligand in 
Drosophila is currently unknown. To gain insight into the molecular interactions 
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involved in Ret signaling, the laboratory of Ross Cagan at the Mount Sinai School of 
Medicine in New York generated flies carrying MEN2 versions of Ret. In these flies, 
expression of constitutively active Ret (RetMEN2A or RetMEN2B) is targeted to the 
developing photoreceptors (using the photoreceptor specific driver glass multimer 
reporter, GMR). RetMEN2 flies, in contrast to controls, display a rough eye phenotype 
due to excessive cell proliferation, differentiation defects, defective patterning of 
ommatidia and inter-ommatidial spaces and excessive apoptosis (Figure 16B). The use 
of RetMEN2 flies allows the identification of specific suppressors (mutations that rescue 
the RetMEN2 eye phenotype and restore eye development) or enhancers (mutations that 
further worsen the RetMEN2 phenotype). In the first screen using RetMEN2 flies, Ross 
Cagan and colleagues found that most of the identified interactors are known 
interactors of mammalian WT Ret; in addition, they performed a drug screen and 
discovered a potent RetMEN2 suppressor (ZD6474) that is now in clinical development 
(phase III) and holds promise as the first chemotherapeutic approved for MEN2 (Vidal 
et al., 2005). Thus, the use of RetMEN2 flies allows identification of novel Ret 
interactors.  
 
1.10. Functions of BDNF and GDNF in substantia nigra neurons  
 
Following differentiation into DA neurons and establishment of connections with the 
target area, the striatum, the nigrostriatal pathway is thought to be further refined 
during two waves of naturally occurring cell death (Burke, 2003). The first wave takes 
place shortly after birth and achieves its peak two days after; the second wave of 
apoptosis takes place two weeks after birth and lasts approx. one week. Thus, an 
important fraction of SN neurons are eliminated during the naturally occurring 
postnatal cell death and it is during this period that pro-survival molecules secreted by 
the target area, the striatum, might actively control survival of SN neurons. Several 
trophic factors have been shown to have neurotrophic effects on developing SN 
neurons, and might therefore be candidates as target-derived neurotrophic factors for 
SN neurons: BDNF; GDNF and the related NRTN; NT-4 and fibroblast growth factor 2 
(FGF-2) (Krieglstein, 2004; Smidt and Burbach, 2007). I will discuss below the 
evidence for BDNF and GDNF as candidate neurotrophic factors for SN neurons.  
 
1.10.1. BDNF as a candidate target-derived neurotrophic factor  
 
BDNF meets all the important criteria to be considered as a candidate neurotrophic 
factor for SN neurons. Thus, BDNF is expressed in the striatum, the SN target area 
(Friedman et al., 1991; Hofer et al., 1990) and was shown to be retrogradely transported 
by DA neurons when injected into the striatum (Mufson et al., 1994). In addition 
BDNF (and the related neurotrophins, except NGF) promotes survival of cultured 
midbrain DA neurons (Hyman et al., 1991) and stimulates their activity (Knusel et al., 
1991). The in vivo evidence for BDNF acting as a target-derived neurotrophic factor is 
incomplete. Thus, mice lacking BDNF or the TrkB receptor in all cells die early after 
birth due to several sensory and motor defects (Klein, 1994) and their DA system was 
therefore not evaluated.  
 
To understand the in vivo relevance of BDNF/TrkB signaling for developing neurons, 
mice heterozygous for TrkB null alleles have been used. These animals display a 
moderate loss of SN neurons (26 %) specifically during aging and interestingly, 
removal of both TrkB and TrkC increased the loss of SN neurons to 34 % (von Bohlen 
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und Halbach et al., 2005). Another group generated hypomorphic TrkB mice (in which 
TrkB levels were reduced to 25 % of wild-type levels) and found a 40 % loss of SN 
neurons, but during development, together with increased levels of striatal dopamine 
(Zaman et al., 2004). Most BDNF constitutive knockout mice die after 2 weeks, while 
some survive up to 4 weeks. At postnatal day 14, absence of BDNF function did not 
affect survival of SN DA neurons (Jones et al., 1994). Interestingly, conditional 
removal of BDNF function from the midbrain-hindbrain (using the Wnt1-Cre line) area 
led to a 23 % loss of SN neurons at postnatal day 21 (Baquet et al., 2005). These two 
studies seem therefore to suggest that BDNF is dispensable for the initial establishment 
and survival (up to P15) of SN neurons, but might be required between P15 and P21 for 
their survival.  
 
A major problem with the above-mentioned studies is that the function of TrkB was not 
specifically removed from SN neurons, and thus additional non-cell autonomous effects 
might be involved in the regulation of SN neuron survival. Moreover, removal of 
BDNF from several neuronal populations might also generate non-cell autonomous 
effects; finally, the findings that TrkB might regulate maintenance during aging (von 
Bohlen und Halbach et al., 2005) or initial SN development (Zaman et al., 2004), while 
BDNF rather regulates early maintenance (Baquet et al., 2005) are partially conflicting 
and additional evidence is required to establish whether BDNF is a target-derived 
neurotrophic factor for developing neurons.  
 
1.10.1. GDNF as a candidate target-derived neurotrophic factor  
 
GDNF was initially identified as a potent survival factor for cultured embryonic DA 
neurons (Airaksinen and Saarma, 2002; Lin et al., 1993) and numerous subsequent 
studies confirmed its pro-survival effects in vitro (Burke, 2003). GDNF is expressed 
throughout the CNS and high levels are detected in the striatum (Choi-Lundberg and 
Bohn, 1995; Springer et al., 1994), specifically in the dopaminoceptive medium size 
striatal neurons, (Burke, 2004).  Moreover, its developmental pattern of expression also 
correlates with that of striatal innervation and naturally occurring cell death of SN 
neurons (Burke, 2004) and GDNF undergoes retrograde transport in SN neurons 
(Tomac et al., 1995).  
 
The in vivo evidence for GDNF acting as a target-derived neurotrophic factor for SN 
neurons is currently missing. Considering the known in vitro pro-survival effects of 
GDNF/Ret on DA and motor neurons, it came as a surprise that the CNS development, 
including DA neurons, in mice lacking GDNF, GFRα1 or Ret was mostly unaffected 
(Paratcha and Ledda, 2008). These results suggest that GDNF/Ret signaling is 
dispensable for the initial establishment of the nigrostriatal system; however because 
these mice die before the complete establishment and maturation of the nigrostriatal 
system, the role of GDNF/Ret signaling as a target derived neurotrophic factor for SN 
neurons remains unclear.  
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1.11. BDNF and GDNF as a therapy for Parkinson’s disease? 
 
Besides potentially regulating SN neuron function and survival in vivo, both BDNF and 
GDNF showed potent rescuing effects in vitro and in animal models of PD, in which 
adult or aging neurons were challenged; however, GDNF consistently showed more 
promising effects in these studies (Kordower, 2003). Several delivery modes into the 
brain were tested pre-clinically for GDNF, including: 1) Direct injections or chronic 
pump perfusions in the striatum 2) gene therapy, using adeno-associated viruses (AAV) 
or lentiviruses 3) encapsulated cell technology, in which cells engineered to secrete 
GDNF are implanted in the striatum. Lentiviral delivery is perhaps the most promising 
strategy to be applied clinically in the near future. However, safety issues including a 
regulatable promoter to control gene expression in vivo and the exact injection site of 
the viral vector need to be addressed before considering human clinical trials (Kirik et 
al., 2004; Kordower, 2003; Kordower and Olanow, 2008).   
 
Three clinical trials on GDNF delivery have been performed so far. Two delivered 
GDNF directly into the striatum of five (Gill et al., 2003) or ten (Slevin et al., 2005) PD 
patients; the third study, was placebo-controlled and injected either GDNF or a placebo 
in the striatum of 34 PD patients (Lang et al., 2006). The first two studies reported 
positive effects on motor function after 18 and 6 months, respectively, while the third 
study failed to detect any improvement after 6 months. Several reasons might explain 
the conflicting results in these clinical trials. First, the major problem is that these trials 
have reduced statistical power, given the reduced number of patients that were tested. 
Second, the age of the PD-patients was relatively atypical in the third study (their mean 
age was 46 while the mean age at PD onset is considered to be 68).Third, the delivery 
of GDNF was not enough standardized in all three studies. Fourth, the patients were 
followed for only a short period, precluding the analysis of later-onset positive effects 
(Barker, 2006). These results suggest that additional technical (Kordower and Olanow, 
2008) and non-technical improvements are required in order to properly evaluate the 
potential therapeutic effects of GDNF and other neurotrophic factors in PD. One such 
necessary improvement was suggested to be a better understanding of the biological 
roles played by neurotrophic factors in the aging dopaminergic system.   
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1.12. The thesis project 
 
 
The present work deals with the survival requirements of SN neurons, the neuronal 
population that degenerates in PD. To begin characterizing the cellular and molecular 
networks mediating SN survival, we characterized genetically the roles and interaction 
between two candidate survival pathways: neurotrophic support and oxidative stress 
suppression. GDNF and BDNF neurotrophic factors were proposed to exert pro-
survival effects in SN neurons, however, their physiological roles in the establishment 
and maintenance of the nigrostriatal system remained unknown. Inactivation of the 
oxidative stress suppressor DJ-1 leads to Parkinson’s disease but animal models 
lacking DJ-1 show no DA neurodegeneration, suggesting that additional factors interact 
with loss of DJ-1 function to cause nigral degeneration. The major aims of my work 
were: 
 
 
1. To determine whether Ret and TrkB, the signaling receptors for GDNF and BDNF 
respectively, are required for long-term maintenance of SN neurons. 
 
2. To determine whether Ret interacts genetically with DJ-1 in the aging mouse 
dopaminergic system. 
 
3. To evaluate whether mouse dopaminergic neurons lacking Ret-mediated support are 
sensitive to cellular stress caused by misfolded alpha-synuclein. 
 
4. To determine whether mice lacking Ret and DJ-1 function recapitulate pathological 
features of PD. 
 
5. To assess whether DJ-1 interacts genetically with constitutively active Ret signaling 
in Drosophila melanogaster. 
 
6. To investigate the molecular mechanisms underlying the genetic interaction between 
DJ-1 and Ret in Drosophila melanogaster. 
 
 
 
Here, I provide genetic evidence that GDNF/Ret, but not BDNF/TrkB signaling is 
required for long-term maintenance of SN neurons. I also provide the first in vivo 
evidence for a pro-survival role of the PD-associated gene and oxidative stress 
suppressor DJ-1. Aging mice lacking Ret and DJ-1 function loose 51 % of SN neurons 
projecting to the striatum, suggesting that the triple interaction between aging, trophic 
insufficiency and cellular stress might cause Parkinsonism. Interestingly, Ret-deprived 
SN neurons are not sensitive to alpha-synuclein aggregation in vivo, suggesting some 
degree of specificity for the interaction between Ret and DJ-1. Furthermore, using 
genetic analysis in Drosophila melanogaster, I show that DJ-1 interacts genetically 
with Ret and associated Ras/ERK signaling and uncover a novel physiological role for 
the Drosophila orthologue DJ-1B during retinal and wing development. 
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A.  Ret signaling maintains a fraction of aging 
substantia nigra neurons 
 
 
To circumvent the early lethality of TrkB and Ret null mice, a conditional approach 
was taken in our laboratory and conditional knockout mice lacking Ret or TrkB 
function in defined tissues were generated. Mice carrying floxed alleles of Ret (Retlx) 
or TrkB (TrkBlx) were crossed to mice in which the expression of Cre recombinase 
was driven either in the whole nervous system (using the Nestin-Cre mouse line) or in 
the dopaminergic (DA) system only (using the dopamine transporter [DAT]-Cre line). 
After several crosses, DAT-Cre;Retlx/- (referred to as DAT-Ret) , DAT-Cre;TrkBlx/- 
(DAT-TrkB), DAT-Cre; Retlx/-;TrkBlx/- (DAT-Ret/TrkB), Nes-Cre;Retlx/- (Nes-Ret) and 
Nes-Cre;TrkBlx/- (Nes-TrkB) mice and corresponding controls (Retlx/lx, Retlx/-, TrkBlx/lx, 
TrkBlx/-, Dat-Cre, Nes-Cre) were generated. Nes-Cre mice display robust Cre 
expression in the whole nervous system, starting during embryonic (E10.5) 
development (Kramer et al., 2006; Tronche et al., 1999). Cre expression is induced at 
embryonic day 15 in DAT-Cre mice when almost all (95 %) TH-positive cells in the 
SN and VTA areas of the ventral midbrain express the Cre protein. Weak expression 
was detected in DA neurons in the olfactory bulb and hypothalamus and no Cre 
expression was seen in the striatum (Zhuang X, 2005). Ret is highly expressed in the 
SN and VTA areas, and Ret expression is efficiently removed from these areas in 
DAT-Ret mice (Kramer et al., 2007). TrkB is expressed in nigral DA neurons but also 
in other neuronal populations in the ventral midbrain. Single-cell PCR analysis 
revealed a 65 % reduction of TrkB mRNA-positive DA neurons in the SN of DAT-
TrkB mice compared to controls (Kramer et al., 2007).  
 
DAT-Ret, DAT-TrkB and DAT-Ret/TrkB mice develop normally without any obvious 
morphological defects, while Nes-Ret mice develop with stiff hind limbs, reflecting a 
critical requirement for Ret signaling during motoneuron axon guidance (Kramer et 
al., 2005). Nes-TrkB mice are born but display an increased lethality after 3 months of 
age and were not used in this study. Mutant and control mice were allowed to age and 
animals were analyzed at different time points during the aging process for the 
integrity of the nigrostriatal system.  
 
2.1. Ret is required for long-term maintenance of substantia nigra neurons  
 
To determine whether Ret or TrkB signaling is required for the establishment and the 
maintenance of the DA system, we performed stereological quantifications of DA 
neurons in mutant and control animals at diverse time points during adulthood and 
aging. Using several DA independent markers (tyrosine hydroxylase, Dopa-
decarboxylase, Pitx3) Edgar Kramer detected a progressive loss of DA neurons in the 
SN, but not VTA area in DAT-Ret, DAT-Ret/TrkB and Nes-Ret but not DAT-TrkB 
aging mice (12 to 24 months); out of approx. 13 000 DA neurons in SN, about 30 % 
were lost in aging DAT-Ret mice. Remarkably, no loss of DA neurons was observed 
in 3-month-old mutant and control animals, suggesting that Ret and TrkB signaling 
are dispensable for the development of SN and VTA neurons (Kramer et al, 2007). 
These observations raised the possibility that in the absence of Ret signaling, a 
fraction of SN DA neurons died in aging conditions.  
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To provide more definitive evidence of SN neuron cell death, I used the general 
neuronal marker NeuN, which labels almost all post-mitotic neurons in the nervous 
system and investigated whether aging DAT-Ret mice have altered numbers of NeuN-
immunoreactive neurons in the SN. To allow delineating the SN area, I co-stained the 
NeuN labeled sections with TH (Figure 17A,B). I found that aging (12 and 24-
months) control mice display approx. 19 000 NeuN-immunoreactive neurons in the 
SN while the absence of Ret signaling in DA neurons leads to loss of approx. 3 500 
neurons, starting after 12 months (Figure 17C; n=4-5 mice/group * p < 0.001 and ** p 
< 0.0001 for 12- and 24-months-old DAT-Ret vs. control mice, respectively). These 
independent quantifications correlate very well with the differences seen by Edgar 
Kramer when using dopaminergic specific markers and suggest that DA neurons are 
the only affected neuronal population in the SN of aging DAT-Ret mice. In addition, 
these results rule out the possibility of decreased expression of DA markers in aging 
DAT-Ret mutants and indicate that a fraction of Ret-deficient DA neurons are actually 
lost during aging. Thus, absence of Ret signaling in the mouse dopaminergic system 
leads to a progressive loss of SN neurons.  
 
To determine whether DA neuron degeneration in the SN has any influence on the 
neighboring glial cells, I used Nissl staining to label all neurons and glia cells in the 
ventral midbrain (Figure 17D). To allow delineating the SN area in the ventral 
midbrain, I performed tyrosine hydroxylase (TH) immunohistochemistry (Figure 
17D,E) and quantified the number of Nissl-stained cells in the SN of aging (12 
months) DAT-Ret and control mice. I found that both DAT-Ret and control mice 
display about 75 000 neurons and glial cells in the SN (Figure 17F). This suggests that 
the overall tissue integrity and composition is grossly maintained in aging DAT-Ret 
mutants and the only affected population are the DA neurons (n = 4 mice/group and 
DAT-Ret vs. CTRL p=0.17, t-test). Thus, absence of Ret signaling in aging DA 
neurons causes cell-autonomous DA neurodegeneration in a subpopulation of aging 
SN neurons suggesting that Ret, but not TrkB signaling is required for long-term 
survival of SN DA neurons. 
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Figure 17.  Loss of substantia nigra neurons in aging DAT-Ret mice.  (A-C) Aging DAT-Ret mice 
display loss of neurons in the substantia nigra (SN). (A) Double immunostaining for NeuN and TH 
(very weak staining to outline the SN [stippled area]). (B) higher magnification view of the stippled 
area, showing cytoplasmic TH and nuclear NeuN labeling. (C) Stereological quantification of NeuN-
positive neurons in the SN of 12- and 24-month-old control and DAT-Ret mice (n = 5 [at 12 months] 
and n = 4 [at 24 months] mice/group; * p < 0.001 and ** p < 0.0001 for 12- and 24-months-old DAT-
Ret  vs. control mice, respectively).(D-F) Similar numbers of Nissl-positive cells in 12-month-old DAT-
Ret and control mice. (D) Coronal section of a 12-month-old control mouse showing DA neurons in the 
ventral midbrain labeled for both Nissl (blue) and TH (brown) (E) Higher magnification view of the 
boxed area of (D) showing the presence of numerous cells labeled only by Nissl and not by TH (F) 
Stereological quantification of Nissl-stained cells in the SN of 12-month-old control and DAT-Ret mice 
(n = 4 mice/group, p = 0.17). Scale bars indicate 200 μm.  
 
2.2. Ret is required for long-term maintenance of striatal dopaminergic fibers  
 
Dopaminergic neurons in the SN send axonal projections that densely innervate the 
dorsal striatum. To evaluate whether GDNF/Ret and BDNF/TrkB signaling are 
required for the establishment and maintenance of SN DA target innervations, I 
immunolabeled the DA fibers innervating the striatum using the DA-specific marker 
TH. TH labeling of brain coronal sections revealed the presence of a dense network of 
DA fibers that innervates the striatum in control animals (Figure 18C,D). Remarkably, 
the DA fiber network of aging DAT-Ret mice was visibly altered (Figure 18D,E). 
Using a semi-automated method I then performed extensive quantifications of DA 
fiber density in Ret and TrkB mutant and control animals (Figure 18G,I). At 12 
months, the DA fiber density was markedly reduced (40 %) in the dorsal striatum of 
DAT-Ret, DAT-Ret/TrkB and Nes-Ret, but not DAT-TrkB mice, as compared to control 
animals (Figure 18G-dorsal). The same situation was observed in the ventral striatum, 
although the degree of fiber loss was less pronounced, consistent with the innervation 
preference of SN neurons for the dorsal striatum (Greengard et al., 1999) (Figure 
18G-ventral).  
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Figure 18 Ret is required for long-term maintenance of substantia nigra axons. (A–D, E, F) 
Photomicrographs showing dopaminergic fibers labeled by immunofluorescence using antibodies 
against TH (A–D) and DAT (E and F) in control (A, B, E), DAT-Ret (C, D) and Nes-Ret (F) mutants at 
12 (A, C, E, F) and 24 months of age (B and D). (G) Quantification of TH-immunoreactive fiber 
density in dorsal versus ventral striatum of 12-month-old controls (n = 16), DAT-TrkB (n = 4), DAT-Ret 
(n = 6), double DAT-Ret/TrkB (n = 5), and Nes-Ret mutants (n = 7). Significant reaductions in TH fiber 
density were observed for DAT-Ret, double DAT-Ret/TrkB, and Nes-Ret mutants in dorsal (p < 0.001) 
and ventral striatum (p < 0.01). (H) The density of DAT-immunoreactive fibers was quantified in 12-
month-old Nes-Ret mutants and age-matched controls (n = 4 per genotype; p < 0.001, t-test). (I) Time 
course of TH-positive fiber loss from 3 to 24 months of age. The loss of TH fibers begins after 6-9 
months (p = 0.09 and p < 0.05 at 6 months and 9 months, respectively) and is very pronounced at 24  
months (p < 0.0001). DAT-TrkB mutant mice do not show any signs of fiber loss even at 24 months of 
age (p = 0.13). *, p < 0.05; **, p < 0.01 t-test. Scale bar indicates 25 μm. n.s.-non significant.  
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A similar degree of fiber loss was observed in dopaminergic-specific DAT-Ret and 
whole nervous system-specific Nes-Ret mutant mice, suggesting that the loss of DA 
fibers in aging Ret mutants is cell autonomous. Moreover, the degree of fiber loss was 
similar in DAT-Ret and DAT-Ret/TrkB suggesting that Ret does not cooperate with 
TrkB signaling to promote maintenance of DA fibers innervating the striatum. These 
results indicate that Ret, but not TrkB signaling is required for maintenance of striatal 
innervation in aging mice.  
 
I next determined whether the initial growth and striatal targeting of DA axons is 
altered in mice lacking Ret and TrkB-mediated trophic support. I used sections from 
3-month-old Ret and TrkB mutants and control animals. Intriguingly, the density of 
DA fibers in the striatum was similar in all mutant and control animals, suggesting 
that both Ret and TrkB signaling are dispensable for the initial development, striatal 
targeting and maintenance of DA fibers (Figure 18I). These results also correlate with 
the previous stereological results obtained by Edgar Kramer, which suggested a 
normal development of SN cell bodies in Ret and TrkB mutants.  
 
To determine the onset of DA fiber degeneration in dopaminergic- and whole nervous 
system-specific Ret mutant mice, I performed a time-course analysis of DA 
innervation density in Ret-deficient and control animals. DAT-Ret mice display the 
first significant loss (approx. 10 %) of DA fibers after 9 months (Figure 18I). 
Remarkably, the loss of fibers is dramatically increased (60 %) in 24-month-old 
animals, as compared to controls and to DAT-TrkB mice (no fiber loss). To rule out 
that the observed fiber loss is due to an age-dependent downregulation of TH 
expression, I used an independent marker, the dopamine transporter (DAT) to label 
the dopaminergic fibers (Figure 18E,F). A dense network of DAT-immunoreactive 
striatal fibers was observed in control animals (Figure 18E). Because DAT-Ret mice 
have altered levels of DAT protein (due to the insertion of the Cre coding sequence in 
the 5’ UTR of the DAT gene; data not shown), we used Nes-Ret mice for this 
analysis. I found, similarly, that the DA fiber network is visibly altered in 12-month-
old Nes-Ret mutants (Figure 18F) and the DA fiber density is reduced by 35 % 
relative to age-matched controls (Figure 18H). Taken together, these results indicate 
that Ret, but not TrkB signaling is required for maintenance of DA fibers innervating 
the striatum, specifically during aging.  
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2.3. Post-synaptic dysfunction in aging DAT-Ret mice 
 
Dopaminergic input to post-synaptic striatal neurons is necessary for proper 
movement control. Given the significant loss of DA neuron cell bodies and fibers, I 
wondered whether these anatomical changes in the DA pre-synapse have any impact 
on the post-synaptic striatal neurons (Figure 19). To evaluate the overall impact of 
DA innervation (and thus presynaptic input) loss on striatal neurons, I used the 
general neuronal marker NeuN to label all striatal neurons, including interneurons. 
Analysis of 24-month-old DAT-Ret and control mice revealed that Ret mutant mice 
display an overall weaker NeuN labeling in the striatum (Figure 19A,B). 
Quantification of NeuN-immunoreactive neuron density in the dorsal striatum 
revealed a small but significant reduction of NeuN-labelled neurons (8 %; n=5 
mice/group, p< 0.05 Student’s t-test) in the striatum of 24-month-old DAT-Ret mice 
compared to age-matched control animals (Figure 19C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Postsynaptic dysfunction in aging DAT-Ret mice.  Immunolabelings revealing the 
expression of NeuN (A,B), DARPP-32 (D,E) and parvalbumin (G, H) in the dorsal striatum of 24-
month-old control (A, D, G) and DAT-Ret mutants (B, E, H). Histograms showing the density of 
NeuN-positive (C), DARPP-32–positive (F), and parvalbumin-positive cells (I) in DAT-Ret mutants 
and age-matched controls (n = 3–5 animals/group). Note the reduced NeuN and DARPP-32 staining 
intensities in DAT-Ret compared to control mice. *, p < 0.05; **, p < 0.01 (Student t-test). Scale bars 
indicate 50 μm. n.s.- non significant. 
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To investigate more specifically the postsynaptic dopaminoceptive neurons in the 
striatum, I used a more specific marker for this neuronal population. The protein 
DARPP-32 (dopamine and cAMP-regulated phosphoprotein, 32 kDa) is expressed by 
nearly all dopaminoceptive striatal projection neurons (Greengard et al., 1999) and 
plays an important role in dopamine-mediated signaling. Dysfunctional striatal 
projection neurons were found to have reduced DARPP-32 expression (Alves et al., 
2008; Canals et al., 2004; Regulier et al., 2002). Remarkably, when analyzing the 
density of DARPP-32-immunoreactive striatal projection neurons, I found a 20 % 
decrease in density in 24-month-old DAT-Ret mutant relative to control mice (Figure 
19D-F; n=3 mice/group, p<0.01, Student’s t-test). It is likely that abnormalities in 
dopamine signaling have a direct effect on the expression and activation status of 
dopamine downstream transducers, including DARPP-32. Therefore, dysfunction in 
the pre-synaptic DA compartment in aging DAT-Ret mice induces post-synaptic 
dysfunction and possibly loss of striatal dopaminoceptive neurons.  
 
To determine whether this observed striatal dysfunction in DAT-Ret mice is specific 
to dopaminoceptive neurons, I analyzed a striatal interneuron population which 
expresses the calcium-binding protein parvalbumin (Parent et al., 1996). Labeling of 
parvalbumin-immunoreactive striatal interneurons revealed a similar staining intensity 
in both DAT-Ret and control mice (Figure 19G,H). In addition, the density of 
parvalbumin-immunoreactive striatal interneurons was similar in both DAT-Ret and 
control mice (Figure 19I), further confirming that the loss of DA fibers in DAT-Ret 
mice affect specifically the post-synaptic striatal projection neurons. Taken together, 
these results suggest that loss of striatal innervation in aging DAT-Ret mice exerts an 
indirect (non cell-autonomous) effect on the function of dopaminoceptive striatal 
neurons.  
 
2.4. Enhanced reactive gliosis in the striatum of aging DAT-Ret mice 
 
Axonal dysfunction and degeneration was previously associated with recruitment of 
reactive astrocytes (Butt et al., 2004) and an increased density of reactive astrocytes 
was detected in the nigrostriatal system of PD patients (Hunot and Hirsch, 2003). We 
asked whether degenerating SN somata, loss of DA axons and post-synaptic 
dysfunction in DAT-Ret mice would cause gliosis by recruitment of reactive 
astrocytes.  
 
I used the astrocytic marker glial fibrillary acidic protein (GFAP) to detect alterations 
in astrocyte number in the brains of Ret and TrkB mutant and control mice. GFAP-
labeled astrocytes displayed their typical star-shape morphology (Figure 20) and were 
found in several brain regions, including the cortex, the striatum or the SN (data not 
shown). The measurement of GFAP-immunoreactive astrocyte density in the dorsal 
striatum revealed a similar (low) astrocyte density in both 12-month-old DAT-Ret and 
control mice (Figure 20A-C; n=3 mice/group, p=0.9, Student’s t-test). Remarkably, at 
24 months, a massive striatal astrogliosis was detected in DAT-Ret mice as compared 
to control and DAT-TrkB mice (Figure 20D-F; n=4-5 mice/group, DAT-Ret vs. CTRL 
or DAT-TrkB p<0.001, Student’s t-test). This result raises the possibility that 
degenerating DA fibers or post-synaptic dysfunction in DAT-Ret mice causes a late 
recruitment of reactive astrocytes to the striatum. Interestingly, no increased 
astrogliosis was detected in the SN of 24-month-old DAT-Ret relative to age-matched 
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control mice, despite the marked degeneration of DA neuron cell bodies in this area 
(Figure 20G-I; n=3 mice/group, p=0.24, Student’s t-test). Thus, degenerating DA 
fibers and/or dysfunctional post-synaptic MSNs in DAT-Ret mice trigger a late 
recruitment of reactive astrocytes to the striatum, while degenerating SN cell bodies 
do not appear to be a strong recruiting signal for astrocytes. Because Ret is not 
genetically ablated in astrocytes, these results suggest that the astrogliosis in the 
striatum of aging DAT-Ret mice is caused by DA fiber degeneration, in a non-cell 
autonomous manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20.  Enhanced reactive gliosis in the striatum of aging DAT-Ret mice.  (A, B, D, E, G, H) 
Bright-field photomicrographs of dorsal striatum (STR; A, B, D, E) and substantia nigra (SN; G, H) of 
12-month-old (A, B) and 24-month-old (D, E, G, H) control (A, D, G) and DAT-Ret mutants (B, E, H) 
stained for the astrocytic marker GFAP. (C, F, I) Histograms showing the density of GFAP-positive 
reactive astrocytes (n = 3–5 mice/group). There is a 2-fold increase in the number of reactive astrocytes 
in the striatum of 24-month-old DAT-Ret mutants relative to wild-type controls and DAT-TrkB mutants 
(F) (p < 0.0001, Student’s t-test), whereas no difference is seen in 12-month-old DAT-Ret mutants 
compared to controls (C) (p = 0.9, Student’s t-test). No significant increase in the number of reactive 
astrocytes is seen in the SN of 24-month-old DAT-Ret mutants compared to controls (I) (p = 0.24). **, 
p < 0.01 Student’s t-test. Scale bars indicate 50 μm. n.s.–non significant.  
 
 
2.5. Enhanced microglial recruitment in aging DAT-Ret mice 
 
Inflammatory processes are associated with a wide variety of neuronal pathologies 
and post-mortem analysis of PD patients revealed massive neuro-inflammation in the 
substantia nigra (Hirsch et al., 2003; Hunot and Hirsch, 2003; Teismann and Schulz, 
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2004). Microglial cells recruited in areas of neurodegeneration are able to change 
morphology and acquire phagocytic properties, thus helping eliminate neuronal 
corpses that underwent apoptosis (Hunot and Hirsch, 2003). We asked whether dying 
SN cell bodies and axons in aging DAT-Ret mice would cause recruitment of 
microglial cells in the SN or the striatum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Enhanced inflammation in the substantia nigra of aging DAT-Ret mice.  (A, B, D–I, K, 
L) Immunohistochemical stainings of dorsal striatum (STR; A,B) and substantia nigra (SN; D–I, K, L) 
of 24-month-old control (A, D, E, H, and K) and DAT-Ret mice (B, F, G, I, and L) for Iba-1 (A, B, E, 
G, H, I), TH (D, F), and MAC1/CD11b (K, L). To localize microglial cells in SN, adjacent sections 
were stained for TH to define the SN area which was copied to the adjacent section stained for 
microglial cells. (C, J, M) Histograms showing the density of Iba-1–positive (C, J) and MAC1-positive 
(M) cells in the striatum (C) and SN (J, M) of 24-month-old (C, J) DAT-Ret mice and controls. Similar 
densities of Iba-1–positive cells were detected in the striatum of 24-month-old mutants and controls (C; 
n = 4, p = 0.065, Student’s t-test). In the SN however, there was a significant increase in the density of 
Iba-1–positive cells in 24-month-old DAT-Ret mice compared to controls (J; n = 5, p < 0.05). Using 
MAC1 as a second, independent marker for microglia, a similar result was observed (M) (n = 3, p < 
0.05, Student’s t-test). * p < 0.05 Student’s t-test. Scale bars indicate 100 μm. n.s.-non significant. 
 
I used immunohistochemistry for the Ionized binding calcium adapter molecule (Iba)-
1 to specifically label microglia in brains of DAT-Ret and control mice. Iba-1 labeling 
revealed the presence of microglial cells both in the striatum (Figure 21A,B) and the 
SN (Figure 21H,I) of mutant and control mice. I first used Iba-1 stained sections form 
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the striatum of mutant and control mice and determined the density of microglial cells 
in this area. The density of microglial cells in the striatum is similar in 24-month-old 
DAT-Ret and control mice (Figure 21A-C; n=4 mice/group, p=0.065, Student’s t-test), 
suggesting that degenerating DA fibers and post-synaptic dysfunction in DAT-Ret 
mice are not a strong recruiting signal for microglial cells. 
 
I then set up to determine the density of microglial cells in the SN area. For each 
coronal section stained for Iba-1, I used the consecutive section stained for TH, to 
allow precise delineation of the SN area (Figure 21D-G). I found that 24-month-old 
DAT-Ret mice display a significantly increased density (45 %) of Iba-1 positive 
microglial cells in the SN as compared to age-matched controls and DAT-TrkB mice 
(Figure 21H-J; n=5 mice for DAT-Ret and controls and n=3 for DAT-TrkB mice; 
p<0.05 Student’s t-test). I then used a second, independent marker to label microglial 
cells, the macrophage antigen alpha (MAC1, CD11b, or CR3; Figure 21K,L). I found, 
similarly, a significant increase in the number of MAC1-positive microglial cells in 
the SN of 24-month-old DAT-Ret mice compared to controls (Figure 21M; n=3 
mice/group, p<0.05, Student’s t-test). Interestingly, when analyzing the density of 
microglial cells in the SN of 12-month-old DAT-Ret and control mice, no difference 
in the microglial cell density was detected (data not shown). These results raise the 
possibility that degenerating DA cell bodies, in contrast to axons, are a strong 
recruiting signal for microglial cells. Moreover, the recruitment of microglial cells is 
delayed compared to the onset of SN neuron degeneration, suggesting that microglial 
cells do not play a causative role in the neurodegeneration of SN cell bodies. Similar 
to reactive astrocytes, Ret expression was not ablated in microglial cells of DAT-Ret 
mice, suggesting that the enhanced microglial recruitment in the SN of aging DAT-Ret 
mice occurred as a result of DA neuron cell death.  
 
2.6. No major behavioral alterations in aging DAT-Ret mice 
 
Release of dopamine in the striatum is an essential event required for the proper 
control of movement initiation. Dramatic depletion of DA as seen in PD leads to the 
typical signs of the disease that include the inability to initiate movement, tremor, 
postural instability and rigidity. We wanted to determine whether any behavioral and 
physiological changes accompanied the loss of a fraction of DA neurons in aging 
DAT-Ret mice.  
 
I performed a series of behavioral tests that are routinely used to detect motor 
alterations in rodents (Figure 22). To evaluate the balance and coordination abilities of 
mutant and control mice, the rotarod test and the swimming test were used; the open-
field and forced swimming test allowed the analysis of both general and horizontal 
activity. Because in DAT-Ret mice the levels of DAT protein are altered (due to the 
insertion of the Cre transgene in the 5’UTR of the DAT gene), the control groups also 
included DAT-Cre mice. When recording the spontaneous general activity of mutant 
and control mice in the open-field arena, no major differences between DAT-Ret and 
control animals were observed (data not shown). When analyzing the general and 
horizontal activity in the forced swimming test, no difference was observed between 
the different groups of mice (Figure 22B). Similarly, the coordination and balance 
abilities as assessed in the rotarod and swimming tests were similar in aging DAT-Ret 
and control mice (Figure 22A,C, n>15, p=NS, Student’s t-test).  
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Figure 22. No major behavioral alterations in aging DAT-Ret mice.  General activity (B) and motor 
performance (A, C) were tested in 18-24 month-old mice. Motor coordination was tested in the rotarod 
test (A) and in a swimming tank (C) while the forced swimming test allowed the measurement of 
horizontal activity (B). No major behavioral alterations were detected in DAT-Ret mice as compared to 
controls carrying floxed alleles of Ret or the DAT-Cre construct (n > 15, p=NS student’s test).  
 
 
Moreover, measurements performed by Edgar Kramer also revealed that the total 
levels of striatal dopamine were not significantly altered in aging DAT-Ret and DAT-
TrkB mice compared to controls (data not shown). Thus, although at the anatomical 
level aging DAT-Ret mice display a moderate loss of DA neurons and a marked loss 
of DA fibers, the nigrostriatal system compensates physiologically by maintaining an 
optimal dopamine output, suggesting that aging DAT-Ret mice are in a pre-
symptomatic state of nigral pathology. Indeed, studies of PD patients revealed that 
motor deficits only become apparent after a “threshold” for SN cell body and axon 
loss (situated at 50-60 % loss of SN cell bodies and approx. 80 % for DA terminals) is 
reached (Dauer and Przedborski, 2003).   
 
 
In summary, the results presented so far suggest that Ret, but not TrkB signaling is 
necessary for maintenance of aging DA neuron cell bodies and axons. In the absence 
of Ret signaling and during aging, additional histological changes occur indirectly as 
consequences of DA dysfunction and include postsynaptic dysfunction, increased 
astrogliosis and neuroinflammation. Despite these anatomical changes, aging DAT-
Ret mice are in a pre-symptomatic state of nigral pathology. The moderate anatomical 
phenotype and the absence of behavioral alterations in DAT-Ret mice suggest that 
additional factors are required for maintenance and functioning of aging DA neurons.  
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B. DJ-1 promotes survival of Ret-deficient substantia 
nigra neurons 
 
 
We searched for additional Ret-interactors in the process of DA neuron maintenance. 
We chose to investigate DJ-1 as a potential Ret interactor, for several reasons. First, 
loss of DJ-1 function in humans causes Parkinson’s disease, suggesting that DJ-1 is 
required for survival of human DA neurons. Surprisingly, mice lacking DJ-1 function 
do not display loss of SN neurons and DA fibers during aging (Chandran et al., 2008; 
Chen et al., 2005; Goldberg et al., 2005; Kim et al., 2005b; Yamaguchi and Shen, 
2007) suggesting the existence of additional factors that compensate for loss of DJ-1 
function in the mouse. Second, DJ-1 is expressed in SN and the nearby ventral 
tegmental area (Bader et al., 2005) of the mouse brain, similar to Ret (Kramer et al., 
2007). Third, DJ-1 is an oncogene and was suggested to interact with RTK-related 
signaling pathways including PI3K/Akt (Gorner et al., 2007; Kim et al., 2005a; Yang 
et al., 2005b) and p53 (Fan et al., 2008a; Fan et al., 2008b; Giaime et al., 2009).   
 
To address a possible pro-survival role for DJ-1 in neurons lacking Ret-mediated 
trophic support, I generated animals lacking Ret in the dopaminergic system and DJ-1 
in all cells (DAT-Cre; Retlx/lx; DJ-1-/- in short DAT-Ret/DJ-1) and corresponding 
controls. To determine whether Ret and DJ-1 show convergent pro-survival activities 
in DA neurons, I analyzed adult and aging mutant and control mice for the integrity of 
the nigrostriatal system.   
 
 
2.7. Enhanced loss of substantia nigra neurons in aging DAT-Ret/DJ-1 mice 
 
We hypothesized that loss of Ret and DJ-1 function would accelerate the 
neurodegenerative process in the DA system of aging DAT-Ret mice. To test our 
hypothesis, I first performed stereological quantifications to determine the number of 
SN DA neurons in adult and aging DAT-Ret/DJ-1, DAT-Ret, DJ-1-/- and control mice.   
 
Using brain coronal sections immunostained for the DA marker TH (Figure 23A-C), I 
determined the number of TH-positive DA neurons in the SN of 3-month-old mutant 
and control animals.  The same number of DA neurons was found in DAT-Ret;DJ-1 
double mutant and in control animals, indicating that the nigrostriatal system 
developed normally in the absence of Ret and DJ-1 function (Fig. 23G). I then 
evaluated the number of aging (18- and 24-month-old) SN neurons in mutant and 
control mice (Figure 23).  
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Figure 23. DJ-1 promotes survival of aging Ret-deprived substantia nigra neurons. (A-F) 
Photomicrographs of 18-month-old control (A,D), DAT-Ret (B,E) and DAT-Ret/DJ-1 (C,F) double 
mutant coronal brain sections showing DA neurons in the substantia nigra (SN) and the ventral 
tegmental area (VTA) stained for the DA markers TH (A-C) and Pitx3 (D-F). The images in panels D-
F are higher magnification views of the stippled area in the insets (D’-F’) of each panel. (G-K) 
Stereological quantifications of TH- and Pitx3-immunoreactive DA neurons in the SN of 3-month-old 
(G), 18-month-old (H,J,K) and 24-month-old (I) mice of the indicated genotypes (n=5 mice per 
genotype) * p<0.05, ** p<0.01,*** p<0.001, Student’s t-test. Scale bars: (C,F’) 250 μm, (F) 50 μm. 
n.s.- not significant. 
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I found that 18-month-old mice lacking DJ-1 function have a normal complement of 
SN neurons, consistent with the previously mentioned studies (Figure 23H; DJ-1-/- vs. 
CTRL p= NS, Student’s t-test). DAT-Ret mice display a moderate loss of DA neurons 
(25 % loss), in agreement with our previous observations (Figure 23H; n=5 
mice/group, DAT-Ret vs. CTRL p<0.01 Student’s t-test). Remarkably, when 
analyzing 18-month-old DAT-Ret/DJ-1aging mice, I found a significant decrease in 
the number of SN neurons (37 % loss) compared to DAT-Ret mice and DJ-1-/- and 
controls mice (Figure 23H; n=5 mice/group; DAT-Ret/DJ-1 vs. CTRL p<0.001, DAT-
Ret/DJ-1 vs. DJ-1-/- p<0.001  and DAT-Ret/DJ-1 vs. DAT-Ret p<0.01, Student’s t-
test).  At 24-months, DAT-Ret/DJ-1 mice lost 41 % of their SN neurons, in contrast to 
DAT-Ret (25 % loss), DJ-1-/- and control mice (no loss of SN neurons; Figure 23I; 
n=5 mice/group; DAT-Ret/DJ-1 vs. CTRL p<0.001, DAT-Ret/DJ-1 vs. DJ-1-/- 
p<0.001 and DAT-Ret/DJ-1 vs. DAT-Ret p<0.01, Student’s t-test). The difference 
between DAT-Ret/DJ-1 double and DAT-Ret single mutant mice was statistically 
significant and was not additive, suggesting that Ret interacts genetically with DJ-1 to 
promote survival of aging SN DA neurons.  
 
I then used as a second, independent DA marker to rule out that the previously 
observed effects were due to downregulation of TH expression; I used an antibody 
against Pitx-3 (Figure 23D-F), which is expressed by all differentiated DA (Smidt et 
al., 2004). I found, similarly, that 18-month-old DJ-1-/- mice have a normal 
complement of SN neurons and DAT-Ret mice display a moderate loss of SN neurons 
(25 %; Figure 23J; DJ-1-/- vs. CTRL p=NS; DAT-Ret vs. CTRL p<0.01 Student’s t-
test). 18-month-old DAT-Ret;DJ-1 double mutant mice lost  41 % of their SN 
neurons, significantly more than age-matched DAT-Ret, DJ-1-/- and control mice 
(Figure 23J;  n=5 mice/group; DAT-Ret/DJ-1 vs. CTRL p<0.001, DAT-Ret/DJ-1 vs. 
DJ-1-/- p<0.001  and DAT-Ret/DJ-1 vs. DAT-Ret p<0.01, Student’s t-test).  Thus, 
combined deletion of Ret and DJ-1 causes loss of neurons rather than reduced TH 
expression in a subpopulation of the SN. Furthermore, to exclude that the DAT-Cre 
transgene and the mutant DJ-1 allele somehow genetically interacted, I compared the 
numbers of TH-positive neurons in 18-month-old DAT-Cre;DJ-1-/- mice, DAT-Cre 
transgenics and littermate controls; in all these three mutant lines, a similar number of 
SN neurons was found (Fig. 23K). In addition, quantifications performed by Pontus 
Klein revealed no loss of VTA neurons in 18-month-old DAT-Ret/DJ-1 mice as 
compared to controls, further suggesting that the survival dependency on Ret and DJ-
1 signaling is specific for SN neurons (data not shown). Taken together, these results 
indicate that DJ-1 is required for survival of aging SN neurons that were impaired in 
receiving Ret-mediated trophic signals. 
 
2.8. Ret and DJ-1 maintain substantia nigra neurons that express GIRK2 
 
Two subpopulations make up the SN: the predominant population of neurons is 
located ventrally, expresses the G-protein gated, inwardly rectifying potassium 
channel GIRK2 and projects to the dorsal striatum; the second subpopulation is 
located dorsally, expresses the calcium-binding protein Calbindin and projects to 
different areas including limbic and neocortical regions (Bjorklund and Dunnett, 
2007). It is the GIRK2 neurons that are preferentially lost in PD (Liang et al., 1996; 
Yamada et al., 1990). We asked whether both subpopulations require Ret and DJ-1 
activity for survival during aging (Figure 24).  
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Figure 24. Ret and DJ-1 maintain GIRK-2- positive substantia nigra neurons. (A-H) 
Photomicrographs of 24-month-old control (A,E), DJ-1single (B,F), DAT-Ret single (C,G), and DAT-
Ret/DJ-1 double mutant (D,H) coronal brain sections stained for GIRK2 (A-D) and Calbindin (E-H). 
All images are higher magnification views of the stippled area in the insets of each panel. (I,J) 
Stereological quantification of GIRK-2- (I) and Calbindin-immunoreactive neurons (J) in the SN of 24-
month-old mice of the indicated genotypes (n=5 mice per genotype; n.s., not significant;* p<0.05, ** 
p<0.01, *** p<0.001, t-test). Scale bars: (d,h) 50 μm, (d’,h’) 250 μm. 
 
I stained coronal brain sections from mutant and control mice for GIRK2 (Figure 
24A-D) and performed stereological quantifications to determine the number of 
GIRK2-positive SN neurons in 24-month-old animals. Removal of DJ-1 had no effect 
on the number of GIRK2-positive neurons (Figure 24A,B,I). Remarkably, while 
removal of Ret function alone caused a partial reduction of GIRK2-positive neurons 
(33% loss), combined removal of Ret and DJ-1 had the strongest effect (51% loss; 
p<0.001 DAT-Ret/DJ-1 double vs. CTRL; p<0.01 DAT-Ret/DJ-1 double vs. DAT-Ret 
single mutants, Student’s t-test; Figure 24C,D,I). Therefore, Ret and DJ-1 activity is 
required to maintain half of the GIRK2-immunoreactive DA neurons in the SN during 
aging.  
 
The second DA population in the SN was labeled using a Calbindin-specific antibody. 
Interestingly, the Calbindin-immunoreactive subpopulation in the SN was unaffected 
in all groups (Figure 24E-H,J). Thus, the neuronal population that is most critically 
dependent on Ret and DJ-1 function is the GIRK2-positive subpopulation, while the 
other midbrain dopaminergic cells are grossly unaffected in the mutant mice. 
Furthermore, given that the SN sub-population most dependent on Ret and DJ-1 
activity contains the GIRK2-imunoreactive SN neurons which project exclusively to 
the striatum, these results raise the possibility that the target of DA neurons is also a 
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factor of neuronal vulnerability during aging. Therefore, aging GIRK2-, but not 
Calbindin-positive neurons require DJ-1 and Ret function for survival.  
 
2.9. DJ-1 is dispensable for long-term maintenance of Ret-deficient axons 
 
We next evaluated the possibility that Ret and DJ-1 cooperate in maintaining target 
innervation of nigral DA neurons. I labeled DA fibers in the striatum using TH as a 
marker and compared the fiber density in 18- and 24-months mutant and control mice 
(Figure 25A-D). Quantification of TH-positive fiber density confirmed a marked 
decrease in the dorsal striatum of 18- and 24-month-old DAT-Ret single mutants 
compared to age-matched controls (Figure 25C,H,I; n= 5 mice/group; DAT-Ret vs. 
CTRL p<0,001, Student’s t-test). In contrast, no significant reductions in the density 
of DA fibers were observed in the striatum of DJ-1 single mutant mice (Figure 
25B,H,I). Interestingly, DAT-Ret/DJ-1 double mutants displayed reductions of TH-
positive fibers that were in the same range as DAT-Ret single mutants (46 % at 18-
months and 52 % at 24-months, DAT-Ret/DJ-1 vs. DAT-Ret p=NS, Student’s t-test; 
Figure 25D,H,I).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. DJ-1 is dispensable for maintenance of Ret-deficient dopaminergic fibers. (A-G) 
Photomicrographs of DA fibers innervating the dorsal striatum in 24-month-old control (A,E), DJ-1 
single (B), DAT-Ret single (C,F) and DAT-Ret/DJ-1 double (D,G) mutant mice labeled by 
immunofluorescence  using the DA markers TH (A-D) and DAT (DAT; E-G). (H,I) Quantification of 
TH-fiber density in the dorsal striatum of 18-month-old (H) and 24-month-old (I) mice of the indicated 
genotypes (n=5-7 mice per genotype; p<0.01, Student’s t-test). (J) Quantification of DAT-fiber density 
in the dorsal striatum of 24-month-old mice of the indicated genotypes (n=5-7 mice per genotype; ** 
p<0.001, t-test). Scale bars: (D,G) 10μm. n.s.-not significant. 
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I then used the dopamine transporter (DAT) as a second, independent marker for DA 
axons (Figure 25E-G). DAT-Cre knock-in mice were used as controls, since they have 
reduced levels of DAT protein (the Cre transgene being inserted in the 5’-UTR of the 
DAT gene). Both DAT-Ret and DAT-Ret/DJ-1 24-month-old mutants displayed a 54 
% reduction in DAT-immunoreactive fiber density relative to age-matched DAT-Cre 
control mice (n =4-5 mice/group; DAT-Ret or DAT-Ret/DJ-1 vs. DAT-Cre p< 0,001 
and DAT-Ret vs. DAT-Ret/DJ-1 p=NS, Student’s t-test; Figure 25E-G,J;). Thus, DJ-1 
activity is dispensable for long-term maintenance of DA fibers deprived of Ret-
mediated trophic support.   
 
2.10. No enhanced striatal pathology in aging DAT-Ret/DJ-1 mice 
 
Aging DAT-Ret mice were found to have post-synaptic defects (Figure 19), enhanced 
glial cell recruitment in the dorsal striatum (Figure 20) but no significant behavioral 
deficits (Figure 22). To determine whether the increased degeneration of SN DA cell 
bodies in DAT-Ret/DJ-1 mice has any impact on neuroinflammatory processes in the 
striatum, I labeled microglial cells and astrocytes in the dorsal striatum of 18- and 24-
months old control, DAT-Ret and DJ-1-/-single and DAT-Ret/DJ-1 double mutant mice 
(Figure 26).  
 
No visible differences in the density of Iba-1-immunoreactive microglial cells in the 
striatum were observed among the aforementioned groups of animals (Figure 26A-D). 
This situation parallels the previous finding that 24-month-old DAT-Ret and control 
mice have similar microglial cell densities in the striatum (Figure 21A-C). I then used 
an anti-GFAP antibody to label astrocytes in 18- and 24-months animals. At 18-
months, the density of GFAP-labeled astrocytes was similar in all mutant and control 
groups (Figure 26E-H,M). At 24 months however, the astrocyte density was visibly 
increased in both DAT-Ret and DAT-Ret/DJ-1 mice, relative to control and DJ-1 
deficient mice (Figure 26I-L), consistent with the previously observed increase in 24-
month-old DAT-Ret vs. control mice (Figure 20D-F). Quantification of astrocyte 
density revealed a 2-fold increase in 24-month-old DAT-Ret and DAT-Ret/DJ-1 mice 
relative to control and DJ-1 mutant mice, but no significant difference between DAT-
Ret single and DAT-Ret/DJ-1 double mutants (n=4-5 mice/group; DAT-Ret or DAT-
Ret/DJ-1 vs. CTRL p< 0,01 and  DAT-Ret vs. DAT-Ret/DJ-1 p=NS, Student’s t-test; 
Figure 26N). Therefore, combined deletion of Ret and DJ-1 does not accelerate the 
striatal neuroinflammatory processes observed in aging DAT-Ret deficient mice.  
 
To understand whether absence of Ret and DJ-1 function affects the DA 
neurotransmission in the striatum we performed, together with Pontus Klein, open-
field analysis on 18-month-old mutant and control mice (Figure 26O). Mice were 
tested, without previous training, in an open-field arena and their horizontal activity 
was measured during two consecutive sessions. 
 
Figure 26. No enhanced neuroinflammation and behavioral deficits in aging DAT-Ret/DJ-1 mice. 
(A-L) Photomicrographs of 18-month-old (A-H) and 24-month-old (I-L) control (A,E,I), DJ-1 (B,F,J), 
DAT-Ret (C,G,K) and DAT-Ret/DJ-1 (D,H,L) mouse striatal sections stained for the microglial marker 
Iba-1 (A-D) and the astrocytic marker GFAP (E-L). (M,N) Quantification of astrocyte density in the 
dorsal striatum (STR) at 18 and 24 months. At 24 months, DAT-Ret and DAT-Ret/DJ-1 mice display a 
similar increase in astrocyte density (n=4-5 mice/group, ** p<0.01, t-test). (O) Open field behavioral 
assessment of 18-month-old animals of indicated genotypes. DJ-1 mice were hypoactive, while DAT-
Cre, DAT-Ret and DAT-Ret/DJ-1 mice had similar horizontal activities (n=7-16, ** p<0.01, t-test). 
Scale bar indicates 200 µm. n.s.-non significant. 
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Consistent with previous reports (Chen et al., 2005; Goldberg et al., 2005) we found 
that DJ-1 deficient mice were moderately hypoactive as compared to controls carrying 
floxed alleles of Ret or heterozygous Ret-mutants (n=7-16 mice/group and DJ-1-/- vs. 
CTRL p<0,01 Student’s t-test; Figure 26O). In contrast, mice carrying the DAT-Cre 
transgene were found to be hyperactive (CTRL vs. DAT-Cre p<0.01, Student’s t-test; 
Figure 26O); this is likely due to reduced levels of dopamine transporter, caused by 
the insertion of the Cre transgene in the DAT 5’-UTR (data not shown). Reduced 
levels of dopamine transporter allow more dopamine to accumulate at the synapse, as 
a result of decreased reuptake by DA presynaptic terminals; indeed, mice that partially 
or completely lack the dopamine transporter are hyperactive and display more 
dopamine in the striatum (Perona et al., 2008). When analyzing the horizontal activity 
of DAT-Ret and DAT-Ret/DJ-1 mice, we found that these animals remained 
hyperactive compared to controls that have normal DAT levels (Retlx/+, Retlx/lx and 
Retlx/-) while their horizontal activity did not significantly differ from that of DAT-Cre 
mice (n= 7-16 mice/group; DAT-Ret or DAT-Ret/DJ-1vs. CTRL p<0,05; DAT-Ret or 
DAT-Ret/DJ-1vs. DAT-Cre p=NS, Student’s t-test; Figure 26O). Measurement of total 
levels of striatal dopamine (performed by Pontus Klein) revealed normal dopamine 
levels in DJ-1 mutant mice as compared to controls with normal DAT levels and 
increased dopamine levels in DAT-Cre, DAT-Ret and DAT-Ret/DJ-1 mice (these 3 
mutant groups had similar dopamine levels; data not shown). Taken together, these 
results suggest that combined deletion of Ret and DJ-1 does not enhance the DA 
neurotransmission and striatal pathology observed in aging DAT-Ret mutants.   
 
2.11. Ret-deprived nigral neurons are not sensitive to α-syn aggregation stress 
 
Mice lacking Ret and DJ-1 have an enhanced nigral degeneration compared to mice 
that only lack Ret, suggesting that absence of Ret signaling renders SN neurons more 
vulnerable to loss of protective DJ-1 function. Are Ret-deficient SN neurons more 
vulnerable to any kind of cellular stress?  
 
To evaluate this possibility, DAT-Ret mutant mice were crossed to mice 
overexpressing an aggregation-prone mutant of α-syn in SN neurons. Transgenic mice 
overexpressing a PD-causing mutant (Ala30Pro) version of human α-syn under the 
control of the TH promoter (TH-α-synA30P) were previously  shown to have very 
mild DA deficits and displayed no loss of DA neurons, up to 12-months of age 
(Rathke-Hartlieb et al., 2001).  
 
I first confirmed that mutant α-synA30P shows abnormal accumulation in SN cell 
bodies. Using an antibody that recognizes both the endogenous and the human 
transgenic α-syn, I found that endogenous α-syn is located at axon terminals in control 
animals (Figure 27C), and no protein is detected in SN cell bodies (Figure 27A). In 
contrast, transgenic α-syn Ala30Pro localizes at axon terminals (Figure 27, compare D 
with C) but also accumulates in the SN cell body (Figure 27B).  
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Figure 27. No synergistic effects of Ret deficiency and α-syn aggregation in nigral neurons. (A-H) 
Photomicrographs of 3-month-old control (A,C,E,G) and TH-α-synA30P (B, D, F, H) brain coronal 
sections from the substantia nigra (SN; A,B,E,F) or the striatum (STR; C,D,G,H) stained for total 
(endogenous and transgenic; A-D) and human transgenic (E-H) alpha-synuclein (α-syn). Antibodies 
against α-syn recognized both mouse and human (g-syn) or only the human (h-syn) protein. Note the 
abnormal accumulation of human α-syn in the SN (B,F) of TH-α-synA30P mice. (I-L) TH labeling of 
striatal DA fibers in 12-month-old control (I), TH-α-synA30P (J), DAT-Ret (K) and DAT-Ret;TH-α-
synA30P (L) mice. (M) Quantification of DA fiber density for the genotype groups mentioned above 
(n=4-5 mice/group; ***p<0.001, t-test). (N) Stereological quantification of TH-positive SN neurons in 
24-month-old control, TH-α-synA30P, DAT-Ret and DAT-Ret;TH-α–synA30P mice. While TH-α-
synA30P mice lose 20 % and DAT-Ret mice lose 18 % SN neurons, the loss in DAT-Ret;TH-α –
synA30P mice is additive (36 % loss) and not synergistic (n=4-5 mice/group; * p<0.05,** p<0.01, 
***p<0.001, Student’s t-test). Scale bars indicate 250 µm.  
 
The same conclusion was reached using a human specific α-syn antibody; the 
transgenic protein localizes both to the striatum (Figure 27H) and SN cell body 
(Figure 27F), while the endogenous α-syn is not detected by the human-specific 
antibody (Figure 27E,G). Thus, overexpressed mutant Ala30Pro α-syn shows 
abnormal accumulation in the SN cell body and is a potential source of cellular stress.   
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I then determined whether the presence of α-syn aggregates in SN DA fibers renders 
them more vulnerable to loss of Ret-mediated trophic support. I analyzed the DA fiber 
density in the striatum of 12-month-old control, TH-α-synA30P, DAT-Ret and DAT-
Ret ;TH-α-synA30P animals using TH as a marker for DA axons (Figure 27I-L). I 
found that DAT-Ret mice display a moderate loss of DA fibers innervating the 
striatum (30 %; n=5 mice/group; DAT-Ret vs. CTRL p<0,01, Student’s t-test; Figure 
27M), as previously mentioned (Figure 18). Interestingly, the degree of DA fiber loss 
in 12-month-old DAT-Ret;TH-α-synA30P mice was not different from that of age-
matched DAT-Ret mice (n=5 mice/group; p=NS, Student’s t-test; Figure 27M), 
suggesting that DA axons deprived of Ret-mediated trophic support are not more 
vulnerable to the presence of misfolded alpha-synuclein.   
 
Second, to investigate whether SN cell bodies deprived of Ret function are more 
vulnerable to aggregation of α-syn, I determined the number of SN cell bodies in 24-
month-old mutant and control animals. 24-month-old animals were chosen since the 
interaction between Ret and DJ-1 in controlling survival of SN cell bodies is maximal 
at this time point. I found surprisingly that 24-month-old TH-α-synA30P transgenic 
and DAT-Ret single mutant mice lose about 20 % of TH-positive DA neurons in the 
SN, relative to controls (Figure 27N). This suggests that the presence of aggregated α-
synA30P leads to the degeneration of a fraction of aging SN neurons. Furthermore, 
DAT-Ret;TH-α-synA30P mice lose 36 % of TH-positive DA neurons in the SN, as 
compared to controls (n=5 mice/group; DAT-Ret;TH-α-synA30P vs. CTRL p<0.001 
and DAT-Ret;TH-α-synA30P vs. DAT-Ret or TH-α-synA30P p<0.01, Student’s t-test; 
Figure 27N). Comparison of neuronal loss in TH-α-synA30P, DAT-Ret single and 
DAT-Ret;TH-α-synA30P mutants suggests that SN neuron loss in DAT-Ret;TH-α-
synA30P mice is additive and is not caused by a genetic interaction between trophic 
insufficiency (Ret loss) and increased cellular stress due to protein aggregation (α-syn 
overexpression); moreover, this result further suggests that distinct neurons are 
affected by loss of Ret function and α-syn aggregation. Therefore, aging SN cell 
bodies lacking Ret signaling are not more sensitive to the presence of aggregated α-
syn.  
 
Taken together, these two lines of evidence suggest that Ret deficiency does not 
render SN cell bodies and axons more vulnerable to any kind of cellular stress, but 
rather to defined types of dysfunction (e.g. absence of DJ-1 function) that amplify the 
effects of trophic deprivation in aging conditions. 
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C. Genetic interaction between Ret and DJ-1 in 
Drosophila melanogaster 
 
 
The convergent pro-survival activities of Ret and DJ-1 in aging SN neurons raised the 
possibility that these two proteins might function in similar pathway(s) or influence 
common downstream targets. To understand how Ret and DJ-1 activities mutually 
interact, we decided to use the fruit fly Drosophila melanogaster as a starting point 
for more detailed signal transduction studies. Drosophila has a long and successful 
history in signal transduction studies and allowed the identification and 
characterization of many critical regulators of cellular signaling. The ability to 
manipulate lethal mutations in non-essential fly tissues (e.g. retina, wings), to spatially 
and temporally control transgene expression and to specifically label diverse cellular 
populations has greatly accelerated cell signaling research. In addition, a vast majority 
of cell signaling regulators in Drosophila are conserved throughout evolution, further 
validating studies in this simpler organism. Signaling via receptor tyrosine kinases 
(RTKs) controls many aspects of Drosophila development and function (Voas and 
Rebay, 2004); for example, Drosophila eye development is very sensitive to dosage 
changes in RTKs like sevRTK or EGFR and downstream components of the PI3K/Akt 
and Ras/MAPK pathways (Duffy and Perrimon, 1994). Genetic alterations in these 
pathways lead to defects in eye development and adult eye morphology that can be 
easily analyzed and thus allow identification of novel interactors.   
 
Drosophila has two DJ-1 genes, named DJ-1A and DJ-1B. While Drosophila DJ-1B 
is ubiquitously expressed, DJ-1A appears to be enriched in certain tissues such as 
testes (Menzies et al., 2005; Meulener et al., 2005). Using a DJ-1B specific antibody, 
I confirmed that endogenous DJ-1B is expressed in Drosophila heads at postnatal day 
5; in addition, DJ-1B expression is lost in DJ-1A-/-;DJ-1B-/- flies (Figure 28A). 
Similarly, Pontus Klein used RT-PCR to show that the DJ-1A transcript is present in 
fly heads (data not shown). I then tested whether overexpression of constitutively 
active versions of Ret, Raf, ERK/rolled or wild-type Akt1 in the Drosophila eye 
system modulates the levels of endogenous DJ-1B protein. I used the photoreceptor 
neuron specific glass multimer reporter (GMR) which allows transgene 
overexpression via the GAL4/UAS system in post-mitotic photoreceptor neurons in 
the developing retina, starting in late larval stages (Read et al., 2005). I found that 
increased levels of constitutively active Ret, Raf, ERK or increased levels of WT 
Akt1 did not modify endogenous DJ-1B levels (Figure 28A). This suggests that the 
expression of DJ-1B is not modified following activation of Ret, Ras/ERK or Akt 
signaling. Moreover, I found that flies homozygous for DJ-1A and/or DJ-1B null 
alleles and flies overexpressing DJ-1A or DJ-1B in the eye (using the GMR driver) 
displayed normal development and eye ultrastructure (Fig. 18B and data not shown).  
Therefore, DJ-1A/B activity is dispensable for normal fly development.  
 
Our mouse experiments suggested that while DJ-1 function is dispensable for 
development and long-term maintenance of SN neurons, DJ-1 activity is required for 
survival of a subset of aging SN neurons deprived of Ret-mediated trophic support. 
We therefore addressed the possibility that the roles of DJ-1 in Drosophila might 
become important in situations of increased or decreased Ret and RTK signaling. We 
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started by testing whether DJ-1A/B interacts with constitutively active Ret and its 
downstream signaling during eye development.  
 
2.12. Ret interacts genetically with DJ-1A/B in the Drosophila eye system 
 
The roles of Ret signaling in Drosophila are poorly understood. Although Ret 
expression in Drosophila roughly parallels that in mammals, the ligand responsible 
for its activation remains unknown (Abrescia et al., 2005; Hahn and Bishop, 2001). In 
contrast, the use of constitutively active versions of Ret circumvents this regulation 
step and allows expression of ligand-independent active Ret protein in tissues like the 
developing retina. Flies carrying constitutively active versions of Ret fused to the 
GMR promoter (GMR-dRetMEN2) were generated by the laboratory of Ross Cagan at 
the Mount Sinai School of Medicine in New York and shown to interact with many 
already-identified WT Ret interactors (Read et al., 2005). GMR-dRetMEN2B flies 
develop with adult eyes of reduced size and rough morphology; this phenotype results 
from excessive proliferation, patterning defects and increased apoptosis triggered by 
overactive Ret (Read et al., 2005). I confirmed that GMR-dRetMEN2B flies develop with 
retinal defects and then complemented this observation with a quantitative evaluation 
of the GMR-dRetMEN2B phenotype. The overall eye size in GMR-dRetMEN2B flies was 
decreased by 30 % compared to controls (Figure 28B,C,E). I then sectioned the fly 
eyes and used a contrasting agent (toluidine blue) to highlight retinal organization. I 
found, as previously reported, that numerous ommatidia are often fused together and 
display abnormal polarity and poorly patterned inter-ommatidial spaces (Figure 28G). 
In addition, I found that the average ommatidium size was increased by 35% in GMR-
dRetMEN2B mutants relative to controls (that carried the GMR-Gal4 construct; Figure 
28G,I); a similar increase in photoreceptor cell size is seen in mutants overexpressing 
constitutively active Sevenless/Ras or PI3K/Akt components (Rubin et al., 1997; 
Vanhaesebroeck et al., 1997).  
 
 
 
 
 
 
 
Figure 28. Genetic interaction between Ret and DJ-1A/B in the Drosophila eye. (A) Western blot 
analysis showing normal levels of endogenous DJ-1B after overexpression of constitutively active Ret, 
Raf, ERK/rl or wild-type Akt1and DJ-1B, using the GMR promoter.  No DJ-1B was detected in DJ-1A-
/-DJ1B-/- heads. (B-D) Transgenic GMR-dRetMEN2B flies have smaller and rougher eyes (C) compared to 
wild-type controls (B); this phenotype is suppressed in a background of reduced DJ-1A/B activity (D). 
(E) Quantification of eye sizes in the indicated mutant and control flies (n=17-25 eyes/genotype; *** 
p<0.001, Student’s t-test).(F-H) Photomicrographs of ultrathin eye sections stained with toluidine blue 
showing the normal size and pattern of individual ommatidia of an adult control fly (F), the larger 
ommatidia of a GMR-dRetMEN2B fly (G), and the near normal ommatidia of a GMR- dRetMEN2B;DJ-1B+/- 
fly (H). (I) Quantification of ommatidia sizes in the indicated mutant and control flies (n=4 
eyes/genotype and n>150 ommatidia analyzed per animal; ** p<0.01, *** p<0.001, Student’s t-test). 
(J-L) Flies carrying a GMR-dRetMEN2A construct display smaller and rougher eyes (K) as compared to 
controls (J); this phenotype is rescued in a background of reduced DJ-1A/B activity (L).  (M) 
Quantification of eye sizes in the indicated mutant and control flies (n >10 eyes/genotype; *** 
p<0.001, t-test). (N-P) Overexpression of dRetMEN2A using the GMR promoter (GMR/UAS-dRetMEN2A) 
leads to a moderate rough eye phenotype (O) compared to control (N), which can be further enhanced 
by DJ-1A co-overexpression (P). GMR/UAS-dRetMEN2A/UAS-DJ1A eyes are rougher, have a glassy 
appearance (P), and a reduced size compared to control and GMR/UAS-dRetMEN2A flies (Q; 
quantification of n>10 eyes per genotype, ***p<0.001, Student’s t-test). 
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To determine whether DJ-1 is a Ret interactor, I crossed GMR-dRetMEN2B flies with 
flies carrying DJ-1A and/or DJ-1B microdeletions that specifically inactivate DJ-1A 
or DJ-1B function (here named “knockout alleles”) (Meulener et al., 2005). 
Remarkably, reducing DJ-1A/B activity lead to a strong suppression of GMR-
dRetMEN2B phenotype (Figure 28D,E), the resulting eyes having an improved overall 
organization. At the histological level, the ommatidial organization of GMR-
dRetMEN2B flies heterozygous for DJ-1A (GMR-dRetMEN2B;DJ-1A+/-) or DJ-1B (GMR-
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dRetMEN2B;DJ-1B+/-), or lacking completely DJ-1A (GMR-dRetMEN2B; DJ-1A-/-) was 
significantly restored and the size of ommatidial units was almost completely rescued 
(Figure 28I). Thus, DJ-1A/B activity is required for full manifestation of RetMEN2B-
induced eye phenotype.   
 
We next asked whether reducing DJ-1A/B activity ameliorates the retinal defects 
induced by another constitutively active Ret form (dRetMEN2A). GMR-dRetMEN2A flies 
also display a rough eye phenotype and a reduction in total eye size (Figure 28K,M). 
Remarkably, when DJ-1A/B function is reduced (GMR-dRetMEN2A;DJ-1A+/-;DJ-1B-/- 
flies) the phenotype caused by RetMEN2A overexpression is strongly suppressed (Figure 
28L,M). Therefore, DJ-1A/B activity is required for full manifestation of RetMENA-
induced eye phenotype.  
 
I then evaluated whether increasing DJ-1 activity is sufficient to further impair eye 
development in flies overexpressing constitutively active RetMEN2. For this, I used the 
moderate phenotype caused by RetMEN2A overexpression in photoreceptor neurons 
using the GAL4/UAS system (GMR-Gal4/UAS-dRetMEN2A; Figure 28O,Q). When DJ-
1A was co-expressed with RetMEN2A in developing photoreceptor neurons (GMR-
Gal4/UAS-dRetMEN2A/UAS-DJ1AWT) the eye phenotype was further enhanced, and the 
resulting eyes became even smaller (Figure 28P,Q).  Therefore, DJ-1A/B activity is 
both necessary and sufficient to allow manifestation or to modulate RetMEN2-eye 
phenotypes in Drosophila, suggesting that DJ-1A/B interact genetically with RetMEN2 
in the developing fly retina.   
 
To further confirm that the modulatory effects on RetMEN2-eye development can be 
attributed specifically to DJ-1A/B, I used independent DJ-1A/B loss-of-function 
alleles. P-element insertions that disrupt both DJ-1A (Ins[2R]k04204) and DJ-1B 
(Ins[3R]16805) genes have been previously generated and are predicted to function as 
either hypomorphic (reduced protein function) or null (complete loss of protein 
function) alleles. Similarly, chromosomal deficiencies that remove several genes 
including DJ-1A (Df[2R]CX1) or DJ-1B (Df[3R]7917) are null alleles for DJ-1A or DJ-
1B, respectively. I generated GMR-dRetMEN2B flies that carried these loss-of-function 
alleles and characterized their retinal organization and ultrastructure. I found 
remarkably, that the defects in eye and organization and size induced by overactive 
RetMEN2B were strongly suppressed in these backgrounds of reduced DJ-1A/B activity; 
the resulting eyes displayed an improved retinal organization and restored eye size 
(Figure 29C-F,G). Similarly, the abnormal increase in ommatidia size and abnormal 
ommatidial fusion induced by overactive RetMEN2B were significantly suppressed in a 
DJ-1A heterozygous background (GMR-dRetMEN2B/ Df(2R)CX1; Figure 29H-K). Thus, 
the GMR-dRetMEN2B-mediated eye phenotype is partially suppressed in backgrounds of 
reduced DJ-1A/B activity.  
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Figure 29. Active Ret interacts with independent DJ-1A/B loss-of-function alleles. (A-F) 
Overexpression of constitutively active Ret in the developing retina (GMR-dRetMEN2B)  leads to a rough 
eye phenotype (B) which can be rescued in backgrounds of reduced DJ-1A or DJ-1B activity (C-F); 
deficiencies that remove DJ-1A (C) or DJ-1B (E) genes or insertions in the DJ-1A (D) or DJ-1B (F) 
genes were used.  (G) Quantification of eye sizes in the indicated mutant and control flies (n>15 
eyes/group; *** p<0.001, Student’s t-test). (H-J) Photomicrographs of ultrathin eye sections stained 
with toluidine blue showing enlarged ommatidia in GMR-dRetMEN2B flies (I) as compared to controls 
(H) and near normal ommatidia in GMR-dRetMEN2B flies carrying a DJ-1A deficiency (J). (K) 
Quantification of ommatidia sizes in the indicated mutant and control flies (n=4 eyes/genotype and 
n>150 ommatidia analyzed per animal; *** p<0.001, Student’s t-test).   
 
Taken together, these independent lines of evidence suggest that DJ-1A/B interact 
genetically with RetMEN2 in the developing fly retina.   
 
 
2.13. No interaction between PI3K/Akt signaling and DJ-1A/B 
 
Activation of the Ret RTK leads to the activation of two major signaling pathways: 
PI3K/Akt and MAPK signaling. To understand whether the interaction between Ret 
and DJ-1 involves these Ret-mediated signaling pathways, I investigated the capacity 
of fly DJ-1A/B to genetically modify the phenotypes associated with altered activity 
in the PI3K/Akt and MAPK signaling. 
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In the developing eye system of Drosophila, PI3K/Akt signaling controls 
photoreceptor patterning, proliferation, differentiation and cell size (Vanhaesebroeck 
et al., 1997). Consequently, upon strong overexpression of wild-type PI3K using the 
photoreceptor specific driver GMR (GMR/PI3KWT at 30°C), I observed a 25% 
increase in eye size and a disorganized retina compared to controls (GMR-Gal4) 
(Figure 30A,B,A’,B’,D). This phenotype is likely due to excessive cell proliferation, 
increase in cell size and patterning defects. To test whether the absence of DJ-1B 
function can suppress this phenotype, I generated flies that overexpress GMR-driven 
PI3KWT in a DJ-1B-/- background (GMR/PI3KWT; DJ-1B-/-). The increase in eye size 
and retinal defects were not suppressed in these flies (Figure 30C,C’,D), suggesting 
that DJ-1B activity does not play a role in the PI3KWT overexpression phenotype.  
 
I next tested whether overexpression of DJ-1A or DJ-1B is sufficient to enhance the 
phenotype of increased PI3K/Akt signaling. For this, I used the moderate eye 
phenotype induced by wild-type Akt1 overexpression (GMR/Akt1WT at 25ºC), which 
causes a 25 % increase in eye size without creating other visible morphological 
defects (Figure 30E,F,I). At the histological level, GMR/Akt1WT retinas display a 20% 
increase in ommatidia sizes, consistent with the role of PI3K/Akt signaling in cell size 
regulation (Leevers et al., 1996) (Figure 30E’,F’,J). When DJ-1A or DJ-1B were co-
overexpressed with Akt1WT, no additional increase in eye size was observed nor did 
the resulting eyes become disorganized (Figure 30G,H,I). Histologically, 
GMR/Akt1WT/DJ1A and GMR/Akt1WT/DJ1B ommatidia displayed the same size 
increase as those in GMR/Akt1WT flies (Figure 30 G’,H’,J). Similar results were 
obtained in flies expressing a constitutively active version of PI3K (PI3KCAAX) which 
is membrane-bound PI3K; the increase in eye size and mild rough eye phenotype 
(Figure 30O,P,S) were not further modulated after altering the levels of DJ-1A or DJ-
1B (Figure 30Q,R,S). Thus, DJ-1A/B fails to interact with overactive PI3K/Akt 
signaling. 
 
 
Figure 30. No interaction between PI3K/Akt and DJ-1A/B in the Drosophila eye. (A-C) 
Overexpression of PI3KWT in photoreceptor neurons (GMR-Gal4; UAS-PI3KWT) leads to a rough eye of 
increased size (B), as compared to control (A); in a DJ-1B-/- background, this phenotype is not modified 
(C). Flies were raised at 30ºC to enhance the phenotype; similar results were obtained at 25ºC (data not 
shown). (D) Quantification of eye sizes in the indicated mutant and control flies (n>25 eyes/group; *** 
p<0.001, Student’s t-test). (A’-C’) Photomicrographs of ultrathin eye sections stained with toluidine 
blue showing the normal size and pattern of individual ommatidia of an adult control fly (A’), and the 
disorganized eyes of both GMR/PI3KWT (B’) and a GMR/PI3KWT; DJ-1B-/- fly (C’). (E-H) No 
enhancement of Akt1WT overexpression (GMR/Akt1WT) phenotype by DJ-1A or DJ-1B co-
overexpression or in a heterozygous DJ-1B knockout background. The increased eye size compared to 
controls (E) after Akt1WT overexpression (F) is not further modified after DJ-1A (G) or DJ-1B (H) 
overexpression or in a DJ-1B heterozygous background (I). Similarly, the increased ommatidial size 
induced by Akt1WT overexpression (F’, J) is not modified by DJ-1A (G’,J) or DJ-1B (H’,J) 
overexpression. (I,J) Quantifications of eye (n>25 animals) and ommatidia sizes (n=4 eyes/genotype 
and n>150 ommatidia analyzed per animal; *** p<0.001, Student’s t-test). (K-M) No further 
enhancement of a dominant-negative PI3K overexpression phenotype in a DJ-1B null background. The 
decreased eye size after PI3KD954A overexpression (at 30ºC; L, N) is not modified in a DJ-1B null 
background (M, N). Similarly, the retinal defects induced by PI3KD954A (L) are not enhanced by DJ-1B 
loss-of-function (M). (N) Quantification of eye sizes (n>25 animals per group, *** p<0.001, Student’s 
t-test). (O-R) DJ-1A and DJ-1B do not modulate the eye phenotype induced by overexpression of 
constitutive active PI3K. The increased eye size and eye roughness after PI3KCAAX overexpression (P) 
are not modified after DJ-1A (Q, S) or DJ-1B (R, S) co-overexpression or in a DJ-1B heterozygous 
background (S). (S) Quantification of eye sizes (n>25 animals per group, *** p<0.001, Student’s t-
test).  
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I then considered the possibility that DJ-1 might interact with decreased levels of 
PI3K/Akt signaling. I used a dominant-negative version of the PI3K (PI3KD954A) 
which carries a mutation in the catalytic domain leading to reduced kinase activity 
(Leevers et al., 1996). When PI3KD954A is targeted to developing photoreceptors 
(GMR/PI3KD954A), the development of the eye is severely impaired; although total eye 
size is only moderately reduced (10-20%; Figure 30K,L,N), many photoreceptor 
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neurons are lost, suggesting that apoptosis in the retina occurs relatively late during 
development (Figure 30K’,L’). When overexpressing PI3KD954A in a DJ-1B null 
background (GMR/PI3KD954A;DJ-1B-/-), no enhancement of retinal phenotype relative 
to GMR/PI3KD954A flies was observed; the total eye size (Figure 30M,N) and retinal 
morphology (Figure 30M’) remained similar. Therefore, absence of DJ-1B activity 
does not further exacerbate the loss of PI3K activity in the developing fly retina.   
 
Taken together, these independent experiments results suggest that DJ-1A/B do not 
interact with the PI3K/Akt pathway in controlling eye development in Drosophila.  
 
2.14. DJ-1A/B activity is sufficient to suppress the PTEN-mediated eye phenotype 
 
A previous report suggested that Drosophila DJ-1A is both necessary and sufficient to 
interact with the tumor suppressor PTEN during the development of the retina and in 
mammalian cell culture (Kim et al., 2005a). Moreover, DJ-1 also modulated the 
activation status of the Akt kinase in vitro (Gorner et al., 2007; Kim et al., 2005a). 
Our findings that DJ-1A/B do not interact with PI3K/Akt signaling are in apparent 
contrast to these published reports. To determine whether DJ-1A/B interact genetically 
with PTEN in the Drosophila eye system, I used the eye specific promoter eyeless, 
which induces transgene expression already in proliferating cells. As previously 
reported (Kim et al., 2005a), such a strong overexpression of PTEN (ey/PTEN) leads 
to an adult eye of severely reduced size (Figure 31A,B,K). At the histological level, 
the resulting ommatidia are smaller, consistent with the role of PTEN as negative 
regulator of the PI3K/Akt signaling (Figure 31A’,B’,L). Interestingly, this PTEN-
mediated phenotype can be partially suppressed when WT Ret, DJ-1A or DJ-1B 
activity is increased (Figure 31C-E,K); the resulting ommatidia have a partially 
restored size (Figure 31A’-E’,L). These results confirm the previous observations that 
DJ-1A is a novel PTEN regulator, and also identify DJ-1B as a potential PTEN 
interactor.  
 
To determine whether DJ-1A or DJ-1B activity is required to suppress the PTEN-
induced eye phenotype, I used flies in which PTEN was mildly overexpressed to 
allow testing for enhancement. For this, I used the GMR driver which is active in 
postmitotic cells only, in contrast to eyeless is activated in actively proliferating cells. 
In contrast to the more affected ey/PTEN flies, which display reduced cell 
proliferation and cell size, GMR/PTEN flies display only a (moderately) reduced cell 
and retina size (Figure 31F,G). Surprisingly, GMR/PTEN flies with reduced levels of 
DJ-1A/B do not display more severe eye phenotypes as compared to flies carrying 
GMR/PTEN in a wild-type background (Figure 31H,I). In addition, GMR/PTEN flies 
lacking completely DJ-1B function (GMR/PTEN;DJ-1B-/-) were similarly not more 
affected than GMR/PTEN flies (Figure 31J).   
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Figure 31. DJ-1 activity is sufficient to suppress the PTEN-mediated eye phenotype. (A-E) Images 
of the normal eye of an adult control fly (A), the smaller and rough eye of a fly overexpressing PTEN 
controlled by the eyeless promoter (B; ey-Gal4; UAS-PTEN), and rescued eyes of ey-PTEN flies that 
co-overexpress RetWT (C) DJ-1A (D) or DJ-1B (E). (A’-E’) Photomicrographs of ultrathin eye sections 
stained with toluidine blue showing the normal size and pattern of individual ommatidia of an adult 
control fly (A’), the smaller ommatidia of an ey-PTEN fly (B’), and the rescue of ommatidial sizes in 
ey-PTEN flies that co-overexpress RetWT (C’), DJ-1A (D’) or DJ-1B (E’). (K) Quantification of eye 
sizes in the indicated mutant and control flies (n>25 eyes per genotype; *** p<0.001, t-test). (L) 
Quantification of ommatidia sizes in the indicated mutant and control flies (n=4 eyes/group and n>150 
ommatidia analyzed/eye; * p<0.05 and ** p<0.01, t-test). (F-J) Little effect of DJ-1A/B inactivation on 
the phenotype induced by PTEN overexpression. Images of an adult control eye (F), the slightly 
reduced eye size of a fly overexpressing PTEN controlled by the GMR promoter (Q; GMR-Gal4; UAS-
PTEN), and eye of similar size in GMR/PTEN flies heterozygous knockout for DJ-1A (H) or DJ-1B (I) 
or homozygous knockout for DJ-1B (J).  
 
Thus, while DJ-1 overexpression is sufficient to inhibit the effects of PTEN-
overexpression, DJ-1A/B is not required to mediate this inhibiting effect. Therefore, 
DJ-1 might interact with PTEN only in defined situations (e.g. in oncogenic 
conditions), but in a PI3K-Akt independent manner (see Discussion). 
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2.15. DJ-1 interacts genetically with overactive Ras/ERK signaling  
 
Activation of Ras/MAPK signaling in Drosophila controls cell differentiation, 
proliferation and size (Friedman and Perrimon, 2006; Prober and Edgar, 2000). Flies 
with increased Ras/Raf/ERK activity display patterning and proliferation defects and 
exhibit an increase in the number of photoreceptors per ommatidium, while reducing 
the activity in this pathway leads to failure of non-neuronal cells to differentiate into 
neurons (Biggs et al., 1994). Moreover, a tight regulation of Ras/MAPK signaling is 
required during the embryonic development of numerous structures, including eye and 
wing (Friedman and Perrimon, 2006; Johnson Hamlet and Perkins, 2001).  
  
To investigate whether DJ-1 interacts with the Ras/ERK pathway, I used 
constitutively active versions of Ras and the MAPK ERK/rolled (rl), which impair 
eye development by promoting excessive proliferation and altered cell differentiation 
(Brunner et al., 1994). Point mutations in the Ras oncogene are found in 30 % of all 
cancers. The most common mutation is the substitution of glycine 12 with valine 
(RasG12V, also called RasV12), that leads constitutive association with GTP; Ras is 
“locked” in this GTP-bound state and is therefore constitutively active (Dhillon et al., 
2007). Ras/ERK signaling was found to be particularly important for the development 
of the seventh photoreceptor neuron (R7) contained in each ommatidium. 
Overexpression of consitutively active RasV12 in R7 photoreceptor neurons driven by 
the R7-neuron specific promoter sevenless (that is fused to the coding sequence for 
RasV12; Sev-RasV12) is sufficient to induce abnormal differentiation of additional cells 
into R7 photoreceptors; as a result, multiple R7 photoreceptors are induced in each 
ommatidium (Karim et al., 1996). To test whether DJ-1A/B interacts genetically with 
activated Ras, I generated flies expressing Sev-RasV12 in either a wild-type background 
or a background of reduced DJ-1A/B activity (Figure 32). As expected, flies 
expressing Sev-RasV12 in a wild-type background developed with rough eyes (Figure 
32B); histological examination of their retina revealed that the total number of 
photoreceptor neurons in each ommatidium increased to an average of 8,5 
photoreceptors /ommatidium (P/O; Figure 32B’,P).  
 
Figure 32. DJ-1A/B interact genetically with Ras signaling in Drosophila. (A-E, P) DJ-1A/B interact 
genetically with constitutively active Ras in the fly retina. (A-E) eye images showing a normal control 
eye (A), the rough eye phenotype of flies carrying a Sev-RasV12 construct (B) and the rescue of the 
rough eye in a DJ-1A/DJ-1B heterozygous knockout background (C). GMR-mediated DJ-1A 
overexpression further enhances the Ras-induced phenotype (Sev-RasV12/GMR/DJ1A, E) as compared 
to control (Sev-RasV12/GMR, D). (A’-E’) Photomicrographs of ultrathin eye sections showing normal 
control ommatidia (A’), the Sev-RasV12-induced increase in photoreceptors and fused ommatidia (B’, 
stippled lines indicate missing separations due to abnormal fusions of ommatidia) and the rescue after 
reducing DJ-1A/B function (C’). (E’) Further increase of the number of photoreceptors/ommatidium 
and worsening of retinal ultrastructural defects after DJ-1A overexpression as compared to control (D’). 
(P) Quantification of the numbers of photoreceptors/ommatidium (n=4 eyes/group and n>150 
ommatidia analyzed per eye; ** p<0.01 and *** p<0.001, t-test). (K-O,Q) No further modulation of 
constitutively active rolled-induced eye phenotype by DJ-1A or DJ-1B. (K-O) eye images showing a 
control eye (K), the rough eye phenotype induced by rlSEM overexpression (L; GMR-Gal4; UAS-rlSEM), 
and the lack of modulation after co-overexpression of DJ-1A (M) or DJ-1B (N) or after decreasing DJ-
1B function (O). (K’-O’) Photomicrographs of ultrathin eye sections showing normal control 
ommatidia (K’), the GMR/rlSEM-mediated increase in photoreceptor number/ommatidium (L’) and the 
lack of modulation after co-overexpression of DJ-1A (M’), DJ-1B (N’) or after decreasing DJ-1B levels 
(O’). (Q) Quantification of the numbers of photoreceptors/ommatidium (n=4 eyes/group and n>150 
ommatidia analyzed per eye; *** p<0.001, t-test). 
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When reducing the DJ-1A/B levels (Sev-RasV12;DJ-1A+/-;DJ-1B+/-), this phenotype 
was significantly rescued (Figure 32C) the Sev-RasV12;DJ-1A+/-;DJ-1B+/-flies 
displaying an improved retinal morphology while the number of P/O was restored 
(Figure 32C’,P). In addition, while in Sev-RasV12 flies 67 % of ommatidia were 
abnormally fused with their neighbors, only 5 % abnormally fused ommatidia were 
detected in the rescued Sev-RasV12;DJ-1A+/-;DJ-1B+/- flies (Figure 32 C’and data not 
shown). Thus, DJ-1A/B activity is required for the full manifestation of the RasV12-
induced eye phenotype.  
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To test whether DJ-1 is sufficient to modulate the RasV12-mediated eye phenotype, I 
co-overexpressed RasV12 in R7 neurons (Sev-RasV12) and DJ-1A in all photoreceptor 
neurons (using the GMR driver). While Sev-RasV12and Sev-RasV12/GMR-Gal4 flies 
displayed the same moderate eye phenotype (Figure 32D,D’,P), Sev-RasV12/GMR/DJ-
1A eyes were severely affected and very rough (Figure 32E). At the histological level, 
Sev-RasV12/GMR/DJ-1A eyes displayed a strong increase in the number of P/O (11 on 
average) compared to Sev-RasV12 and Sev-RasV12/GMR-Gal4 retinas (Figure 32E’,P). 
Thus, DJ-1 activity appears sufficient to modulate the RasV12-mediated eye 
development.  
 
The use of a constitutively active version of Ras also allows us to determine whether 
the novel Ras interactor DJ-1 functions upstream, downstream or in parallel to Ras in 
controlling photoreceptor neuron development. Constitutively active RasV12 cannot be 
further regulated by any upstream interactor that normally regulates the wild-type 
Ras. In contrast, the phenotype mediated by RasV12 could still be modulated by 
interactors acting downstream of Ras or in a parallel pathway. Since modulation of 
DJ-1A/B levels caused a modification of the RasV12-mediated eye phenotype, DJ-
1A/B functions either downstream of Ras or in a parallel pathway that cooperates with 
Ras signaling to control Drosophila eye development.   
 
I then assessed the modulation of constitutively active rolled(Erk) signaling by DJ-1. 
A substitution of a single conserved amino acid in the kinase domain of rolled (called 
sevenmaker) is sufficient to constitutively activate its Ser/Tyr kinase activity; the 
mutation was named sevenmaker (SEM) because its targetting to the developing retina 
leads to the formation of multiple R7 photoreceoptor neurons in each ommatidium 
(Brunner et al., 1994). I overexpressed rlSEM in all photoreceptor neurons using the 
GMR driver. The resulting GMR/rlSEM eyes were rough, slightly reduced in size and 
relatively disorganized compared to control GMR-Gal4 eyes (Figure 32L). When 
analyzing the retinal ultrastructure, I found an increase in the number of P/O (9,5 P/O 
on average; Figure 32Q). I then generated flies that co-overexpress rlSEM and DJ-1A 
(GMR/rlSEM/DJ-1A) or DJ-1B (GMR/rlSEM/DJ-1B); I also generated flies 
overexpressing rlSEM in a DJ-1B heterozygous knockout background (GMR/rlSEM;DJ-
1B+/-). The rough eye phenotype induced by rlSEM overexpression was not further 
enhanced after DJ-1A/B overexpression (Figure 32M,N) nor did a decrease in DJ-1B 
activity exert a suppressing effect on the rlSEM-mediated phenotype (Figure 32O); at 
the histological level, the increase in the number of P/O caused by rlSEM 
overexpression was not further modulated after modifying the levels of DJ-1A/B 
(Figure 32M’-O’,Q). Because DJ-1A/B activity failed to further modulate the 
constitutively active rolled signaling, DJ-1A/B function either upstream of 
Rolled/ERK or in parallel to the Rolled/ERK signaling pathway to control cell 
differentiation and proliferation in the retina.   
 
 
Taken together, these results indicate that DJ-1A/B interacts with Ras-mediated 
signaling and DJ-1A/B function either between Ras and ERK or in parallel to 
Ras/ERK signaling to control eye development induced by overactive Ras/ERK 
signaling.  
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2.16. DJ-1 and ERK interaction controls Drosophila eye and wing development  
 
The interaction between endogenous DJ-1A/B and the ectopically expressed 
overactive Ras/ERK prompted us to investigate whether DJ-1A/B and the endogenous 
Ras/ERK interact during the normal development of the fly. To test whether DJ-1A/B 
interacts with endogenous ERK signaling in Drosophila, I performed double loss-of-
function experiments. I investigated this potential interaction in two places where 
ERK/Rolled is known to play a crucial role during development: the development of 
photoreceptor neurons and wing venation (Friedman and Perrimon, 2006).  
 
I used a rolled(rl)/ERK hypomorphic allele (rl1) that leads to a moderate loss of 
rl/ERK activity. Flies carrying two rl1 alleles (rl1/rl1) are viable and display moderate 
rl-associated phenotypes. Consistent with a role for rl/ERK in proper photoreceptor 
neuron development, rl1/rl1 eyes were slightly smaller and displayed a mild reduction 
in the number of P/O (6.64; Figure 33C,C’,I,J,K). Remarkably, while control and DJ-
1B-/- flies had a normal appearance and a normal complement of 7 P/O (Figure 
33A,A’,B,B’,I,J,K), eyes with reduced rl/ERK function and lacking DJ-1B (rl1/rl1;DJ-
1B-/-) flies were significantly smaller, rough and displayed on average only 5.34 P/O 
(Figure 33D,D’,I,J,K; p<0.05 CTRL vs. rl1/rl1; p<0.001 rl1/rl1 vs. rl1/rl1;DJ-1B-/-, 
Student’s t-test). In addition, while a fraction of rl1/rl1 ommatidia contained 6 P/O, 
many ommatidia in rl1/rl1;DJ-1B-/- flies have 5, 4 or 3 P/O (Figure 33J). This suggests 
that DJ-1B is required as a rolled interactor to control photoreceptor neuron 
development.  
 
I then investigated the development of the wing and found that rl1/rl1 flies had a very 
mild defect in wing venation, the vein L4 being sometimes thinner (in about 20 % of 
the animals; Figure 33F,F’,L) (Brunner et al., 1994). While in control and DJ-1B-/- 
flies the L4 vein developed normally, in wings with reduced rl/ERK activity and 
lacking DJ-1B (rl1/rl1;DJ-1B-/-) the thinning of the L4 vein was either short (in 33 % 
of animals), long (37 % of all cases) or the L4 vein was interrupted (in 25 % of 
animals; Figure 33G,G’,H,H’,L). Such an enhanced phenotype was previously seen in 
flies with a very strong reduction in rl/ERK function – these flies carried a 
combination of rl1 and the stronger allele rl10 (a deficiency; Brunner et al., 1994). DJ-
1B is thus required, as a rolled interactor, to control the development of the wing.  
 
These results uncovered, for the first time, a role for DJ-1B in the unchallenged fly 
and suggest that DJ-1B cooperates with Ras/MAPK signaling during photoreceptor 
neuron and wing imaginal disc development. 
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Figure 33. DJ-1B cooperates with endogenous Ras/ERK signaling to control eye and wing 
development. (A-D,I-K) Interaction between DJ-1B and rolled/ERK controls photoreceptor neuron 
development. (A-D) Images of normal eyes of control (A) and DJ-1B-/- (B) flies, of a smaller rl1/rl1 eye 
(C; rl1 is a hypomorphic rolled allele) and a very small and rough eye in a fly with reduced rl1 activity 
and completely lacking DJ-1B function (rl1/rl1; DJ1B-/-; D). (I) Quantification of eye sizes (n>50 eyes 
per group, *** p<0.001 t-test). (A’-D’) Photomicrographs of ultrathin eye sections showing the normal 
retina of control (E) and DJ-1B-/- flies (F), the mild reduction in photoreceptors/ommatidium (P/O) in 
the rl1/rl1 retina (G) and the stronger reduction seen in the rl1/rl1; DJ1B-/- retina (H). (J) Histogram 
showing the distribution of photoreceptor neurons/ommatidium in DJ-1B-/-, rl1/rl1 and rl1/rl1;DJ-1B-/- 
flies. All ommatidia in DJ-1B-/- flies carry 7 photoreceptor neurons in one plane (identical to wild-type 
control flies; not shown). While some rl1/rl1 ommatidia have 6 P/O, many rl1/rl1;DJ-1B-/- ommatidia 
develop with less than 6 P/O. (K) Quantification of the average number of photoreceptors/ommatidium 
(n=4 eyes/group and n>150 ommatidia analyzed per eye, * p<0.05 and *** p<0.001, t-test). (E-H,L) 
Interaction between DJ-1B and rolled/ERK controls wing vein development. (E-H) images of full-size 
wings and (E’-H’) magnifications showing the central portion of the L4 vein (arrows). DJ-1B-/- flies 
develop with normal wings (E,E’) while in rl1/rl1 flies the L4 vein has short stretches of thinner 
diameter (F, F’). In contrast, rl1/rl1 DJ1B-/- flies often develop with the L4 vein having long stretches of 
thinner diameter (G,G’) or with an interrupted L4 vein (H,H’). (L) Quantification of the L4 vein 
phenotype categorized as wild-type, with short stretches of thinner diameter, with long stretches of 
thinner diameter, or interrupted. The observed frequencies are shown for the different genotypes 
(n>115 wings analyzed per animal). 
 
2.17. DJ-1 controls oxidative stress response in Drosophila 
 
Oxidative stress was proposed to one of the major pathological events that lead to 
dopaminergic neurodegeneration (Abou-Sleiman et al., 2006). The control of 
oxidative stress might play a pivotal role in therapies for PD. Flies lacking DJ-1B 
were previously shown to be deficient in control of oxidative stress response. When 
challenged with toxins associated with PD (paraquat, rotenone) and with other 
oxidative stress inducers (H2O2), DJ-1B mutants were significantly more sensitive and 
displayed an enhanced lethality ; they were not, however, more sensitive to any toxic 
stress, as these mutants were not more sensitive to other toxins like DTT (reducing 
agent and protein denaturant) or MG132 (proteasome inhibitor). This lethality was 
rescued by overexpression of either Drosophila DJ-1B or DJ-1A genes (Menzies et 
al., 2005; Meulener et al., 2005).  
 
I administered either paraquat or H2O2 to WT and DJ-1A or DJ-1B single and DJ-
1A/DJ-1B double knockout flies and tested their long-term survival. Absence of DJ-
1B function (in DJ-1B single and DJ-1A/DJ-1B double KO) rendered the flies more 
sensitive to these toxins, consistent with previous observations (Figure 34A). In 
contrast, flies lacking DJ-1A function were only mildly affected. These results suggest 
that DJ-1B controls the oxidative stress response to PD-associated toxins. My 
preliminary results also suggest that overexpression of human DJ-1 is able to partially 
rescue the increased sensitivity due to loss of fly DJ-1B, suggesting that the anti-
oxidant activity of DJ-1 is evolutionary conserved (data not shown). I am now 
determining whether flies with reduced rl and DJ-1B function show increased toxin-
sensitivity compared to rl1 and DJ-1B deficient flies and whether activation of rl 
signaling (using a rlSEM allele that is expressed in all cells) can complement the toxin-
sensitivity of DJ-1B null flies.  
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Figure 34. DJ-1B controls oxidative stress response and interacts with FOXO in Drosophila. (A) 
Survival of wild-type (black line), DJ-1A-/- (red line), DJ-1B-/- (blue line) and DJ-1A-/-; DJ-1B-/- double 
mutant (green line) adult flies exposed to 20 mM paraquat. Flies lacking DJ-1B function show an 
enhanced sensitivity to paraquat, as compared to controls, while lack of DJ-1A function only partially 
affects fly survival.  (B-E) DJ-1A/B interact genetically with FOXO in the Drosophila eye system. 
Overexpression of FOXO in photoreceptor neurons (GMR-Gal4; UAS-FOXO) leads to a smaller, rough 
eye (C) compared to control (B). Co-overexpression of DJ-1A (D) or DJ-1B (E) partially rescues the 
GMR/FOXO eye phenotype, the resulting rescued eyes displaying an improved overall organization.  
 
 
A major regulator of oxidative stress response, longevity and apoptosis is the 
Forkhead family member FOXO; FOXO is required to protect against oxidative 
stress, while increased levels of FOXO during chronic stress can induce apoptosis 
(Giannakou et al., 2004; Junger et al., 2003). Remarkably, the extension of longevity 
mediated by Sirtuins (Sir2) in several organisms involve the deacetylation of FOXO, 
which switches the function of FOXO from pro-apoptotic to pro-survival (Giannakou 
and Partridge, 2004). I tested whether DJ-1 can interact with FOXO signaling in the 
developing retina. In this system, overexpression of FOXO induces excessive 
apoptosis and generates a rough eye of reduced eye size (Figure 34C). Remarkably, 
when DJ-1A or DJ-1B are co-overexpressed with FOXO in developing photoreceptor 
neurons (using the GMR driver), the FOXO-induced phenotype is partially 
suppressed, the resulting retina displaying less irregularities (Figure 34D,E). These 
initial results suggest that DJ-1 interacts genetically with the transcription factor 
FOXO, and raise the possibility that DJ-1 might control stress response by modulating 
this master transcriptional regulator.  
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The mechanisms underlying the selective death of SN neurons in PD are incompletely 
understood. Although several symptomatic therapies exist, none of them is able to halt 
PD progression, suggesting that a better understanding of the molecular mechanisms 
regulating maintenance and degeneration of SN neurons is needed in order to 
successfully fight against PD. Although neurotrophic factors like GDNF and BDNF 
are considered to be rescuing agents for dysfunctional SN neurons, the results from 
clinical trials where they were administered to PD patients are conflicting. To 
understand the physiological relevance of GDNF and BDNF signaling for the aging 
DA system, we deleted their respective signaling receptors Ret and TrkB in 
dopaminergic neurons specifically.  
 
The present work identifies the GDNF signaling receptor Ret as a critical regulator of 
SN long-term survival. Mice lacking Ret, but not the TrkB receptor, show progressive 
degeneration of SN neurons and their axons, postsynaptic dysfunction in the SN target 
area, the striatum, and enhanced neuroinflammation.  
 
The identification of genes causing familial PD has raised hopes for a better 
understanding of the molecular pathology underlying nigral degeneration. These 
initial expectations were tempered by the lack of SN degeneration in mice genetically 
engineered to carry PD-causing mutations. This raises the possibility that several 
independent pathological defects of reduced severity add up to cause SN cell death. 
To unravel additional pro-survival regulators of reduced power in the aging DA 
system, we analyzed the survival requirements of trophically deprived DA neurons.  
 
Remarkably, we found that the PD-associated gene DJ-1, although dispensable for 
survival of wild-type SN neurons, is required for survival of Ret-deprived DA neurons 
during aging. Ret and DJ-1 double knockout mice show an enhanced loss of SN 
neurons, specifically in the GIRK2 subpopulation, which projects exclusively to the 
striatum and is specifically affected in PD patients. Thus, the triple interaction 
between aging, trophic insufficiency and cellular stress due to loss of DJ-1 function 
causes degeneration of 51 % SN neurons that innervate the striatum. Using 
Drosophila genetics, we found that Ret and DJ-1 interact genetically to control eye 
development; moreover, DJ-1 interacts with Ras/ERK, but not PI3K/Akt pathway to 
promote photoreceptor neuron and wing development.  
 
 
Taken together, these results indicate that aging SN DA neurons rely on a pro-survival 
network that includes Ret and DJ-1. Therefore, mice lacking Ret and DJ-1 could serve 
as models to further investigate the pathological mechanisms underlying PD and 
associated disorders. Moreover, we suggest that activation of Ret signaling (including 
for example, the striatal delivery of GDNF) might be employed as a therapeutic 
strategy to mitigate SN neurodegeneration in PD patients carrying DJ-1 mutations.  
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3.1. Ret and TrkB are dispensable for the establishment of the nigrostriatal 
system 
 
Neurotrophic factors are potent mediators of neuronal development. The development 
of DA neurons is initiated at the embryonic day E7.5 when the first progenitors 
engage in the differentiation process to eventually become dopaminergic. After birth, 
DA neurons undergo two rounds of programmed cell death (at postnatal days 2 and 
14) which are thought to eliminate an important fraction of DA neurons. This 
situation is seen in vivo for the majority of developing neurons and it is estimated that 
20-80 % of neurons undergo cell death shortly after their axons reach their targets 
(Davies, 2003; Oppenheim, 1991). During this postnatal period, DA neurons might 
require trophic support for survival.  
 
GDNF was initially identified as a potent survival factor for cultured embryonic 
midbrain dopaminergic neurons (Lin et al., 1993). Similarly, BDNF was found to 
promote survival of cultured embryonic DA neurons (Hyman et al., 1991). Our 
finding that Ret and TrkB signaling are dispensable for the initial maintenance of the 
DA system (Figures 18 and 23; see also Kramer et al., 2007) was unexpected and 
suggests several possibilities. First, the removal of both Ret and TrkB function was 
defined by the activity of the Nestin or DAT promoters (which induced the expression 
of the Cre recombinase); the Nestin promoter induces Cre expression after E10.5 
(Kramer et al., 2006; Tronche et al., 1999) while the DAT promoter is activated at 
E15 (Zhuang et al., 2005). Although unlikely, it remains possible that the initial 
expression of Ret or TrkB before onset of Nestin or DAT activity was sufficient to 
provide trophic support for the developing embryonic DA neurons. A second, more 
plausible explanation is that Ret and TrkB signaling are indeed dispensable for 
survival of embryonic DA neurons, and that GDNF-Ret independent and BDNF-TrkB 
independent signaling might promote survival of DA neurons; the analysis of DA 
neuron development in NCAM and p75NTR deficient mice might clarify this 
possibility. A third possibility is that embryonic neurons deprived of GDNF or BDNF 
trophic support gain access to alternative trophic pathways; because DAT-Ret/TrkB 
mice also show a normal development, we can rule out that Ret-deficient DA neurons 
use TrkB signaling for survival, and vice versa. To test if other survival pathways are 
upregulated in DAT-Ret and DAT-TrkB knockout mice, the activation status of 
alternative survival pathways could be evaluated.  
 
 
3.2. TrkB is dispensable for long-term maintenance of the nigrostriatal system 
 
Previous studies suggested that BDNF/TrkB might be required for survival of SN 
neurons in vivo, starting from P15 (Baquet et al., 2005; von Bohlen und Halbach et 
al., 2005).  Our finding that removal of TrkB signaling did not affect the survival of 
aging SN neurons (Figure 18 and Kramer et al., 2007) was rather unexpected. The 
efficiency of Cre-mediated recombination in DAT-TrkB mice was estimated by Edgar 
Kramer to be at least 60 % (using single-cell PCR analysis; Kramer et al., 2007). It is 
therefore possible that some DA neurons still have access to TrkB-mediated trophic 
support during aging. Another source of differences between the previous studies and 
ours relates to the regional specificity of BDNF or TrkB inactivation. Thus, while 
previous studies deleted TrkB or BDNF expression in either all cells (von Bohlen und 
Halbach et al., 2005) or in the entire midbrain-hindbrain region (Baquet et al., 2005), 
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we deleted TrkB specifically in DA neurons. Therefore, the TrkB activity in SN 
neurons might indeed be dispensable for cell survival, in which case the effects 
observed in mice with decreased TrkB levels in all cells must be non cell-
autonomous, meaning that they are not caused by removal of TrkB function from DA 
neurons. Loss of TrkB in non-DA neurons might have indirectly impacted on the 
long-term survival of SN DA neurons in these mice. Similarly, mice lacking BDNF in 
the midbrain-hindbrain region might have suffered other non-DA alterations that 
exerted an indirect effect on SN neuron function and survival. Additional studies, in 
which TrkB is deleted using independent TrkB floxed alleles and DA-specific Cre 
lines will address this possibility. Moreover, the analysis of mice in which TrkB is 
deleted in non-DA territories will reveal whether aging DA neurons engage in specific 
cell-cell interactions that promote their function and survival during aging.   
 
3.3. Ret signaling mediates survival of a fraction of aging substantia nigra 
neurons 
 
In contrast to TrkB, we found that Ret signaling is crucial for long-term maintenance 
of SN axons and cell bodies (Figures 17, 18, 23, 24). We observed that aging mice 
lacking Ret signaling in DA neurons display a marked loss of DA axons innervating 
the striatum (up to 60 % in 24-month-old mice), while the loss of SN cell bodies was 
relatively moderate (about 30 % in 24-month-old mice). This suggests that SN DA 
axons are more dependent on Ret signaling than the SN cell bodies. Indeed, mounting 
evidence suggests that neurotrophic factors exert different actions at nerve terminals 
and in the cell body (Zweifel et al., 2005). Although the exact temporal, spatial and 
molecular dynamics for GDNF/Ret signaling in DA neurons is unknown, results from 
studies on neurotrophin signaling showed the existence of local and long-distance 
signaling (Ibanez, 2007). While signaling at the axon terminal is more transient in 
nature and controls exocytosis or cytoskeleton rearrangement, signaling in the cell 
body is more sustained and mediates neuronal survival (Reichardt, 2006).  
 
Three possibilities might explain the increased vulnerability of axons relative to cell 
somata following loss of Ret function. First, both DA axon terminals and somata 
require Ret signaling for maintenance, although DA terminals depend more on Ret 
signaling than DA cell bodies. In this scenario, Ret signaling at DA terminals might 
control processes crucial for terminal maintenance, while its functions in the soma are 
less critical for survival.  Second, Ret signaling might only be required for survival of 
DA cell bodies, but not axons. Loss of about 30 % DA cell bodies should lead to a 
corresponding decrease in terminal density (30 %), unless a fraction of DA neurons 
have exceedingly large terminal arbours compared to the remaining neurons. 
However, since single-cell labeling of individual DA neurons revealed a relative 
uniformity of DA neuron terminal fields (Finkelstein et al., 2000), we find this 
possibility unlikely. A third more likely explanation is that the axonal compartment is 
the first affected by the degenerative process, followed retrogradely by SN cell bodies 
(i.e. ‘dying back’ process). This situation was also observed in post-mortem 
histological analysis of PD-brains (Bernheimer et al., 1973; Lach et al., 1992). At the 
onset of PD symptoms, about 50-60 % SN cell bodies are lost while the loss of 
dopamine in the striatum exceeds 80 % (Dauer and Przedborski., 2003). Experimental 
evidence for the ‘dying back’ model also comes from studies on MPTP-treated 
monkeys in which loss of striatal terminal precedes the loss of SN cell bodies 
(Herkenham et al., 1991) while protection of axon terminals prevents loss of SN 
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somata in MPTP-treated rats (Wu et al., 2003). To test whether the axon terminal 
compartment is indeed the first affected by the degenerative insult, the time-course 
analysis on DAT-Ret and control mice could be extended to include additional time 
points. Thus, while the loss of DA fibers starts at 9 months (Figure 18), no 
information about the first degeneration signs in the soma compartment is available, 
the first measurement being performed at 12 months (Kramer et al., 2007). 
Furthermore, there is compelling evidence that loss of axon terminals in 
neurodegenerative disease is preceded by micro-structural deficits like synaptic loss 
(Conforti et al., 2007). Therefore, it would be interesting to determine whether 
synaptic loss precedes the relatively delayed loss of axons in DAT-Ret mice. Finally, 
retrograde tracings might be used to determine whether some DA cell bodies in DAT-
Ret mice are deprived of terminal arbor, before the onset of SN soma degeneration.   
 
If GDNF is a survival factor for aging DA neurons, why is there only partial 
neurodegeneration in DAT-Ret mice? The loss of a fraction of SN DA neurons in 
aging DAT-Ret mice suggests that additional survival factors are active in aging DA 
neurons. A recent study found that chronic removal of GDNF function from the brain 
(at 2 months of age, using tamoxifen-induced Cre-mediated recombination of a floxed 
GDNF allele in all cells) leads to a dramatic degeneration of SN neurons (60 % 
neurons lost after 5 months); in addition, the neighbouring VTA was also affected (70 
% loss after 5 months) and the noradrenergic locus coeruleus was virtually absent in 
GDNF knockout mice (Pascual et al., 2008). These results suggest that GDNF has a 
more important role in regulating DA neuron survival than Ret. One possibility is that 
GDNF controls DA neuron survival via a Ret-independent signaling pathway. The 
alternative receptor for GDNF, NCAM, is a good candidate for such a pro-survival 
effect. NCAM is expressed in adult DA neurons and interestingly, application of anti-
NCAM blocking antibodies to cultured DA neurons strongly decreased the neurite 
outgrowth promoting effects of GDNF while delivery of NCAM blocking antibodies 
into the SN of rats inhibited the effects of GDNF on locomotor activity (Chao et al., 
2003). A second possibility is that GDNF might use a yet non-identified receptor to 
mediate survival of aging SN neurons, and the existence of additional GDNF 
receptor(s) was suggested (Pozas and Ibanez, 2005). A third possibility that explains 
the mild DA phenotype in DAT-Ret vs. adult GDNF KO mice is the existence of 
trophic compensation in Ret-deficient SN neurons, via up-regulation of alternative 
trophic pathways. CDNF was identified as a novel putative neurotrophic factor for 
DA neurons and was shown to completely rescue the effects of 6-hydroxydopamine 
when injected in the mouse striatum (Lindholm et al., 2007).  Therefore, the analysis 
of aging NCAM deficient mice and investigation of the activation status of alternative 
neurotrophic factor pathways in DAT-Ret mice should better define the role of GDNF 
signaling in the dopaminergic system.  
 
DAT-Ret mice display a normal complement of SN neurons at 3 months (Figure 23 
and Kramer et al., 2007) while degeneration in the SN starts during aging (12-24 
months; Figures 18 and 23). Why do aging, but not adult DA neurons require Ret-
mediated signaling for survival?  
 
While during embryonic development neurons are ‘competent to die’ and require 
neurotrophic input to survive, it appears that adult neurons switch to become 
‘competent to live’ and require active pro-apoptotic processes to undergo apoptosis 
(Benn and Woolf, 2004). Factors that might actively induce apoptosis in mature 
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neurons are for example ROS and other kinds of cellular stress, as those seen in 
neurodegenerative disease. Therefore, it remains possible that adult SN neurons do 
not require trophic signaling (or at least GDNF/Ret or BDNF/TrkB) for survival.  
 
Aging SN neurons, in contrast to adult neurons, might re-become vulnerable to a 
series of age-related changes and might re-activate trophic signaling pathways to 
actively promote neuronal survival. It is possible that aging SN neurons start using 
several survival pathways, which would explain the moderate DA neurodegeneration 
in our aging DAT-Ret mice. Hence, a combination of age-related adaptive changes 
and trophic support might be necessary for maintenance of SN neurons. In this 
scenario, age-related deleterious sub-threshold changes that do not directly impact on 
cell survival might become critically amplified in the absence of neurotrophic support 
and might lead to neurodegeneration. Extensive research into the mechanisms of 
aging identified several classes of proteins that regulate longevity, including the 
Sirtuins, FOXO and p53 transcription factors, heat shock proteins or components of 
the insulin signaling pathway (Curtis et al., 2005; Vijg and Campisi, 2008). These 
pathways promote longevity by adapting the cell to different kinds of cellular 
stressors, including ROS, genotoxic stress and other consequences of cellular 
senescence. It is interesting to note that some of these pathways regulating aging are 
also regulated by RTKs, raising the possibility that RTK activity might regulate some 
aspects of the aging process in neurons. It remains therefore possible that removal of 
trophic factors generates additional cellular stress in DA neurons or deprives the cell 
of some critical anti-aging signals. A better understanding of the molecular pathways 
that regulate organism and tissue-aging and the connection between aging regulators 
and RTK signaling might uncover common regulators that could be employed as 
therapeutic targets for age-related diseases caused by decreased trophic signaling. 
 
3.4. DJ-1 promotes survival of trophically impaired substantia nigra neurons 
 
To extend our understanding of the survival networks used by midbrain DA neurons, 
we searched for additional interactors of Ret in the process of DA neuron 
maintenance. We focused our attention on the Parkinson’s disease-associated gene 
DJ-1. Loss of DJ-1 in humans is sufficient to cause PD (Bonifati et al., 2003), while 
mice lacking DJ-1 show no overt neurodegeneration in the SN (Gasser, 2009), 
suggesting additional compensatory mechanisms in DJ-1 mice; in addition, 
experiments in mammalian cell cultures and Drosophila suggested that DJ-1 interacts 
with RTK-related pathways, like the PI3K/Akt (Gorner et al., 2007; Kim et al., 2005a; 
Yang et al., 2005b). We therefore generated mice lacking Ret in DA neurons and DJ-1 
in all cells (DAT-Ret/DJ-1 mice). While these animals developed normally and 
showed no overt behavioral alterations, we found surprisingly that combined loss of 
Ret and DJ-1 leads to enhanced loss of midbrain DA neurons as compared to mice 
lacking Ret alone. About 40 % SN cell bodies were lost in 24-month-old Ret/DJ-1 
mice, compared to only 25 % in mice lacking Ret function (Figure 23). The 
interaction between Ret and DJ-1 is restricted to SN neurons (the VTA neurons are 
not affected) and is age-dependent, as adult (3-month-old) DAT-Ret/DJ-1 mice do not 
display DA neurodegeneration. The enhanced degeneration seen in mice lacking Ret 
and DJ-1 indicates that DJ-1 promotes survival of SN dopaminergic neurons deprived 
of Ret-mediated trophic support, specifically during aging.  
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Our results that DJ-1 promotes cell survival only under conditions of environmental 
(trophic) stress are in agreement with previous published observations. DJ-1 
inactivation in mice and flies does not cause cell loss in the unchallenged animal, but 
increases its sensitivity PD-related toxins (Andres-Mateos et al., 2007; Chen et al., 
2005; Goldberg et al., 2005; Kim et al., 2005b; Menzies et al., 2005; Meulener et al., 
2005; Yamaguchi and Shen, 2007). The reported photoreceptor degeneration after 
Drosophila DJ-1A RNAi knock down (Yang et al., 2005b) cannot be reproduced by us 
and is not observed in DJ-1A/B genetic mutants (data not shown) suggesting either the 
existence of some compensatory mechanisms in the DJ-1A/B null mutants or 
unspecific off-target effects in the DJ-1A RNAi knock down flies. In vitro, DJ-1 
inactivation in neuronal cells does not lead to increased cell death, but renders these 
neurons more sensitive to oxidative stress (Martinat et al., 2004; Taira et al., 2004). 
One of the advantages of the present study is that it provides evidence for DJ-1 
promoting cell survival in the unchallenged or uninjured mouse brain. The genetic 
changes in the DAT-Ret/DJ-1 mutant mice are well defined and allow the further 
analysis of the underlying mechanisms.  
 
Does absence of DJ-1 function renders cells more sensitive to any kind of cellular 
stress? A remarkable recent finding is that combined deletion of all three PD-
recessive genes DJ-1, PINK1 and Parkin does not cause degeneration of SN neurons, 
even in 27-month-old mice (Kitada et al., 2009), suggesting that the pro-survival 
activity of DJ-1 becomes critical only in specific situations. It appears therefore that 
increased cellular stress and mitochondrial dysfunction are not sufficient to trigger SN 
cell death, as long as SN neurons receive trophic signals like the ones mediated by 
GDNF/Ret. Additional studies evaluating the long-term maintenance of SN neurons 
deprived of Ret and Parkin or PINK1 function will reveal if other PD-linked genes are 
essential for survival of trophically impaired SN neurons.  
 
In DAT-Ret mice the degree of fiber loss (50%) exceeds the degree of SN cell body 
loss (25 %); this suggests that a fraction of aging SN neurons deprived of Ret-
mediated signaling might have lost their target innervation. When analyzing the 
density of DA fibers in DAT-Ret/DJ-1 mice, we found interestingly that it matches 
exactly the degree of fiber loss in DAT-Ret mice (50 % in both groups, Figure 25). 
The simplest explanation is that additional DJ-1 removal caused degeneration of Ret-
deficient SN cell bodies that lost their target innervation (the target deprived pool), 
while Ret-deficient SN cell bodies with functional connections were largely 
unaffected (Figure 35). Alternatively, removal of DJ-1 could affect both the target-
deprived cells and the cells properly connected to the striatum; however, this would 
imply that some SN neurons would have to re-sprout during aging to compensate for 
the enhanced fiber loss. Work in Jörg Schulz and our own laboratory indicates, 
however that DA neurons lacking Ret signaling cannot re-sprout to re-establish a 
functional DA terminal arbor following toxic (MPTP) lesions, in contrast to wild-type 
DA neurons, further suggesting that Ret signaling is required for the re-sprouting of 
DA terminals (Kowsky et al., 2007). Therefore, we favor the model in which DJ-1 
deficiency causes degeneration of the target-deprived pool of Ret-deficient DA 
neurons (Figure 35). To test the validity of this model, we are currently performing 
tracing experiments in which the retrograde tracer Fluoro-gold is injected in the 
striatum. We will determine the percentage of SN cell bodies that send projections to 
the striatum in control, DAT-Ret and DAT-Ret/DJ-1 mice. To validate our model, we 
expect the percentage of functionally connected cell bodies in DAT-Ret to be 
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decreased relative to control or DAT-Ret/DJ-1 mice, in spite of DAT-Ret/DJ-1 mice 
having less DA cell bodies (i.e. all remaining cell bodies in DAT-Ret/DJ-1 mice are 
functionally connected with their target area).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Enhanced loss of substantia nigra cell bodies in DAT-Ret/DJ-1 mice. Removal of DJ-1 
function does not affect the survival of SN neurons (upper part), which send axonal projections to the 
striatum to participate in the control of movement. Ret-deprived SN neurons loose a fraction (25 %) of 
SN cell bodies while the loss of DA fibers innervating the striatum (51%) exceeds that of cell body. 
Therefore, we hypothesize the existence of a DA population of neurons in the SN of DAT-Ret mice 
which are devoid of target innervation (in pink). It is this target-deprived subpopulation of neurons that 
might be primarily lost in DAT-Ret;DJ-1 mice, in which the density of target innervation in the 
striatum matches exactly that of DAT-Ret mice, although the degree of SN cell body loss (41 %) is 
enhanced. In addition, both Ret and DJ-1 deficiency affect primarily the survival of GIRK2-positive 
neurons (shown here) that project exclusively to the dorsal striatum.  
 
Our finding that DJ-1 promotes survival of Ret-deficient SN cell bodies but not axons 
suggests that the SN cell body might be the primary site of DJ-1 pro-survival activity. 
Neurotrophic factor receptors, such as Ret, are transported from distal sites to the cell 
body, where they signal to promote survival. Components of the signaling machinery 
including activated Ras are also transported to the cell body in signaling vesicles 
(Howe et al., 2001). The signaling mediated by RTKs at axon terminals vs. the soma 
appears to have at least some distinct aspects; for example, while activation of 
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Ras/ERK via Shc/Grb2/SOS interactions promote a transient activation at the axon 
terminal and activates mainly the ERK1/2 MAPKs, in the cell body Ras/ERK is 
activated via FRS2/Crk binding to receptor-containing endosomes to provide a 
sustained pro-survival signal (Huang and Reichardt, 2003; Reichardt, 2006). It is 
therefore possible that DJ-1 interacts with the Ras/ERK machinery that is activated in 
SN cell bodies to promote DA neuron survival.  
 
The differential effects we observed in the maintenance of SN axons vs. somata in 
DAT-Ret mice raise the possibility that the axonal and cell body compartments might 
have different survival regulations and requirements. Indeed, increasing evidence 
suggests that these two compartments might be at least partially uncoupled with 
respect to their survival requirements. Specific molecules were found that primarily 
regulate maintenance of cell bodies, but not axons - including Bax, Bcl2 and JNK 
(Conforti et al., 2007; Ries et al., 2008); conversely, molecules like the Wallerian 
degeneration slow protein Wlds  promote axonal maintenance but not soma survival in 
6-hydroxydopamine (Sajadi et al., 2004) or MPTP (Hasbani and O'Malley, 2006) 
challenged SN neurons. Remarkably, a very recent paper by Marc Tessier-Lavigne 
and colleagues suggested that trophically-deprived neurons activate two distinct 
capsases to mediate loss of axons and somata. Thus, during trophic (NGF, BDNF, 
NT3) deprivation, the shedding of surface β-amyloid precursor protein (APP) by the 
β-secretase (BACE) generates a pro-apoptotic shedded product that interacts with the 
transmembrane death receptor 6 (DR6) protein. DR6 mediates apoptosis by activating 
caspase-3 in cell soma and caspase-6 in axons (Nikolaev et al., 2009). Another very 
recent interesting observation is that DJ-1 is proteolytically cleaved by caspase-6 in 
vitro to generate a C-terminal fragment that exhibits anti-apoptotic activity by 
negatively regulating p53-dependent transcription (Giaime et al., 2009). A better 
understanding of the molecular mechanisms regulating axon and soma maintenance 
and the role of DJ-1 in these processes is required and DAT-Ret/DJ-1 mice could be 
valuable tools for this purpose. Understanding the differential vulnerability of the 
axonal and cell-body compartments to aging and degenerative insults might improve 
our understanding of neurodegeneration and open new therapeutic avenues. 
 
3.5. Neuroinflammatory changes and postsynaptic dysfunction in Ret-deficient 
mice 
 
Although the family of glial cells has three prominent members (astrocytes, 
oligodendrocytes and microglia), only astrocytes and microglia have been implicated 
in the pathogenesis of PD so far (Hunot and Hirsch, 2003; Teismann and Schulz, 
2004; Teismann et al., 2003). Astrocytes regulate extracellular potassium 
concentration and regulate synaptic activity by uptake of synaptic transmitters like 
glutamate (Filosa et al., 2009) thereby critically regulating neuron function. Following 
neuronal dysfunction, astrocytes become activated and increase the expression of the 
Glial fibrillary acidic protein (GFAP), followed by the enlargement of the cell body 
and extension of processes into the injured area (Eddleston and Mucke, 1993). In 
contrast to astrocytes, the role of microglial cells in the brain is less well understood 
(Teismann and Schulz, 2004). Microglia arise from macrophages outside of the 
nervous system and they are not related to the other cells in the nervous system; 
however, they might become activated during seizures, injury or neuronal 
dysfunction, and they undergo proliferation, migration and eventually acquire 
macrophage-like properties to actively participate in the clearance of dying cells 
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(Banati et al., 1993). Interestingly, SN is relatively rich in resting microglia in 
comparison to other brain region (Kim et al., 2000) leading to the proposal that the 
increased microglia density might also represent a vulnerability factor in PD 
(Andressoo and Saarma, 2008; Teismann et al., 2003).   
 
Post-mortem examination of patients with PD revealed massive neuroinflammation in 
the SN and the striatum (Hunot and Hirsch, 2003; Teismann and Schulz, 2004). 
Interestingly, the degree of microglial activation was found to be more robust than 
that of astrocyte recruitment and activation, and the microglial activation was found in 
the SN rather than in the striatum (McGeer et al., 1988). The microglial activation 
observed in the SN was dramatic (Banati et al., 1998; Mirza et al., 2000) and 
numerous microglial cells were found in close proximity to DA neurons, onto which 
they sometimes agglomerated to produce an image of “neuronophagia” (McGeer et 
al., 1988). In addition, the density of CD8 cytotoxic T cells  was also increased in the 
SN of PD patients (McGeer et al., 1987).  In contrast, the increase in astrocyte density 
was found to be relatively mild, both in the SN and the striatum (Forno et al., 1992; 
Mirza et al., 2000). Activated glial cells might exert both protective and deleterious 
effects on neurons; thus, they can secrete neurotrophic factors (GDNF or BDNF) and 
are able to scavenge toxic compounds released by dysfunctional or dying neurons 
(Batchelor et al., 1999; Hirsch et al., 1999). On the other hand, activated glial cells 
also secrete a variety of toxic and pro-apoptotic molecules including noxious 
compounds (diverse types of ROS) and pro-inflammatory and pro-apoptotic cytokines 
(including tumor necrosis factor alpha [TNF-α], interleukins [IL-1β/2/4/6], interferon-
γ [IFN-γ]) that might activate pro-apoptotic pathways and might thus accelerate 
neurodegeneration (Hunot et al., 1999). It is therefore unclear whether activated gilal 
cells are protective or deleterious for neurons, or both, and research in animal models 
could clarify their mode of action.  
 
We detected an increased density of reactive astrocytes in DAT-Ret mice, specifically 
during aging (24 months) and in the striatum (Figures 20, 26). Two cellular entities 
are altered in the striatum of 24-month-old DAT-Ret mice as compared to age-
matched controls: the DA terminals projecting from the SN are markedly depleted 
(Figures 18 and 25) and the post-synaptic medium spiny neurons (MSNs) 
downregulated the neuronal marker NeuN and the post-synaptic DA marker DARPP-
32, thereby suggesting cellular dysfunction (Figure 19). This suggests that loss of pre-
synaptic DA input leads to post-synaptic alterations in dopaminoceptive cells. The 
increase of astroglial recruitment in this area therefore raises the possibility that 
dysfunctional DA axons or dysfunctional post-synaptic MSNs, or both, represent a 
strong recruiting signal for reactive astrocytes. This astroglial recruitment displays a 
delayed kinetics, as DAT-Ret mice did not display increased astrogliosis at 12 months 
relative to control animals, although they underwent DA neurodegeneration and lost a 
fraction of their DA terminals in the striatum (Figure 18). Therefore, reactive 
astrocytes might not be directly involved in the DA fiber degeneration process, but are 
recruited after the onset of nigrostriatal degeneration. Moreover, since no increased 
density of astrocytes was detected in the SN (where DA neurodegeneration was 
ongoing; Figure 20) it appears that dysfunctional DA axons and/or MSN postsynaptic 
neurons, rather than SN cell bodies, generate recruiting signals for reactive astrocytes.  
 
In contrast to the astrogliosis in the striatum of aging DAT-Ret mice, the microglial 
response we detected was restricted to the substantia nigra (Figure 21). Similar to 
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astrocytes, microglial cells were also recruited after the degeneration occurred (at 24 
but not 12 months). The fact that dysfunctional and dying SN cell bodies induce a 
local recruitment of microglial cells in aging DAT-Ret mice is not surprising, given 
the known roles of microglia in maintaining tissue homeostasis and their robust 
association with SN degeneration in post-mortem PD patients (Hunot and Hirsch, 
2003; Teismann et al., 2003). Microglial cells might thus clear apoptotic SN neurons 
and might prevent the accumulation of cellular debris, which might be deleterious for 
the neighboring unaffected cells. Chronic activation of microglia might on the other 
hand be deleterious for SN neurons, and microglial cells might accelerate 
neurodegeneration in its late stages in PD. Further studies that investigate the 
properties of both astrocytes and microglia at diverse steps in the DA 
neurodegeneration process might provide new clues about the dual role played by 
glial cells in nigral disease.  
 
3.6. Regional specificity of neurodegeneration in mice lacking Ret and DJ-1  
 
The major symptoms in PD are mainly caused by loss of SN neurons and their input 
to the striatum. Although additional brain areas are affected, the degeneration in the 
SN is the most consistent alteration detected in the brains of patients with 
Parkinsonism, including PD patients. The reasons for this relative specificity are 
currently unknown, although it is believed that a combination of intracellular 
metabolic and ionic age-related changes in conjunction with extracellular factors 
(presence of microglia, connectivity, trophic support, toxins) might influence DA 
neuron survival in a unique way (Abou-Sleiman et al., 2006; Andressoo and Saarma, 
2008; Dauer and Przedborski, 2003; Lotharius and Brundin, 2002). For example, SN 
neurons synthesize the neurotransmitter dopamine, which has a high propensity to 
auto-oxidize and generate ROS if it abnormally accumulates in the cytosol; therefore, 
it has been suggested that altered dopamine release and clearance might promote 
neuronal cell death (Lotharius and Brundin., 2002) and dopamine can covalently bind 
and inactivate Parkin, thereby potentially contributing to PD pathogenesis (LaVoie et 
al., 2005).  However, dopamine is produced by other neuronal populations (including 
the VTA) which are less affected in PD, suggesting that other or additional factors 
might underlie the relative specificity of DA neurodegeneration in PD.  
 
Our finding that VTA DA neurons do not require Ret and DJ-1 signaling for survival 
is therefore interesting (Kramer et al., 2007). VTA neurons were previously found to 
be less sensitive than SN neurons to 6-OHDA treatment (Barroso-Chinea et al., 2005) 
or α-syn overexpression (Maingay et al., 2006) and the presence of a functional K-
ATP channel Kir6.2 promotes cell death of SN, but not VTA neurons in two chronic 
mouse models of DA degeneration (Liss et al., 2005). It is therefore possible that 
VTA neurons do not require Ret signaling for survival, in contrast to SN neurons. 
Interestingly, a dramatic loss of VTA DA neurons was observed in the above-
mentioned GDNF adult knockout mouse (Pascual et al., 2008), raising the possibility 
that Ret-independent GDNF signaling (via NCAM or via a yet unidentified receptor) 
is required for survival of VTA neurons. The analysis of VTA neuron survival in 
aging NCAM deficient mice might help solve this issue.  
 
Perhaps more interesting is our finding that loss of Ret and DJ-1 signaling affects a 
subpopulation of SN neurons that project exclusively to the striatum. We found a 
specific requirement for Ret and DJ-1 activity in the GIRK2-positive subpopulation, 
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while the other Calbindin-positive subpopulation did not require Ret/DJ-1signaling 
for survival (Figure 24). Interestingly, Calbindin-positive neurons in the SN were 
found to be specifically spared in PD (Yamada et al., 1990) and in mice treated with 
the PD-causing toxin MPTP (Liang et al., 1996). Conversely, in primary ventral 
mesencephalic cultures treated with MPTP, GIRK2-postive SN neurons showed 
enhanced sensitivity (Chung et al., 2005). It is thus interesting that the GIRK2-
positive SN neurons, which are more prone to degeneration, are also the ones 
depending on pro-survival signals mediated by Ret and DJ-1. It appears that elevated 
levels of the G-protein coupled potassium inwardly rectifying channel GIRK2 is a 
cause of vulnerability, since elevating the levels of GIRK2 further sensitizes these 
neurons (Chung et al., 2005). Remarkably, GDNF was found to acutely modulate the 
excitability of midbrain dopaminergic neurons by inhibiting A-type potassium 
channels, a function that involves specifically the MAPK pathway (Yang et al., 2001). 
It is tempting to speculate that Ret and DJ-1 affect SN intracellular potassium 
concentration by modulating the ERK1/2 signaling and that loss of input from Ret and 
DJ-1 might further exacerbate the increase in intracellular potassium concentration 
induced by the presence of GIRK2. Further studies focusing specifically on the 
GIRK2 subpopulation will better define the exact biochemical processes involved in 
their survival and their interplay with other age-related cellular changes. 
 
3.7. Ret-deprived nigral neurons are not sensitive to alpha-synuclein aggregation 
stress  
 
The enhanced neurodegeneration of Ret-deprived SN neurons when the function of 
the oxidative stress suppressor DJ-1 was removed raised the possibility that Ret-
deficient DA neurons are generally more sensitive to any deleterious agent. To test 
this hypothesis genetically, we used transgenic mice that overexpress an aggregation-
prone version of human alpha-synuclein specifically in dopaminergic neurons. 
Overexpression of Ala30Pro human α-syn in DA neurons was shown to be 
insufficient to trigger overt SN neurodegeneration in these mice, up to 12 months of 
age, despite the presence of aggregated alpha-synuclein in the SN cell body (Rathke-
Hartlieb et al., 2001). When aging DAT-Ret;TH-α-synA30P mice were generated and 
aged, we found surprisingly that they display an accelerated loss of SN cell bodies, 
relative to DAT-Ret mice (Figure 27). We also found, however that overexpression of 
mutant α-syn alone leads to a mild SN neurodegeneration (20 % loss of cell bodies) in 
24-month-old animals. Thus, the increased DA neurodegeneration in DAT-Ret;TH-α-
synA30P mice is due to an additive, but not synergistic effect of Ret and DJ-1 deletion 
on SN neuron survival. We reached a similar conclusion when analyzing the 
maintenance of DA fibers in DAT-Ret;TH-α-synA30P mice (Figure 27); the 
degeneration of DA fibers caused by loss of Ret was not further enhanced when 
mutant α-syn was overexpressed in SN neurons. These results suggest that Ret-
deprived DA neurons are not more sensitive to the cellular stress caused by misfolded 
α-syn. Additional support for this conclusion comes from the study performed in our 
laboratory in collaboration with Jörg Schulz (University of Göttingen) and in which 
the sensitivity of adult Ret-deficient DA neurons towards the PD toxin MPTP was 
evaluated. DA neurons lacking Ret were found to display the same sensitivity towards 
MPTP as wild-type neurons (Kowsky et al., 2007). Therefore, we suggest that DAT-
Ret mice are not generally more sensitive to any cellular stressor, but rather to defined 
types of neuronal dysfunctions (e.g. loss of DJ-1 function) that amplify the negative 
effects of trophic deprivation during aging.  
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3.8. DJ-1 interacts genetically with constitutively active Ret in Drosophila 
melanogaster  
 
The enhanced degeneration of SN neurons in mice that lack Ret and DJ-1 signaling 
suggests that Ret and DJ-1 act in parallel pathways to promote neuron survival. To 
gain insight into the molecular mechanisms used by Ret and DJ-1 to regulate 
maintenance of DA neurons, we employed Drosophila melanogaster.  Drosophila has 
a long and successful history in signal transduction studies and allowed the discovery 
and characterization of important regulators of RTK signaling. In addition, flies that 
lack the PD-associated recessive genes show similar or even aggravated dopaminergic 
phenotypes compared to mice (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). 
Given that GDNF does not bind Drosophila Ret, we used constitutively active 
versions of Ret, in order to overcome this ligand-receptor regulatory step. Two 
constitutively associated versions of Ret (RetMEN2A and RetMEN2B) cause multiple 
endocrine neoplasia in humans, a cancer of neural crest origin (Read et al., 2005). 
Targeted expression of these active Ret versions in the developing photoreceptor 
neurons of the fly disrupts the normal development of photoreceptors by promoting 
excessive cell proliferation, abnormal differentiation and by increasing their size 
(Figures 28, 29); these effects are followed by a secondary apoptotic wave that leads 
to adult flies of reduced size and rough eye morphology (Read et al., 2005). When DJ-
1A/B function is decreased, these retinal defects are significantly rescued and the 
resulting rescued eyes have a completely restored size. Conversely, DJ-1A 
overexpression is sufficient to enhance the RetMEN2A phenotype (Figures 28, 29). 
Therefore, DJ-1A/B represent novel interactors of Ret signaling in Drosophila. Our 
results also suggest that selective inhibition of DJ-1 activity might represent a novel 
therapeutic strategy for patients with RetMEN2 tumors. 
 
We then set out to determine which of the Ret-induced cellular pathways interact 
genetically with DJ-1A/B. We found, surprisingly, that DJ-1 does not modulate the 
phenotypes caused by alterations in the PI3K/Akt signaling (Figure 30). However, 
DJ-1A/B interacted genetically with PTEN, the negative regulator of the PI3K/Akt 
signaling, but only when overexpressed (Figure 31). Previous studies reported that 
DJ-1A interacts genetically with PTEN in Drosophila and in vitro and furthermore, 
DJ-1 modulated the activation status of the Akt kinase (Gorner et al., 2007; Kim et al., 
2005a; Yang et al., 2005b). We could not reproduce the previously reported (Yang et 
al., 2005b) interaction with Akt and the modulation of Akt activation by DJ-1, both in 
Drosophila and in mammalian cell culture systems. Although DJ-1 was sufficient (but 
not necessary) to inhibit the effects of overexpressed PTEN, the negative regulator of 
PI3K activation, we believe that DJ-1 may interact with PTEN only in defined 
pathophysiological situations (e.g. oncogenic). In agreement with this suggestion, a 
recent study showed that DJ-1 interacts with PTEN in  hypoxia conditions, similar to 
those seen in cancer (Vasseur et al., 2009). We predict that the interaction between 
DJ-1 and PTEN in these circumstances is independent of PI3K/Akt signaling. Indeed, 
emerging evidence suggests lipid phosphatase-independent roles of PTEN (Gao et al., 
2000) the best studied being a protein-phosphatase-dependent inhibition of 
Ras/MAPK signaling (Kerr et al., 2006; Nayeem et al., 2007), modulation of JNK 
signaling (Vivanco et al., 2007) and several nuclear functions that involve protein-
protein interactions, to control cell cycle progression maintenance of genomic stability 
or apoptosis (Yin and Shen, 2008). 
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Activation of MAPK signaling by Ras is required for proper photoreceptor 
proliferation and differentiation in Drosophila (Fortini et al., 1992) and constitutively 
active Ras/ERK signaling severely impairs eye development (Figure 32). We found 
surprisingly that DJ-1 modulated the eye phenotype of constitutively active RasV12 
(Figure 32), suggesting that DJ-1 functions downstream of Ras activation or in 
parallel to Ras-mediated signaling to mediate photoreceptor neuron development. To 
map the interaction site between DJ-1 and Ras/MAPK signaling, we used a 
constitutively active version of ERK/rolled, which also induces defects in eye 
development when targeted to developing photoreceptor neurons. The abnormal 
proliferation and eye roughness induced by constitutively active rolled were not 
modulated by DJ-1A/B (Figure 32), suggesting that DJ-1 functions either upstream or 
in parallel to ERK activation. Preliminary evidence suggests that DJ-1 does not 
modulate the phenotype of constitutively active Raf, further restricting the interaction 
site between DJ-1 and the Ras/Raf/MEK/ERK pathway to Ras/Raf. Therefore, we 
suggest that DJ-1A/B act either between Ras and Raf or in a parallel pathway to 
control eye development in Drosophila (see below).  
 
The roles of endogenous Ret signaling in Drosophila are currently unknown; Ret 
expression in the fly parallels the expression in mammals (Hahn and Bishop, 2001) 
and Drosophila Ret elicits neurotrophic activities in cultured mammalian cells 
(Abrescia et al., 2005), suggesting that Ret might mediate trophic signals in 
Drosophila. In this context, it is interesting to note that the relevance of neurotrophic 
factors to Drosophila development is poorly understood (Hidalgo et al., 2006). 
Although neurotrophins and their receptors are not present in Drosophila, it is 
becoming increasingly clear that neurotrophic activities are important for a variety of 
processes; thus, during eye development EGFR RTK exerts neurotrophic activities in 
photoreceptor neurons (Baker, 2001). The identification of the Drosophila ligand for 
Ret might better define the role of Ret signaling during evolution.  
 
 
3.9. DJ-1 interacts with ERK signaling to control eye and wing development in 
the fly 
 
The interaction between DJ-1A/B and ectopic Ras signaling in Drosophila prompted 
us to investigate whether DJ-1 plays any role during the development of the fly. The 
only described functions for DJ-1 in Drosophila are regulation of PTEN and Akt 
signaling (mentioned above) and the control of oxidative stress response (Lavara-
Culebras and Paricio, 2007; Menzies et al., 2005; Meulener et al., 2005; Meulener et 
al., 2006; Moore et al., 2006; Park et al., 2005).  
 
To test whether DJ-1 controls fly development as a Ras/ERK interactor, we focused 
on two tissues where Ras/ERK signaling is known to play a major role: the 
development of the eye (Bergmann et al., 1998; Biggs et al., 1994; Fortini et al., 1992; 
Kim et al., 2006) and wing (Friedman and Perrimon, 2006; Li et al., 2000). We found 
that, while DJ-1B function is dispensable for eye development, lack of DJ-1B 
function severely impairs the development of photoreceptors with reduced ERK (rl) 
levels. While rl1/rl1 flies display about 6.64 photoreceptors/ommatidium (P/O), 
rl1/rl1;DJ-1B-/- flies have only 5.34 P/O (Figure 33). In addition, consistent with 
previous observations (Biggs et al., 1994), additional photoreceptor neurons other 
than R7 failed to differentiate, further implicating the DJ-1/rolled axis in the control 
                                                                                                                        Discussion 
                                                                
110 
 
of proper photoreceptor neuron differentiation in Drosophila. Therefore, DJ-1B is 
required - as a rolled interactor- to control photoreceptor neuron development. This is 
the first evidence for a role of DJ-1B in the intact (unchallenged) fly.  
 
We searched for additional roles for DJ-1B in the development of the fly. Previous 
studies revealed an important role for rolled signaling in the proper induction of wing 
veins, therefore contributing to the establishment of the wing. Flies with reduced 
Ras/ERK signaling all have vein differentiation defects in the wing, although with 
varying degrees of severity, reflecting the amount of Ras, Raf or rolled function that 
was removed (Brunner et al., 1994; Li et al., 2000; Lim et al., 1999).Therefore, wing 
vein development is sensitive to dosages in the Ras/ERK pathway, similar to retinal 
photoreceptor neurons. We hypothesized that reducing the levels of rolled and DJ-1B 
concomitantly would exacerbate the phenotype caused by reducing only ERK levels; 
to test this hypothesis, we analyzed the wing development in control, DJ-1B null, 
rl1/rl1 and rl1/rl1;DJ-1B-/- flies. We found, as expected that removal of DJ-1B function 
does not impact on vein development, while reducing ERK/rolled functio in rl1/rl1 
flies causes a moderate defect in vein differentiation. When rl1/rl1;DJ-1B-/- wings 
were analyzed, more severe defects that in rl1/rl1 flies were observed; the L4 vein was 
often interrupted or poorly differentiated (Figure 33), further suggesting an important 
role for DJ-1B as a rolled interactor in Drosophila development. 
 
As previously mentioned, endogenous Ret plays probably no major role in 
photoreceptor neuron and wing development in Drosophila (Hahn and Bishop, 2001; 
Read et al., 2005) the major regulators of fly photoreceptor neuron development being 
sevRTK and EGRF RTK receptors, while wing development is mainly under the 
control of EGFR (DER) RTK (Baonza et al., 2000). Therefore, DJ-1 might act in 
parallel to sevRTK and/or EGFR RTK in Drosophila. We are currently testing 
whether DJ-1 interacts with EGFR to control eye and wing development in 
Drosophila. Interestingly, the EGFR is also expressed in aging mouse DA neurons 
and EGF was suggested to be a candidate neurotrophic factor for aging and 
dysfunctional SN neurons (von Bohlen und Halbach and Unsicker, 2009) and showed 
rescuing effects when delivered into the brain of rats in which the medial forebrain 
bundle (MFB) was transected (Pezzoli et al., 1991; Ventrella, 1993) or treated with 6-
OHDA (Iwakura et al., 2005). EGF also regulates TH expression in postnatal rats and 
elevates dopamine turnover in the striatum (Futamura et al., 2003) and decreased 
levels of EGF are found in the striatum of PD patients (Iwakura et al., 2005). 
Therefore, it is possible that additional RTKs besides Ret control DA neuron function 
and survival in the mouse and these observations argue for additional investigations in 
Drosophila melanogaster, as a complement to mammalian studies.  
 
3.10. What are the molecular functions of DJ-1 in substantia nigra neurons? 
 
Several functions for DJ-1 emerged from studies in mammalian cell culture and in 
animal models. Besides the above-mentioned regulation of PI3K/Akt, DJ-1 might 
inhibit JNK signaling (Junn et al., 2005; Kahle et al., 2009a; Mo et al., 2008) and 
promotes expression of anti-apoptotic (Fan et al., 2008b; Xu et al., 2005) and anti-
oxidant genes (Clements et al., 2006). In addition, DJ-1 might be activated following 
exposure to moderate levels of ROS and might exert crucial survival promoting 
functions in mitochondria or as a redox-dependent molecular chaperone (Shendelman 
et al., 2004).  DJ-1 was also found to bind mRNA (Blackinton et al., 2009a) and to 
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modulate dopamine release (Goldberg et al., 2005). However, the lack of a strong 
phenotype in DJ-1 null mutants has prevented the analysis of DJ-1 function in vivo 
and the above-mentioned putative functions for DJ-1 remain to be validated in 
physiological and pathophysiological contexts relevant to PD.   
 
How is the expression of DJ-1 regulated in mouse DA neurons and in Drosophila? 
We first tested whether DJ-1 expression is modified by Ret.  Removal of Ret function 
(in the mouse) did not modify DJ-1 protein levels; similarly, in Drosophila, targeted 
expression of constitutively active versions of Ret (RetMEN2) or the related Akt, Raf, 
ERK in the developing retina did not modify DJ-1A/B levels, suggesting that DJ-1 is 
not regulated via Ret and its related PI3K/Akt or Ras/MAPK. Other RTKs might 
induce DJ-1 expression or alternatively, its expression can be regulated by other 
transcription factors in response to e.g. oxidative stress (in aging DA neurons) or other 
developmental cues (in Drosophila). Indeed, the levels of DJ-1 were found to be 
elevated in the brains of PD and AD patients (Choi et al., 2006) and the levels of DJ-1 
in the plasma of sporadic PD patients correlated with disease progression (Waragai et 
al., 2007) suggesting that DJ-1 expression can be upregulated following cellular 
stress. Failure to upregulate DJ-1 expression in conditions of cellular dysfunction (e.g. 
PD patients with DJ-1 mutations) might leads to DA neurodegeneration. This 
possibility is also supported by research in cellular and animal models of PD, in which 
removal of DJ-1 function sensitized DA neurons and other non-DA cells to toxic 
exposure (Kahle et al., 2009a; Menzies et al., 2005; Meulener et al., 2005).  
 
Our genetic analysis provides the first evidence for a crucial pro-survival role of DJ-1 
in aging DA neurons. We found that DJ-1 promotes survival of dopaminergic neurons 
only in conditions of aging and trophic insufficiency suggesting that the function(s) of 
DJ-1 might only be uncovered in specific circumstances.  
 
It is interesting to note that our genetic analysis in the mouse uncovered the same 
interaction pattern between DJ-1and RTK-related signaling as in Drosophila. Thus, in 
both systems DJ-1 is dispensable for cell survival or development; moreover, reduced 
Ret (in the mouse) or RTK (in the fly) signaling leads to moderate effects on cell 
survival or development. If DJ-1 would act in the same pathway as Ret or related 
RTKs, mice and flies lacking DJ-1 should display the same moderate defects as seen 
in Ret and RTK-deficient animals. However, since loss of RTK and DJ-1 function 
leads to a synergistic effect, DJ-1 acts in parallel to RTK-signaling pathways to exert 
its functions.  
 
When using Drosophila to further localize the interaction point between DJ-1 and 
Ras/ERK signaling, we obtained evidence that DJ-1 might function either between 
Ras and Raf or in parallel to the Ras/ERK pathway to control fly development (Figure 
36). Since DJ-1 modulated the phenotypes induced by constitutively active RasV12, 
DJ-1 does not appear to regulate Ras activation. Instead, we propose that DJ-1 might 
control the activation of the Raf kinase, or its subcellular localization.  
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Figure 36. Interaction between DJ-1 and Ras/ERK signaling. Genetic evidence from aging mouse 
DA neurons suggests that DJ-1 acts in parallel to a Ret-associated pathway to control survival. 
Complementary studies in Drosophila suggest that DJ-1 interacts preferentially with the Ras/ERK 
pathway. DJ-1 connects to the Ras/ERK pathway either between Ras and Raf, or acts completely 
independent of Ras/ERK. Thus, DJ-1 might regulate the activation status of Raf by modulating the 
activity of Raf-activating factors; DJ-1 could also regulate Raf localisation and thereby the activation of 
downstream targets. DJ-1 could also act in a parallel pathway to reinforce the pro-survival activity of 
the Ras/ERK pathway. For example, DJ-1 might regulate the transcriptional activity of NFkB, p53 or 
FOXO, but might also have another target not presented here.  
 
The serine/threonine kinase Raf is activated following its recruitment by activated 
Ras-GTP; while association between Raf and a 14-3-3 dimer stabilizes Raf in the 
inactive form, binding to Ras-GTP interferes with 14-3-3 binding and promotes Raf 
phosphorylation at several serine and tyrosine resides (Leicht et al., 2007). It is 
believed that Raf activation involves several rounds of phosphorylation and 
dephosphorylation events and multiple protein-protein interactions. The major 
phosphorylating factors for Raf identified so far are the p21 Rac-activated kinase 
family (PAK) and the Src-family of tyrosine kinases (Leicht et al., 2007). In addition, 
Raf associates with chaperones (HSP-90, HSC-70) and with scaffold proteins (KSR, 
CNK, RKIP) that supposedly promote its activation (Kolch, 2000, 2005; Kyriakis, 
2007), although much remains to be learned about its regulation. Since Raf is a 
mitogen activated protein kinase kinase kinase (MAPKKK), it is interesting to note 
that the previously reported interaction between DJ-1 and JNK signaling in cells 
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stressed with UV light involved the specific association of DJ-1 with MEKK1, the 
MAPKKK upstream of MEK and JNK (Mo et al., 2008). DJ-1 sequesters MEKK1in 
the cytoplasm, thereby preventing it from entering the nucleus and activating 
apoptosis (Mo et al., 2008). Whether DJ-1 also binds Raf remains to be elucidated and 
additional studies are required to address the regulation of Raf by DJ-1.  
 
An alternative route for DJ-1 to interact with Ras/ERK signaling is by acting in an 
independent pathway that cooperates with Ras/ERK signaling during development 
and perhaps in DA neurons. DJ-1 might thus act on targets like p53 (Fan et al., 2008b) 
or FOXO (Figure 34), or might regulate NFkB (Figure 36). It is interesting to note 
that the survival extension mediated by Sirtuins (Sir2) in several organisms requires 
FOXO activity and Sirtuins deacetylate FOXO, thereby shifting its pro-apoptotic 
activity into survival-promoting (Giannakou and Partridge, 2004). Both p53 and 
FOXO possess this dual death/survival switch and it is possible that stress-response 
proteins like DJ-1act to switch the balance towards survival, while absence of DJ-1 is 
pro-apoptotic.  Additional studies will elucidate the interaction between DJ-1 and 
these transcription factors.  
 
Does DJ-1 also control Ras/ERK signaling in aging DA neurons? Mechanistic studies 
in the Ret/DJ-1 mouse model are difficult to pursue, because of the late-onset and 
slowly progressing phenotype. Interestingly, mice over-expressing activated Ras 
(RasV12) in the nervous system have larger neurons and embryonic mesencephalic 
neurons derived from these mice are resistant to MPTP or 6-hydroxydopamine -
induced degeneration, suggesting that Ras signaling promotes survival of SN neurons 
(Heumann et al., 2000). More recently, the analysis of Ret knockin mice revealed a 
critical role for Ras/B-Raf/IKK signaling, but not for PI3K and ERKs, in the survival 
of sympathetic neurons (Encinas et al., 2008). It remains to be shown whether similar 
mechanisms operate in the survival of dopaminergic neurons, but it is interesting that 
this signaling pattern shares resemblance with the interaction we found between Ret 
and DJ-1 in Drosophila.  
 
3.11. Interaction between aging, trophic insufficiency and cellular stress as cause 
for Parkinson’s disease 
 
3.11.1. DAT-Ret/DJ-1 mice as a model for Parkinsonism 
 
Are mice lacking Ret and DJ-1 useful for understanding PD? DAT-Ret/DJ-1 mice 
recapitulate some critical PD characteristics, which were difficult to obtain in 
previous models. First, lack of Ret and DJ-1 causes adult-onset and progressive loss 
of SN neurons similar to PD; moreover, the degeneration shows specificity for the 
GIRK2 subpopulation of SN neurons, and does not affect the neighboring VTA 
neurons. While GIRK2 neurons are indeed preferentially lost in PD (Yamada et al., 
1990), VTA neurons also degenerate in PD (although much less than SN neurons) 
suggesting that additional pathological triggers add-up to cause multi-network 
dysfunction. Second, DAT-Ret/DJ-1 mice also show degeneration of SN axons, 
similar to PD. The loss of axons precedes the loss of SN cell bodies, at least in DAT-
Ret mice, consistent with a “dying back” model suggested for the neurodegeneration 
in PD (Dauer and Przedborski, 2003). Moreover, because DAT-Ret/DJ-1 mice show 
increased degeneration of SN cell bodies but not axons relative to DAT-Ret mice, it is 
possible that two independent pathological alterations act in different sub-neuronal 
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compartments to negatively impact on neuronal viability. Third, DAT-Ret/DJ-1 mice 
show enhanced neuroinflammatory responses (astrogliosis and microgilal recruitment) 
relative to control mice and excessive neuroinflammatory responses were also 
observed in PD patients. Therefore, we conclude that the chain of cellular and 
network changes induced by neurotrophic factor insufficiency and cellular stress in 
DA neurons shows some striking similarities to human DA neurodegeneration, that 
argue for the usefulness of DAT-Ret/DJ-1 mice as PD models. However, DAT-Ret/DJ-
1 mice do not reproduce all pathological alterations seen in PD. Thus, we detected no 
accumulation of aggregated alpha-synuclein in aging DAT-Ret or DAT-Ret/DJ-1 mice 
and these animals are not behaviorally impaired. Therefore, the mechanisms 
regulating protein homeostasis in DA neurons do not require trophic input and appear 
to be independent on the chaperone activity of DJ-1.   
 
The absence of overt behavioral alterations in aging DAT-Ret/DJ-1 mice also parallels 
observations made in human PD studies. The symptoms of PD only become apparent 
when a critical threshold of nigrostriatal degeneration is reached. It is estimated that 
50-60% SN neurons and 80-90 % of their terminals in the striatum must be lost in 
order to trigger motor deficits (Dauer and Przedborski, 2003). The phase preceding 
behavioral alteration, called presymptomatic, might involve several compensatory 
mechanisms that ensure a proper SN output in the basal ganglia or a proper output of 
the basal ganglia when DA neurodegeneration is significant (Bezard et al., 2003). 
Among these physiological compensations, up-regulation of DA signaling – via 
increased synthesis, reduced re-uptake or increased activity of post-synaptic dopamine 
receptors – is believed to compensate for moderate loss of SN neurons; alternatively, 
loss of SN cell bodies might induce re-sprouting of striatal terminals to maintain a 
normal terminal arborisation, despite cell body degeneration (Bezard et al., 2003). 
Interestingly, the process of striatal terminal resprouting in the intact striatum 
(Hudson et al., 1995) or following striatal lesions (Bjorklund et al., 1997) or after 
MPTP treatment (Kowsky et al., 2007) requires GDNF/Ret signaling; remarkably, 
although the current clinical trials dealing with GDNF delivery have reduced power to 
predict the therapeutic outcome of GDNF, post-mortem examination of one PD-
patient treated with GDNF showed extensive resprouting in the striatum (Love et al., 
2005), suggesting that GDNF promotes terminal resprouting in humans and is 
supposedly involved in some aspects of presymptomatic compensation in PD. 
Additional presymptomatic compensations were suggested to take place within the 
basal ganglia (the subthalamic nucleus [STN] and the globus pallidus [GPi] increase 
their activity) or even outside of the basal ganglia (changes in thalamo-cortical 
activity) but they are poorly understood (Bezard et al., 2003). DAT-Ret/DJ-1 mice 
could therefore be used to better understand these presymptomatic compensations; in 
addition, the development of therapeutic strategies that target this compensatory 
period might delay onset of PD in humans.   
 
3.11.2. The multiple hit hypothesis of Parkinson’s disease 
 
The low penetrance of PD and the variability of symptoms in family members who 
inherit PD-associated mutations have raised the possibility that several risk factors 
interact to promote SN neuronal demise (the multiple hit hypothesis of PD (Sulzer, 
2007). Common risk factors for PD are aging, environmental toxins, different 
mutations of low frequency but also developmental and disease-induced abnormalities 
(e.g. neuroinflammation).  At the cellular level, distinct molecular alterations could 
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synergize to cause neuronal dysfunction and cell death. The lack of appropriate 
disease models makes the study of multiple hit interactions difficult. David Sulzer and 
colleagues recently reported that a combination of high cytoplasmic calcium, elevated 
levels of free cytoplasmic dopamine and the presence of alpha-synuclein induces 
selective death of cultured DA neurons at postnatal day 0-2 and interference with any 
of these individual hits alleviated neuronal cell death (Mosharov et al., 2009). We 
report here a chronic and slowly progressive genetic mouse model in which the 
interplay between three factors (aging, trophic insufficiency and increased cellular 
stress due to DJ-1 inactivation) synergize and cause the loss of approx. 50 % of 
GIRK2 DA neurons in the SN. Aging is the critical component of this triple 
interaction network, as young and adult mice lacking Ret and DJ-1 do not display SN 
degeneration. The second risk factor is loss of Ret-mediated trophic support, which 
causes degeneration of a subset of SN neurons during aging. Finally, lack of DJ-1 
function only becomes critical in aging SN neurons deprived of Ret-mediated trophic 
support. This triple-interaction model likely reflects the synergism generated by 
several independent pathological triggers, acting at sub-threshold levels, and which 
together induce degeneration of SN neurons.  
 
We also tested the interaction between aging, loss of Ret-mediated trophic support 
and defective proteostasis. Alpha-synuclein (α-syn) mutations that render the protein 
insoluble cause PD and aggregated α-syn is found in Lewy Bodies, both in monogenic 
and sporadic PD. We found that DAT-Ret mice which overexpress aggregation-prone 
α-syn lose indeed more SN neurons than DAT-Ret single mutants or mice that only 
overexpress α-syn, but the loss is additive and not synergistic. This suggests that some 
pathological changes (loss of Ret and α-syn aggregation), acting in different neurons 
to cause cell death, add up to enhance tissue loss, while others (loss of Ret and DJ-1) 
synergize within the same cells to cause their dysfunction and demise. The distinction 
between additive and synergistic effects of pathological changes is important for the 
choice of therapy, as additive effects require independent management of individual 
causes, whereas synergistic pathological changes might be prevented in one step. The 
fact that mice that lack Ret and overexpress mutant α-syn in DA neurons do not show 
a synergistic loss of neurons also suggests that Ret mutants are not generally more 
sensitive to any deleterious agent, but appear to be specifically sensitive to changes 
that amplify the effects of trophic deprivation. Thus, trophic insufficiency and aging 
predispose neurons more to loss of DJ-1 function rather than to abnormal aggregation 
of mutant α-syn. Further investigation of interactions between different pathological 
changes will lead to a better understanding of the cellular and molecular mechanisms 
that are critical for the function and survival of SN neurons.   
 
3. 12. Perspectives 
    
3.12.1. Toward integrative models of Parkinson’s disease 
 
Two major approaches have been used to mimic PD in an animal model. The first is 
based on the administration of specific dopaminergic toxins, and the second is using 
transgenic animals. These approaches were successful in reconstituting some of the 
major PD characteristics. First, delivery of toxins like 6-OHDA and MPTP induce 
dopaminergic neurodegeneration by inhibiting the mitochondrial complex I of the 
electron transport chain  and lead to dramatic behavioral alterations (Dauer and 
Przedborski, 2003), but the initial acute behavioral changes in mice are reversible, 
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suggesting neuronal recovery. Although these two models show a clear SN cell loss 
and some behavioral phenotypes, their major disadvantage is that they do not - or only 
sporadically- lead to the occurrence of intracellular inclusions. Moreover, although 
some sub-chronic protocols can be applied, they do not resemble the progressive 
course of the disorder. Second, models based on PD-associated genes are successful 
in reproducing defects in proteostasis (e.g. α-syn overexpression) and display 
moderate behavioral phenotypes (Moore et al., 2008); however, they generally fail in 
reproducing SN neurodegeneration.  
 
Therefore, integrated strategies, combining both neurotoxin-based and transgenic 
animals should be used in order to dissect the complex interactions leading to SN 
dysfunction and death. In addition, I propose that the storage, integration and analysis 
of experimental data collected from all PD-models might be amenable to system 
analysis (Figure 37) and might accelerate the pre-clinical and drug development in 
PD. PD is a complex disorder with a strong environmental (90 %) contribution, 
supporting the idea that SN cell death is a multifactorial process (Dauer and 
Przedborski, 2003). This complex biological system can be defined as a highly 
interconnected map of signaling pathways involved in multiple biological processes 
(Figure 37).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Toward integrative models of Parkinson’s disease. Extracellular factors (e.g. 
neurotrophic factors, toxins and other modulators [endogenous or experimentally induced]) interact 
with intracellular factors inside the SN (genetically controlled and subjected to multiple interactions) to 
control their fate. Some pathways inside SN neurons might be preferential, and some factors more 
important than others. Dysfunction in some pathways might lead to specific outcomes. Choosing the 
best PD model for a given application means selecting the combination of factors that generates an 
output best fitting to pre-established criteria. Standardized information about all parameters involved 
(genetic, toxicologic, histologic, behavioral, others) should facilitate the establishment and 
development of integrative models for PD.  
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The input of this system is represented by all extracellular factors acting on SN 
neurons (e.g. cytokines, trophic factors). The processing of all the input signals is 
performed at several sites within SN neurons. The output is represented by the SN 
neuron behavior, that can vary from no or slight dysfunction to cell death. When a 
certain threshold of cell death is reached, behavioral alterations will be visible at the 
organism level. Several requirements are necessary to achieve this purpose: 1. 
Creation of an easily-accessible common resource; this might represent a website 
where all relevant information (concerning the type of model; the type of 
experimental alteration; histological, behavioral and molecular analysis; other 
parameters) is structured and compared in a useful way; 2. Standardization of all 
protocols used during these experiments, or a clear description of them, to allow 
analysis and reproducibility; 3. Development of in silico tools to allow data analysis 
and most importantly, to allow prediction of experimental outcomes; development of 
in silico tools to interactively adjust experimental predictions based on available new 
data; 4. Establishment of a policy concerning the eventual conflicts of interest, data 
sharing and other legal rights.  
 
Because it appears that distinct sets of pathological changes interact in specific ways 
to generate distinct outcomes, it is logical to assume that integrative models of PD 
might require both genetic and non-genetic manipulations. The use of multiple 
experimental hits might lead to more overt degeneration signs, and provided they are 
properly controlled, they might be used for drug development. For example, delivery 
of a specific MPTP dose to a mouse lacking DJ-1 function and overexpressing alpha-
syn in SN neurons might be used to screen for compounds that are more effective for 
DJ-1 linked PD than compound testing on LRRK2 mice treated with MPTP and 
overexpressing alpha-syn. Moreover, DJ-1 deficient mice challenged with MPTP and 
overexpressing alpha-synuclein might also receive defined doses of GDNF in the 
striatum, and the outcome might be compared to other similar studies to allow further 
refinements. The use of a common resource might allow sharing important 
information about associations of pathological changes and their prevalent behavioral 
outcomes. Prediction models based on known pathological associations and 
behavioral correlates could be developed and further refined in this interactive 
common resource.  
 
3.12.2. The future of neurotrophic factor-based therapies for Parkinson’s disease  
 
Although the already existing clinical trials met with several technical problems, 
neurotrophic factors still hold promise as rescuing agents for neurodegenerative 
disease. It is currently acknowledged that serious improvements concerning the 
delivery mode of neurotrophic factors, the ideal time-window for delivery but also 
safety issues are needed before we can critically assess their therapeutic power 
(Barker, 2006; Kordower and Olanow, 2008; Ramaswamy et al., 2009). New 
therapeutic avenues are also provided by the development of small molecule agonists 
that specifically activate neurotrophic factor signaling and several such molecules 
were identified for GDNF. One of them is a non-peptidyl small molecule that binds 
GFRα1 and activates the GFRα1-Ret complex (Tokugawa et al., 2003) and several 
patents for small molecule Ret-modulators exist already (Jurvansuu and Goldman, 
2008). Our current results raise the possibility that activation of Ret signaling via 
these agonists might be beneficial for nigral disease and future research will evaluate 
the effects of activating Ret signaling in Parkinson’s disease patients.  
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A. BUFFERS,  SOLUTIONS AND MEDIA 
   
PBS  10 mM Na2HPO4 pH 7.4   
  2 mM KH2PO4    
  0,137 M NaCl    
  2,7 mM KCl    
       
TBS  50 mM Tris pH 7.4    
  150 mM NaCl    
       
PFA 4 %  40 g PFA in 1 L warm PBS ( 60 ⁰C)  
  add 400 µL NaOH 5M to help dissolving  
  then neutralize with 150 µL HCl 37 %  
  for perfusions, use cold (4 ⁰C) PFA 4 % solution  
       
Sucrose solutions 15 % and 30 % sucrose in PBS    
  used for brain immersion   
       
Cryoprotection solution (1L) 300 mL distilled water   
  300 mL glycerol    
  300 mL Ethyleneglycol   
  100 mL PBS     
  used to store mouse brain sections at -20 ⁰C 
       
Egg embedding mix mix egg yelow and sucrose 10 : 1 (g/g)  
  use cold mix for embedding (4 ⁰C)  
  to polymeraze, add 1 mL glyceraldehyde 25 % to  
  20 mL egg mix; mix well and allow 45 min for  
  after polymerization at r.t., store at -80⁰C  
       
Fly food (1L) 15 g yeast      
  11.7 g agar    
  80 g molasses    
  60 g corn flower    
  6.3 mL propionic acid        
  2.4 g methylparaben    
  yeast paste (yeast granules and fly water) was 
  added to bottles to enhance egg laying  
       
Fly food with paraquat paraquat was directly dissolved in boiled food 
for fly toxicity tests food was dispensed in vials and allowed to dry 
       
H2O2 solutions 5 % sucrose in distilled water   
for fly toxicity tests 2 % H2O2     
       
Fly water  0.8 % acetic acid in distilled water  
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PCR buffer A 25 mM NaOH    
  0.2 mM EDTA    
       
PCR buffer B 40 mM Tris HCl pH 5.0   
       
Blocking buffer 5 % bovine serum albumin (BSA) in TBS   
  0.3 % Triton X-100    
       
Antibody incubation buffer 2 % BSA in TBS      
  0.1 % Triton X-100    
       
Modified RIPA buffer 20 mM HEPES    
  100 mM NaCl    
  10 mM NaF    
  1.5 mM sodium vanadate   
  5 mM EDTA    
  2 % Triton X-100    
  5 mM sodium pyrophosphate   
  1mM sodium molybdate   
  0,1 % SDS    
  1 tablet Complete protease inhibitors  
       
Chloral hydrate 8 % chloral hydrate (Roth, Germany) in PBS 
   
Unless otherwise mentioned, chemicals were purchased from Sigma-Aldrich and 
Merck (Germany).Fly food components were from ProBio and Primavera (Germany).  
 
 
B. MOUSE GENETICS, HISTOLOGY AND BEHAVIOR  
 
 
4.1.   Transgenic animals 
 
The Ret floxed allele was generated by flanking the exon 12 of the Ret gene, which 
encodes the ATP binding site of the tyrosine kinase domain, with loxP sites (Kramer 
et al., 2006). The second exon of the TrkB gene, encoding a part of the tyrosine kinase 
domain, was flanked by loxP sites to generate the TrkB floxed allele (Minichiello et 
al., 1999). Nestin-Cre mice express Cre from a transgene (Tronche et al., 1999), while 
DAT-Cre mice were generated by knocking Cre into the 5’ UTR region of the 
endogenous mouse DAT locus (Zhuang et al., 2005). The DJ-1 gene trap mice were 
generated by Thu-Trang Pham and Daniela Vogt-Weisenhorn (Helmholtz Research 
Center, Germany) using the XE726 ES cell clone (Bay Genomics, USA) in which the 
pGT1Lxf vector (containing a splice acceptor, LacZ and neomycin genes) was 
inserted between the exons 6 and 7 of the DJ-1 gene; this generates a DJ-1 null allele, 
as the resulting DJ-1 protein is unstable (Pham et al., submitted). Mice overexpressing 
a mutant version of human alpha-synuclein (Ala30Pro) under the control of the TH 
promoter (TH-α-synA30P) were from Philipp Kahle and Christian Haass (LMU 
University, Munich, Germany) (Rathke-Hartlieb et al., 2001). The mice used in this 
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study were kept on a C57Bl6/J genetic background with contributions of 129/sv from 
the embryonic stem cell culture and the different Cre mouse lines. Because both DAT-
Cre and Nes-Cre lines show significant recombination in germ cells, the floxed allele 
derived from the parent that carries the Cre recombinase is often constitutively 
recombined; therefore, the homozygous Ret mutants carry one Ret allele recombined 
in a regionally specific manner and one Ret allele recombined constitutively (i.e. exact 
genotypes are DAT-Cre; Retlx/- and Nes-Cre;Retlx/-). The control mice for all 
experiments carried floxed alleles of Ret (Retlx/lx, Retlx/+), TrkB (TrkBlx/lx, TrkBlx/+), or 
one copy of Cre (DAT-Cre or Nestin-Cre), unless otherwise mentioned. The following 
abbreviations are used throughout this thesis: DAT-Ret for DAT-Cre;Retlx/-, DAT-TrkB 
for DAT-Cre;TrkBlx/-, DAT-Ret/TrkB for DAT-Cre;Retlx/-;TrkBlx/-, Nes-Ret for Nes-
Cre;Retlx/-, DAT-Ret/DJ-1 for DAT-Cre;Retlx/-; DJ-1-/-, TH-αsynA30P for TH-α-
syn(Ala30Pro).  
 
4.2. Generation of conditional Ret and TrkB mutants: the Cre/loxP system 
 
To ablate Ret or TrkB expression in defined tissues (dopaminergic system or the 
whole nervous system), the Cre/loxP system was used (Figure 38).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. The Cre/LoxP system. To generate region-specific knockout mice, two lines are required: 
a line carrying the Cre recombinase under the control of a tissue/cell specific promoter (P); a second 
line in which the gene of interest has been engineered to contain loxP sites. Upon crossing these two 
mouse lines, the resulting progeny will express Cre in cells/tissue in which the promoter P is active. In 
these cells/tissue Cre will mediate site-specific DNA recombination and will remove the DNA piece 
contained between the engineered loxP sites. Therefore, the resulting progeny will carry the new 
mutation only in the cells/tissue in which the promoter P was active (conditional knockout mice).   
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The Cre/loxP system allows site-specific DNA recombination in defined cells or 
tissues. The site-specific DNA recombinase Cre catalyses recombination between two 
engineered sites, loxP (locus of X-over P1, a 34-bp site found in the bacteriophage 
P1). Two mouse lines are required to achieve conditional gene deletion. One is a 
conventional transgenic mouse line with Cre targeted to a specific tissue or cell type, 
and the second is a mouse strain in which the target gene (here Ret or TrkB) is flanked 
by two loxP sites in a direct orientation ("floxed allele"). Recombination (excision and 
consequently inactivation of the target gene) occurs only in those cells expressing Cre 
recombinase. Thus, the target gene remains active in all cells and tissues which do not 
express Cre (Figure 38). For example, mice that carry floxed alleles of Ret (Retlx/lx) 
and express the Cre recombinase under the control of a dopaminergic specific (e.g. 
dopamine transporter-DAT) promoter (DAT-Cre; Retlx/lx) will therefore lack Ret 
expression only in dopaminergic neurons. 
 
4.3. Mouse genotyping  
 
DNA extraction. DNA was extracted from mouse tails after incubation with 100 μL 
PCR buffer A (45 minutes at 95°C) and subsequent neutralization with 100 μL PCR 
buffer B. The resulting DNA solution was kept at +4 °C (for immediate use) or at -20 
°C (for long-term storage).  
 
PCR amplification. The PCR mix (50 μL) contained 1 μL from the reverse and 
forward primers (30 μM), 5 μL ThermoPol PCR buffer (New England Biolabs), 5 μL 
of dNTPs mix (10 μM), 1 μL Taq DNA polymerase (New England Biolabs), 36 μL 
distilled water and 1 μL from the DNA solution. The following primers were used: 
 
Primer name Sequence (5'-3') 
DJ-1 Forward AGG CAG TGG AGA AGT CCA TC 
DJ-1 Reverse WT AAC ATA CAG ACC CGG GAT GA 
DJ-1 Reverse mutant CGG TAC CAG ACT CTC CCA TC 
Annealing at 58 °C DJ-1+ (475 bp) and DJ-1- (240 bp) products 
Retlx Forward (geno 5) CCA ACA GTA GCC TCT GTG TAA CCC C  
Retlx Reverse (geno 7) GCA GTC TCT CCA TGG ACA TGG TAG  
Annealing at 62 °C Ret+ (300 bp) and Retlx (350 bp) products 
Cre Forward (A) GCC TGC ATT ACC GGT CGA TGC AAC GA 
Cre Reverse (B) GTG GCA GAT GGC GCG GCA ACA CCA TT 
Annealing at 64°C 500 bp product  
Retrec Forward (geno6) CGA GTA GAG AAT GGA CTG CCA TCT CCC 
Retrec Reverse (3E) ATG AGC CTA TGG GGG GGT GGG CAC 
Annealing at 72 °C 600 bp product  
For each reaction, two primers (indicated above) were used, except for DJ-1 
genotyping where 3 primers were used.  The DJ-1 genotyping was also performed as 
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two separate PCR reactions, to detect either the WT (475 bp product) or the mutant 
(240 bp product) DJ-1 allele. To detect the floxed vs. WT allele of Ret, Retlx forward 
and reverse primers were used and generated a 300 bp product (WT allele) or a 350 bp 
product (floxed allele). The presence of the Cre construct was tested in the Cre PCR, 
while the presence of the recombined Ret allele was detected in a Retrec PCR reaction 
(the product sizes are indicated above). The PCR conditions were: an initial 
denaturation step at 94°C (5 minutes) was followed by 35 cycles that comprised 
denaturation (94°C; 30 seconds), primer annealing (at annealing temperature indicated 
above; 30 seconds) and elongation (at 72°C; 30 seconds); finally, a final elongation 
step at 72 °C (10 minutes) completed the PCR amplification. The PCR products were 
analyzed on 1 % or 2 % agarose gels.  
 
4.4. Histology, immunohistochemistry and Nissl staining 
 
Perfusion and tissue processing. Mice were given a lethal dose (0.5 ml) of 8 % chloral 
hydrate solution. Mice were perfused transcardially with PBS and 4 % PFA (20 
minutes each). Subsequently, brains were removed from the scull, post-fixed 
overnight in the same fixative, and cyroprotected by incubation in 15 % and 30 % 
sucrose solutions. Left and right brain halves were embedded separately in egg yolk 
with 10 % sucrose and 5 % glutaraldehyde, and kept frozen at −80°C until analyzed. 
30 μm–thick coronal sections were cut on a cryostat, collected free floating, and then 
directly used for stainings or stored in a cryoprotection solution at −20 °C until 
utilized. For fluorescent immunohistochemical and Nissl stainings, sections were 
premounted; for all other stainings, free-floating sections were used.  
 
Primary antibodies. The following primary antibodies were diluted in antibody 
incubation buffer:  
 
Antibody   Species Dilution  Source/donor  
Tyrosine hydroxylase  mouse 1: 2000  Immunostar, USA  
Dopamine transporter  rat 1: 500  Chemicon, Germany  
Pitx3   rabbit 1: 1000  M.P. Smidt, Netherlands 
NeuN   mouse 1: 200  Chemicon, Germany  
GFAP   rabbit 1: 500  DakoCytomation, Denmark 
DARPP-32   rabbit 1: 50  US Biological, USA  
Parvalbumin  mouse 1: 10000  Swant, Switzerland  
Iba-1   rabbit 1: 1000  Wako, Germany  
MAC-1/CD11b  rat 1: 200  Serotec, UK   
GIRK2   rabbit 1: 80  Alomone labs, Israel  
Calbindin   mouse 1: 500  Chemicon, Germany  
Alpha-synuclein  sheep 1: 500  Chemicon, Germany  
Alpha-synuclein  rat 1: 500  Philipp Kahle, Germany  
       
Free floating sections were first incubated 1 hour in blocking buffer at room 
temperature (r.t.). The solution containing the primary antibody in antibody 
incubation buffer was then added, and sections were incubated over-night at 4°C. 
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After three washes in TBS (5 minutes each), the sections were incubated 1 hour at r.t. 
with a species-specific biotin-coupled secondary antibody (dilution 1:200 in antibody 
incubation buffer) from Vectastain ABC kits (Vector Laboratories, Burlingame, 
California, United States). After another three washes in TBS, sections were 
incubated with a complex of avidin-biotin (in which a part of biotin-binding sites are 
vacant) coupled to horseradish peroxisade (HRP; dilution 1:200 in TBS buffer; 
incubation 1 hour at r.t.). Finally, after three washes in TBS, a substrate of HRP - the 
diaminobenzidine (DAB; Sigma-Aldrich, Germany) - diluted in tap water was added. 
Sections were incubated until a brown precipitate was formed that allowed specific 
visualization of neurons or glial cells. The exposure times to DAB (typically less than 
20 minutes) were optimized to allow a high signal-to-noise ratio. For NeuN/TH 
double labeling, sections were first stained for NeuN as described above, followed by 
a weak TH staining with more-diluted primary (1:20,000) and secondary antibodies 
(1:2,000) and avidin-HRP/biotin complexes (1:2,000).  
 
To fluorescently label DA fibers, sections were first-premounted, allowed to dry then 
incubated in blocking buffer (1 hour at r.t.). Then, the primary antibody (TH or DAT) 
diluted in antibody incubation buffer was added and the sections were incubated over-
night at 4°C. After three washes in TBS, the secondary biotin-coupled antibody 
(Vectastain ABC kit; Vectorlabs, USA) diluted 1:500 in antibody incubation buffer 
was added (2 hours of incubation at r.t.). After another three washes, Cy3-coupled 
Streptavidin (Sigma-Aldrich, Germany) diluted 1:1,000 in TBS was added (incubation 
1 hour at r.t.). The sections were again washed three times in TBS buffer and then 
mounted in an aqueous mounting medium with anti-fading reagent (Biomedia, Foster 
City, California, United States).  
 
Nissl staining was performed according to standard procedures. Briefly, mounted 
sections were successively dehydrated with 50 % and 100 % ethanol, and then 
incubated in xylene (5 minutes) to remove fat. Sections were then re-hydrated by 
incubation in ethanol solutions of decreasing concentrations (100 %, 70 %, 50 % and 
then in water). Sections were then incubated in a 0.5 % cresyl violet solution for 8 
minutes, followed by a quick wash in water and destaining in 70 % ethanol until an 
optimal contrast is achieved (microscope examination). Finally, after incubation in 96 
% ethanol (5 minutes), butanol (3 minutes) and xylene (10 minutes), sections were 
allowed to dry and were mounted with a non-aqueous mounting medium (DPX). 
  
4.5. Stereological quantification of substantia nigra neurons 
 
Stereological counts were performed with the StereoInvestigator program 
(MicroBrightField, Williston, Vermont, United States) on every third or sixth section 
spanning the SN. After immunolabeling of SN neurons, the exact order of sections 
spanning the SN area was established. On each individual section, the area of the SN 
was delineated and an automated method allowed selection of smaller SN sub-
territories (each territory was a 50 x 50 µm square) that were uniformly distributed 
(distance between two consecutive sub-territories was 75 µm on the x-axis and 100 
µm on the y-axis). Inside each selected sub-territory, neurons found within 10 µm 
depth (z-axis) were counted. After all sections were processed, the program used the 
determined neuronal densities to estimate the total number of neurons found within 
the selected SN volume. 3-5 animals were tested per group.  
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4.6. Determination of dopaminergic fiber density in the striatum 
 
Pictures of fluorescently labeled DA fibers in the striatum were acquired using a 
fluorescence microscope (Axioplan; Zeiss, Göttingen, Germany) at 63x 
magnification. For every section, three pictures in the dorsal striatum and two pictures 
in the ventral striatum were acquired. DA fiber density in the striatum was assessed on 
every third section spanning the striatum (between Bregma +1.10 mm and −0.10 
mm). In order to automatically delineate the fibers and to increase the signal-to-noise 
ratio, the images were first thresholded and subsequently quantified with an automatic 
counting-grid macro implemented in the Metamorph software (Molecular Devices, 
Sunnyvale, California, United States) (Kramer et al., 2007).  
 
4.7. Determination of neuron, astrocyte and microglial densities  
 
Every sixth section from the dorsal striatum or the SN was used to determine the 
density of astrocytes or microglial cells. For each section, the area containing labeled 
cells was delineated. The number of cells was then determined and the density of cells 
in the selected area was calculated. 6-8 sections were analyzed /animal and at least 4 
animals were analyzed per group. 
 
4.8. Behavioral tests 
 
Experimental protocols were approved by the government of Oberbayern, Germany. 
18- and 24-month-old mice were housed individually with free access to water and 
food in a room with 12h/12h reversed day-night cycle. All experiments were 
conducted during the night period in a quiet room with 12 lx light intensity.  
 
Open field. To test the general activity of aging control and mutant mice, animals 
were subjected to open field behavioral assessment. Mice received no prior training. 
They were placed into a 59 cm x 59 cm large arena for 20 minutes and their horizontal 
movement was monitored by an observer and by using the EthoVision software 
(Noldus, Sterling, USA). The experiment was repeated on the consecutive day and the 
average of the two trials per mouse was taken for further analysis (Valenti et al., 
2001). The results represent the average travelled distance (cm)/20 minutes.  
 
Swimming tank. To monitor leg movements, mice were swimming 60 cm in a water 
filled glass-tank (100 cm long and 6 cm wide, filled with 23ºC water to a depth of 20 
cm) to a visible black escape platform (6 cm long, 20.5 cm high) 0.5 cm above the 
water level (Carter et al., 1999). Before testing, mice were given three training 
sessions per day for three consecutive days in which they were allowed to swim 4 
times per session. During the tests, mice were tested 6 times per day (in two separate 
test sessions each comprising 3 consecutive runs) during two consecutive days. The 
tests were videotaped and the time mice needed to reach the platform was determined. 
  
Forced swimming test. To test spontaneous activity, mice (without any previous 
training) were placed in a plexiglas cylinder (20 cm high and 14 cm in diameter) filled 
with water to a height of 10 cm. A camera was used to observe and record the 
animal’s behavior. Within the 6 minutes of the trial, the first 2 minutes the animal was 
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allowed to adjust to the new conditions. In the next 4 minutes, the duration of two 
types of motor activity, struggling and floating status, was recorded. The results are 
expressed as activity (sec)/240sec.  
 
Rotarod. To monitor limb motor coordination and balance, a computerized rotarod 
apparatus was used (TSE, Bad Homburg, Germany). Mice were trained at several 
constant speeds (0, 4, 10, 25 rpm) and increasing speeds (4-10, 10-20, 20-30 rpm) 
three times five minutes each and were placed back on the rod every time they fell. 
After the mice attained a steady baseline level of performance, they were tested 4 
times five minutes at 25 rpm (in separate trials, during one day) and 4 times five 
minutes at increasing speed 4-25 rpm (separate trials, the next day). The latency to fall 
off the rotarod during the 300 sec test was recorded (Valenti et al., 2001).  
 
C. DROSOPHILA GENETICS, HISTOLOGY AND TOXICITY TESTS 
 
4.9. Drosophila lines 
 
The following lines were used during this study:  
 
Drosophila stocks Source/donor 
WT Bloomington stock center (No. 1) 
w1118  Bloomington stock center (No. 5905) 
w1118 Bloomington stock center (No. 6326) 
DJ-1A-/- (Δ72) Nanci Bonini (USA) 
DJ-1B-/- (Δ93) Nanci Bonini (USA) 
DJ-1A-/-; DJ-1B-/- Nanci Bonini (USA) 
Df(2R)CX1 Bloomington stock center (No. 442) 
Ins(2R)k04204 Bloomington stock center (No. 102296) 
Df(3R)7917 Bloomington stock center (No. 7917) 
Ins(3R)16085 Bloomington stock center (No. 16085 ) 
rlSEM Kyoto stock Center (No. 108365) 
rl1 Bloomington stock center (No. 386) 
GMR-dRetMENA Ross Cagan (USA) 
GMR-dRetMEN2B Ross Cagan (USA) 
Sev-RasV12 Marc Therrien (canada) 
GMR-Gal4 (II) Takashi Suzuki (Germany) 
GMR-Gal4 (III) Bloomington stock center (No. 8121) 
Ey-gal4 Takashi Suzuki (Germany) 
Sev-Gal4 Bloomington stock center (No.5793 ) 
Da-Gal4 Bloomington stock center (No. 5460) 
Tubulin-gal4 Gaia Tavosanis (Germany) 
Actin-Gal4 Gaia Tavosanis (Germany) 
UAS-dRetMEN2A Ross Cagan (USA) 
UAS-dRetMEN2B Ross Cagan (USA)
UAS-DJ1A Nanci Bonini (USA) 
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UAS-DJ1B Nanci Bonini (USA) 
UAS-hDJ1 Nanci Bonini (USA) 
UAS-PI3KWT Sally Leevers (UK) 
UAS-PI3KD954A Sally Leevers (UK) 
UAS-PI3KCAAX Sally Leevers (UK) 
UAS-Akt1WT Bloomington stock center (No. 8191) 
UAS-rlSEM Jongkyeong Chung (Korea)  
UAS-RasV12 Bloomington stock center (No. 4847) 
UAS-RafF179 Bloomington stock center (No. 2033) 
UAS-dPTEN Tak Mak (Canada) 
UAS-dFOXO Bloomington stock center (No. 9575) 
 
The following Drosophila stocks were generated during this study: 
 
w1; BL/Cyo; DJ-1B-/TM2 
w1; BL/Cyo; UAS-DJ-1A/TM2 
w1; BL/Cyo; UAS-DJ-1B/TM2 
w1; BL/Cyo; UAS-dRetMEN2B :: DJ-1B-/TM2 
w1; BL/Cyo; da-Gal4 :: DJ-1B-/TM2 
w1; GMR-Gal4/Cyo; TM2/TM6 
w1; GMR-Gal4/Cyo; DJ-1B-/TM6 
w1; GMR-Gal4/Cyo; UAS-DJ-1A/TM6 
w1; GMR-Gal4/Cyo; UAS-DJ-1B/TM6 
w1; GMR-dRetMEN2B/Cyo; TM2/TM6 
w1; GMR-dRetMEN2B/Cyo; DJ-1B-/TM6 
w1; GMR-dRetMEN2B :: DJ-1A-; DJ-1B-/TM2 
w1; GMR-dRetMEN2A/Cyo; TM2/TM6 
w1; GMR-dRetMEN2A/Cyo; DJ-1B-/TM6 
w1; GMR-Gal4/Cyo; UAS-DJ-1A RNAi/TM2 
w1; Sev-Gal4/Cyo; DJ-1B-/TM2 
w1; Sev-Gal4/Cyo; UAS-DJ-1A/TM2 
w1; Sev-Gal4/Cyo; UAS-DJ-1B/TM2 
w1; Elav-Gal4/Cyo; DJ-1B-/TM6 
w1; DJ-A-/-; GMR-Gal4/TM6 
w1; UAS-dRetMEN2A/Cyo; DJ-1B-/TM2 
w1; UAS-dRetMEN2A/Cyo; UAS-DJ-1A/TM2 
w1; UAS-dRetMEN2A/Cyo; UAS-DJ-1B/TM2 
w1; UAS-PI3KWT/Cyo; TM2/TM6 
w1; UAS-PI3KD954A/Cyo; TM2/TM6 
w1; UAS-PI3KWT/Cyo; DJ-1B-/TM6 
                                                                                                     Materials and Methods 
                                                                
128 
 
w1; UAS-PI3KD954A/Cyo; DJ-1B-/TM6 
w1; UAS-dPTEN/Cyo; TM2/TM6 
w1; UAS-dPTEN/Cyo; UAS-DJ-1B-/TM6 
w1; UAS-dPTEN/Cyo; UAS-DJ-1A/TM6 
w1; UAS-dPTEN/Cyo; UAS-DJ-1B/TM6 
w1; DJ-1A-/Cyo; UAS-dRafF179/TM2 
w1; DJ-1A-/Cyo; UAS-rlSEM/TM2 
w1; UAS-hDJ-1/Cyo; DJ-1B-/TM6 
w1; UAS-dFOXO/Cyo; DJ-1B-/TM6 
rl1/Cyo; DJ-1B-/TM2 
rlSEM/Cyo; DJ-1B-/TM2 
 
Unless otherwise stated, flies were raised at 25ºC with 70 % relative humidity on 
standard cornmeal medium. Embryos and larvae were hydrated using fly water. Fly 
stocks were kept at 18ºC on cornmeal medium and were flipped regularly. 
 
4.10. Genotype abbreviations 
 
A fusion between a promoter and a cDNA is indicated by a hyphen (-). For example, 
GMR-dRetMEN2A, GMR-dRetMEN2B and Sev-RasV12 flies carry fusions between the 
photoreceptor neuron specific promoters glass multimer reporter (GMR) or sevenless 
(Sev) and mutated cDNAs of Ret and Ras genes.  
 
Flies that carry promoter-Gal4 constructs and one or several UAS constructs (i.e. 
targeted expression using the GAL4-UAS system) are labeled as in the following 
examples: GMR/DJ-1A (instead of GMR-Gal4; UAS-DJ-1A), GMR/PI3KWT/DJ-1A 
(instead of GMR-Gal4; UAS-PI3KWT; UAS-DJ-1A).  
 
4.11. Assembly of two mutations on the same chromosome (recombination)  
 
During meiosis, Drosophila females, in contrast to males, undergo recombination 
between homologous chromosomes at high rates. This property can be used to 
generate fly lines that carry two distinct mutations on the same chromosome. Two 
stocks each carrying one mutation are crossed together and virgin females (carrying 
both mutations but each on a homologous chromosome) are collected. During 
meiosis, recombination occurs and hybrid chromosomes are eventually produced. To 
screen for flies carrying recombined chromosomes, virgin females are crossed to 
males carrying balancer chromosomes (that do not undergo recombination and whose 
presence in the progeny causes an easily identifiable phenotype); thus, some of the 
resulting progeny will carry a new hybrid chromosome that has both mutations 
(Figure 39). To screen for flies carrying the hybrid chromosome, males issued from 
this cross (and thus potential carriers of the hybrid chromosome) are first allowed to 
mate with virgin females carrying balancer chromosomes (to insure the chromosome 
is maintained in a population); after several days, each individual male is re-isolated. 
To determine which males carry the hybrid chromosome, several strategies can be 
used. DNA from each male can be isolated and tested for the presence of both 
mutations (by PCR). Males can also be genotyped directly, by visual inspection, when 
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the presence of both mutations leads to a visible and unambiguous phenotype. 
Alternatively, males can be crossed to defined virgin females and the progeny can be 
screened by western blotting for expected proteomic changes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Performing recombinations in Drosophila melanogaster. To assemble two mutations (red 
and yellow) on the same chromosome, flies carrying each mutation are crossed; the resulting virgin 
females will undergo recombination between homologue chromosomes at high rates; the frequency of 
recombinants containing both mutations (red and yellow) will depend on the chromosomal distance 
between the two mutations. Virgin females are then crossed to defined males and the presence of the 
recombined chromosomes is detected using several methods (see text for details).  
 
4.12. The GAL4-UAS system  
 
The GAL4-UAS binary system allows the expression of a given transgene under the 
indirect control of a given promoter (Figure 40). (1) The gene (X) to be expressed is 
positioned downstream of an upstream activating sequence (UAS) found in yeast; 
flies carrying the UAS-X construct are generated (line 1). Conventional lines exist in 
which the Gal4 transactivating yeast gene is placed under the control of a cell/tissue 
specific promoter (P; line 2), allowing expression of the Gal4 protein in cells/tissue 
where the promoter P is active. When the two lines 1 and 2 are crossed, the Gal4 
protein generated in defined cells/tissue binds specifically the UAS sequence and 
induces the expression of the X gene in the same cells/tissue. If, for example, P is 
GMR and X is DJ-1A, expression of DJ-1A will be specifically induced in post-
mitotic photoreceptor neurons, where GMR is active.   
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Figure 40. Targeted gene expression using the GAL4-UAS system. The GAL4-UAS system allows 
the expression of a given gene (X) in defined tissue/cells, using a tissue/cell specific promoter (P). One 
fly line carries a transgene in which the coding sequence of the yeast transactivator GAL4 is placed 
downstream of promoter P. Alternatively, the coding sequence of GAL4 can be knocked in 
downstream of an endogenous promoter. A second fly line carries a transgene in which the gene of 
interest (X) is placed downstream of an upstream activating sequence (UAS). Upon crossing these two 
fly lines, the resulting progeny will express the GAL4 transactivator in the cells/tissue defined by the 
promoter P; in these cells, GAL4 binds the UAS sequence and leads to activation of transcription 
downstream of UAS. The gene X is therefore active only in P-positive cells, while it remains inactive in 
all other cells/tissues.   
 
4.13. Imaging of fly eyes and wings  
 
Pictures of postnatal day P1-P5 eyes and wings were acquired using a Leica MZ 9.5 
stereomicroscope equipped with a Leica DFC320 digital camera (LeicaMicrosystems, 
Wetzlar, Germany). Total eye area was determined using the ImageJ software (NIH, 
USA).  
 
4.14. Toluidine blue staining and analysis 
 
To highlight the cellular anatomy of the fly retina and to visualize the sub-cellular 
morphology of photoreceptor neurons, toluidine blue was used as contrasting agent. 
Heads from postnatal day P1-P5 flies were dissected and post-fixed in 2.5% 
glutaraldehyde. After washing with PBS, heads were incubated in a 1% osmium 
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tertaoxide solution (Science Services, Munich, Germany), then dehydrated in ethanol 
solutions of increasing concentrations (25-100 %), followed by a 10 minute 
incubation in propylene oxide. Heads were then incubated overnight in a solution 
containing 50 % propylene oxide and 50 % durcupan epoxy resin, which contained 48 
% component A/M, 40 % hardener B, 2.25 % accelerator C and 9 % plasticizer D 
(Sigma-Aldrich). Then, heads were incubated overnight in 100 % durcupan epoxy 
resin. The next day, heads and fresh durcupan resin were transferred to molds; heads 
were oriented tangentially and then cooked overnight at 60ºC. The polymerized resin 
containing the specimens was then removed from molds and cut using a 2088 
ultrotome (LKB, Bromma, Sweden). 3 μm-thick sections were collected, mounted and 
then stained using a pre warmed toluidine blue solution, that contained 0.1% toluidine 
blue (Serva Electrophoresis, Heidelberg, Germany) and 2.5% sodium carbonate. After 
a quick wash in water, sections were allowed to dry and were then covered with 
paraffin oil. Pictures at different retinal depths were acquired for each head (at 40x 
magnification). To determine ommatidium size and the number of photoreceptor 
neurons/ommatidium at least 150 ommatidia/animal from at least 4 animals were 
analyzed. 
 
4.15. Toxicity tests  
 
Postnatal day P1-P5 fly progeny was first starved in empty vials for 6 hours. Flies 
were then placed in new vials containing either 1) fly food with paraquat (20 mM) or 
2) 2 % H2O2 in 5 % sucrose solution (dispensed on a Whatmann paper at the bottom 
of an empty vial). The number of surviving flies was scored periodically (every 8-12 
hours) and the food-containing vials were exchanged regularly.  
 
4.16. Immunoblotting  
 
Postnatal day P1-P5 fly heads from at least 50 animals were collected and snap frozen 
in liquid nitrogen, then stored at -80ºC. The lysis and detection were performed as 
previously described (Meulener et al., 2005) using an anti-DJ1A/B antibody (rabbit 
polyclonal, 1:500, kind gift from Leo Pallanck, USA). Briefly, fly heads were lysed in 
a RIPA modified buffer, followed by two centrifugations at 13 000 rpm. The 
supernatant was used for immunoblotting using the anti-DJ-1B antibody and anti-
tubulin antibody (mouse monoclonal, 1:1000, Sigma-Aldrich, Germany).  
 
4.17. Statistics  
 
Unpaired Student’s t-test was used to compare mean values and to evaluate 
significance.  Differences were considered statistically significant for p-values inferior 
to 0.05.  
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